<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.0 20040830//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName journalpublishing.dtd?>
  <?SourceDTD.Version 2.0?>
  <?ConverterInfo.XSLTName jp2nlmx2.xsl?>
  <?ConverterInfo.Version 2?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Br J Pharmacol</journal-id>
      <journal-id journal-id-type="publisher-id">bph</journal-id>
      <journal-title-group>
        <journal-title>British Journal of Pharmacology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0007-1188</issn>
      <issn pub-type="epub">1476-5381</issn>
      <publisher>
        <publisher-name>Blackwell Publishing Ltd</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3085875</article-id>
      <article-id pub-id-type="pmid">21265830</article-id>
      <article-id pub-id-type="doi">10.1111/j.1476-5381.2011.01247.x</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Reviews</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Novel therapeutic approaches for pulmonary fibrosis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Datta</surname>
            <given-names>Arnab</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Scotton</surname>
            <given-names>Chris J</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chambers</surname>
            <given-names>Rachel C</given-names>
          </name>
        </contrib>
        <aff>
          <institution>Centre for Respiratory Research, University College London, Rayne Institute</institution>
          <addr-line>London, UK</addr-line>
        </aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Professor Rachel C Chambers, Centre for Respiratory Research, University College London, Rayne Institute, 5 University Street, London WC1E 6JF, UK. E-mail: <email>r.chambers@ucl.ac.uk</email></corresp>
        <fn>
          <p>Re-use of this article is permitted in accordance with the Terms and Conditions set out at <ext-link ext-link-type="uri" xlink:href="http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms">http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms</ext-link></p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>5</month>
        <year>2011</year>
      </pub-date>
      <volume>163</volume>
      <issue>1</issue>
      <fpage>141</fpage>
      <lpage>172</lpage>
      <history>
        <date date-type="received">
          <day>19</day>
          <month>11</month>
          <year>2010</year>
        </date>
        <date date-type="rev-recd">
          <day>10</day>
          <month>1</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>12</day>
          <month>1</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>British Journal of Pharmacology &#xA9; 2011 The British Pharmacological Society</copyright-statement>
        <copyright-year>2011</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/">
          <license-p>Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Pulmonary fibrosis represents the end stage of a number of heterogeneous conditions and is, to a greater or lesser degree, the hallmark of the interstitial lung diseases. It is characterized by the excessive deposition of extracellular matrix proteins within the pulmonary interstitium leading to the obliteration of functional alveolar units and in many cases, respiratory failure. While a small number of interstitial lung diseases have known aetiologies, most are idiopathic in nature, and of these, idiopathic pulmonary fibrosis is the most common and carries with it an appalling prognosis &#x2013; median survival from the time of diagnosis is less than 3 years. This reflects the lack of any effective therapy to modify the course of the disease, which in turn is indicative of our incomplete understanding of the pathogenesis of this condition. Current prevailing hypotheses focus on dysregulated epithelial&#x2013;mesenchymal interactions promoting a cycle of continued epithelial cell injury and fibroblast activation leading to progressive fibrosis. However, it is likely that multiple abnormalities in a myriad of biological pathways affecting inflammation and wound repair &#x2013; including matrix regulation, epithelial reconstitution, the coagulation cascade, neovascularization and antioxidant pathways &#x2013; modulate this defective crosstalk and promote fibrogenesis. This review aims to offer a pathogenetic rationale behind current therapies, briefly outlining previous and ongoing clinical trials, but will focus on recent and exciting advancements in our understanding of the pathogenesis of idiopathic pulmonary fibrosis, which may ultimately lead to the development of novel and effective therapeutic interventions for this devastating condition.</p>
        <sec>
          <title>LINKED ARTICLES</title>
          <p>This article is part of a themed issue on Respiratory Pharmacology. To view the other articles in this issue visit <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/bph.2011.163.issue-1">http://dx.doi.org/10.1111/bph.2011.163.issue-1</ext-link></p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>pulmonary fibrosis</kwd>
        <kwd>fibrosis therapy</kwd>
        <kwd>drug targets</kwd>
        <kwd>myofibroblast</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="">
      <title>Introduction</title>
      <p>Pulmonary fibrosis represents the end stage of several interstitial lung diseases, including the idiopathic interstitial pneumonias, and is characterized by the excessive deposition of extracellular matrix (ECM) within the pulmonary interstitium. Among the idiopathic interstitial pneumonias, idiopathic pulmonary fibrosis (IPF) represents the commonest and most fatal condition with a median survival of 3&#x2013;5 years following diagnosis. Fibrosis in IPF is generally progressive, refractory to current pharmacological intervention and inexorably leads to respiratory failure due to obliteration of functional alveolar units. IPF affects approximately 500 000 people in the USA and Europe (<xref ref-type="bibr" rid="b51">Coultas <italic>et al</italic>., 1994</xref>). This condition therefore represents a major unmet medical need for which novel therapeutic approaches are urgently required. This review will focus on IPF, although the paradigms and potential molecular targets described here may be relevant to a number of other fibrotic conditions, including sarcoidosis and systemic sclerosis.</p>
    </sec>
    <sec sec-type="">
      <title>IPF &#x2013; incidence/aetiology/pathogenesis</title>
      <p>Idiopathic pulmonary fibrosis has a reported incidence of 4.6 per 100 000 people in the UK, but between 1991 and 2003 the incidence increased annually by 11% (<xref ref-type="bibr" rid="b82">Gribbin <italic>et al</italic>., 2006</xref>). Around 4000 new cases are now diagnosed each year in the UK (<xref ref-type="bibr" rid="b82">Gribbin <italic>et al</italic>., 2006</xref>), a disease burden that is currently comparable with that of small cell lung cancer. Clinically, patients generally present with increasing dyspnoea, which may be associated with a dry cough and non-specific systemic upset. A diagnosis of IPF can be made following clinical, radiographic and histological evaluation paying particular attention to exclude secondary causes of pulmonary fibrosis.</p>
      <p>The aetiology of IPF remains unknown, although a number of risk factors have been identified. For example, cigarette smoking has been associated with an increased risk of developing IPF, as have certain latent viral infections, including Epstein-Barr virus and herpesvirus (<xref ref-type="bibr" rid="b123">Kelly <italic>et al</italic>., 2002</xref>; <xref ref-type="bibr" rid="b247">Tang <italic>et al</italic>., 2003</xref>). Three per cent of IPF patients appear to have a familial form, and gene polymorphisms of tumour necrosis factor (TNF)-&#x3B1; and transforming growth factor (TGF)-&#x3B2;1, as well as mutations in surfactant protein C, appear to confer an increased risk of developing IPF (<xref ref-type="bibr" rid="b260">Whyte <italic>et al</italic>., 2000</xref>; <xref ref-type="bibr" rid="b267">Xaubet <italic>et al</italic>., 2003</xref>; <xref ref-type="bibr" rid="b147">Lawson <italic>et al</italic>., 2004</xref>). However, as only a small number of those individuals exposed to known risk factors develop IPF, the aetiology is likely to be multifactorial.</p>
      <p>The classical histopathological pattern of IPF is one of usual interstitial pneumonia characterized by evidence of patchy epithelial damage including type II pneumocyte hyperplasia, together with abnormal proliferation of mesenchymal cells, varying degrees of fibrosis and overproduction and disorganized deposition of collagen and ECM &#x2013; this results in significant distortion of pulmonary architecture and honeycombing (<xref ref-type="fig" rid="fig01">Figure 1</xref>). Fibrotic foci are often observed within the mura of microscopic honeycomb lesions underlying injured and reparative epithelium, as well as within the interstitium &#x2013; these fibrotic (or fibroblastic foci) represent accumulations of fibroblasts and myofibroblasts within organizing ECM, and their presence and distribution, together with the spatial and temporal heterogeneity of the pathology, is crucial to defining a usual interstitial pneumonia pattern (<xref ref-type="bibr" rid="b117">Katzenstein and Myers, 1998</xref>).</p>
      <fig id="fig01" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Fibrotic foci &#x2013; a histological hallmark of idiopathic pulmonary fibrosis. (A) Histological analysis of human IPF tissue reveals the presence of dense collagen deposition within the interstitium (Martius Scarlet Blue staining; original magnification &#xD7;10). Fibroblastic foci are revealed as accumulations of fibroblasts and alpha-SMA<sup>+</sup> myofibroblasts, which are highly synthetic for collagen and have a contractile phenotype (B: Martius Scarlet Blue staining; C: immunohistochemistry for alpha-SMA. Original magnification &#xD7;20). The overlying epithelium is often hyperplastic, with frequent apoptosis and areas of denudation. The presence and distribution of fibrotic foci, together with the spatial and temporal heterogeneity of the pathology is crucial to defining a UIP pattern.</p>
        </caption>
        <graphic xlink:href="bph0163-0141-f1"/>
      </fig>
      <p>Although significant advances have been made in understanding the pathogenesis of pulmonary fibrosis, the specific cellular and molecular mechanisms that contribute to disease progression remain unclear. This article will briefly review the current status of IPF clinical trials (summarized in <xref ref-type="table" rid="tbl1">Table 1</xref>) but will focus on novel therapeutic approaches that are emerging from exciting recent advances in our understanding of pathogenetic mechanisms (see <xref ref-type="fig" rid="fig02">Figure 2</xref>).</p>
      <table-wrap id="tbl1" position="float">
        <label>Table 1</label>
        <caption>
          <p>An overview of completed and ongoing clinical trials in IPF [modified from (<xref ref-type="bibr" rid="b225">Scotton and Chambers, 2007</xref>)]</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th align="left" rowspan="1" colspan="1">
                <bold>Agent/treatment</bold>
              </th>
              <th align="left" rowspan="1" colspan="1">
                <bold>Potential mechanisms of action</bold>
              </th>
              <th align="left" rowspan="1" colspan="1">
                <bold>Example of clinical trial or retrospective series</bold>
              </th>
              <th align="left" rowspan="1" colspan="1">
                <bold>Study design where appropriate</bold>
              </th>
              <th align="left" rowspan="1" colspan="1">
                <bold>End points and duration of trial where appropriate/available</bold>
              </th>
              <th align="left" rowspan="1" colspan="1">
                <bold>Outcome/comments</bold>
              </th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" colspan="6" rowspan="1">Anti-inflammatory/Immunosuppressive</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;Corticosteroids</td>
              <td align="left" rowspan="1" colspan="1">Immunosuppressant and anti-inflammatory</td>
              <td align="left" rowspan="1" colspan="1">Significant lack of studies evaluating prednisolone against placebo<xref ref-type="bibr" rid="b73">Flaherty <italic>et al</italic>. (2001)</xref></td>
              <td align="left" rowspan="1" colspan="1">Open label study; <italic>n</italic>= 41</td>
              <td align="left" rowspan="1" colspan="1">CRP score at 3 months</td>
              <td align="left" rowspan="1" colspan="1">27% responders/46% stable/27% non-responders Adverse effects noted in all patients Cochrane Review of 2003 found no evidence for an effect of corticosteroids in IPF; no high quality prospective studies were identified as suitable for meta-analysis (<xref ref-type="bibr" rid="b55">Davies <italic>et al</italic>., 2003</xref>)</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;Cyclophosphamide</td>
              <td align="left" rowspan="1" colspan="1">Alkylating agent with anti-inflammatory properties</td>
              <td align="left" rowspan="1" colspan="1">
                <xref ref-type="bibr" rid="b49">Collard <italic>et al</italic>. (2004)</xref>
              </td>
              <td align="left" rowspan="1" colspan="1">Retrospective case series; cyclophosphamide + prednisolone vs. no treatment; <italic>n</italic>= 82 in each group</td>
              <td align="left" rowspan="1" colspan="1">Survival at 6&#x2013;12 months</td>
              <td align="left" rowspan="1" colspan="1">No evidence for a therapeutic benefit. Significant potential adverse effects</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;Azathioprine</td>
              <td align="left" rowspan="1" colspan="1">Inhibits adenine deaminase and impairs cell proliferation (particularly leukocytes) Anti-inflammatory</td>
              <td align="left" rowspan="1" colspan="1">
                <xref ref-type="bibr" rid="b210">Raghu <italic>et al</italic>. (1991)</xref>
              </td>
              <td align="left" rowspan="1" colspan="1">Prospective, double-blinded, randomized placebo-controlled trial; prednisolone + azathioprine (<italic>n</italic>= 14) vs. prednisolone + placebo (<italic>n</italic>= 13)</td>
              <td align="left" rowspan="1" colspan="1">Primary end points: &#x394;FVC/DL<sub>co</sub>/A-a gradient at 1 year; survival at 9 years</td>
              <td align="left" rowspan="1" colspan="1">Marginally significant survival benefit in azathioprine/prednisolone group only after age-adjustmentNo significant improvement in remaining parameters</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;Etanercept</td>
              <td align="left" rowspan="1" colspan="1">See text</td>
              <td align="left" rowspan="1" colspan="1">
                <xref ref-type="bibr" rid="b212">Raghu <italic>et al</italic>. (2008)</xref>
              </td>
              <td align="left" rowspan="1" colspan="1">Prospective, double-blinded, randomized placebo-controlled trial; etanercept (<italic>n</italic>= 34) vs. placebo (<italic>n</italic>= 31)</td>
              <td align="left" rowspan="1" colspan="1">Primary end points: &#x394;% pred FVC/% pred DL<sub>co</sub>/&#x394;A-a gradient over 48 weeks</td>
              <td align="left" rowspan="1" colspan="1">No significant difference observed between treatment groups. Etanercept therapy resulted in a non-significant reduction in disease progression in several physiological, functional and QoL end points</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;Azathioprine/prednisolone</td>
              <td align="left" rowspan="1" colspan="1">As above</td>
              <td align="left" rowspan="1" colspan="1">Thorax National Institute, Chile</td>
              <td align="left" rowspan="1" colspan="1">Prospective, double-blinded, randomized placebo-controlled trial; currently recruiting patients, total planned <italic>n</italic>= 100</td>
              <td align="left" rowspan="1" colspan="1">Primary end point: progression free survivalat 2 years</td>
              <td align="left" rowspan="1" colspan="1">Results awaited</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;Azathioprine/prednisolone/N-acetylcysteine (NAC)</td>
              <td align="left" rowspan="1" colspan="1">In addition to above, please refer to text for NAC</td>
              <td align="left" rowspan="1" colspan="1">NHLBI, USA</td>
              <td align="left" rowspan="1" colspan="1">Prospective, double-blinded, randomized placebo-controlled trial; currently recruiting patients, total planned <italic>n</italic>= 390</td>
              <td align="left" rowspan="1" colspan="1">Primary end point: &#x394;FVC at 60 weeks</td>
              <td align="left" rowspan="1" colspan="1">Results awaited</td>
            </tr>
            <tr>
              <td align="left" colspan="6" rowspan="1">Anti-fibrotic/Anti-angiogenic</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;anti-TGF&#x3B2; (1/2/3) antibody (GC1008)</td>
              <td align="left" rowspan="1" colspan="1">See text</td>
              <td align="left" rowspan="1" colspan="1">Genzyme and Cambridge Antibody Technology, UK</td>
              <td align="left" rowspan="1" colspan="1">Non-randomized, open label, single group assignment Phase I study; <italic>n</italic>= 25</td>
              <td align="left" rowspan="1" colspan="1">Primary end points: safety and tolerabilitySecondary end points: potential clinical outcomes up to 3 years</td>
              <td align="left" rowspan="1" colspan="1">Results awaited</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;Anti-&#x3B1;<sub>v</sub>&#x3B2;<sub>6</sub> integrin (STX-100)</td>
              <td align="left" rowspan="1" colspan="1">See text</td>
              <td align="left" rowspan="1" colspan="1">Stromedix, USA</td>
              <td align="left" rowspan="1" colspan="1">Phase I studies completed (Stromedix) &#x2013; awarded orphan drug status (USA) and Phase II studies planned</td>
              <td rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1">Results awaited</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;LPA, antagonist (AM152)</td>
              <td align="left" rowspan="1" colspan="1">See text</td>
              <td align="left" rowspan="1" colspan="1">Amira, USA</td>
              <td align="left" rowspan="1" colspan="1">Phase I clinical study initiated in healthy individuals</td>
              <td align="left" rowspan="1" colspan="1">Safety and pharmacokinetic profiles to be analysed</td>
              <td align="left" rowspan="1" colspan="1">Results awaited</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;Pirfenidone</td>
              <td align="left" rowspan="1" colspan="1">See text</td>
              <td align="left" rowspan="1" colspan="1">
                <xref ref-type="bibr" rid="b248">Taniguchi <italic>et al</italic>. (2010)</xref>
              </td>
              <td align="left" rowspan="1" colspan="1">Prospective, double-blinded, randomized placebo-controlled trial; high dose pirfenidone (<italic>n</italic>= 108) vs. low dose pirfenidone (<italic>n</italic>= 55) vs. placebo (<italic>n</italic>= 104)</td>
              <td align="left" rowspan="1" colspan="1">Primary end point: &#x394;FVC at 52 weeks</td>
              <td align="left" rowspan="1" colspan="1">Significant reduction in FVC decline in high dose treatment arm. However, change in end point during trial, handling of missing data and absence of patient reported outcome means it is difficult to draw firm conclusions at this time</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1">CAPACITY 1 (awaiting publication) (Intermune, USA)</td>
              <td align="left" rowspan="1" colspan="1">Prospective, double-blinded, randomized placebo-controlled trial; high dose pirfenidone (<italic>n</italic>= 171) vs. placebo (<italic>n</italic>= 173)</td>
              <td align="left" rowspan="1" colspan="1">&#x394;FVC at 72 weeks</td>
              <td align="left" rowspan="1" colspan="1">No significant difference in FVC decline between treatment groups</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1">CAPACITY 2 (awaiting publication) (Intermune, USA)</td>
              <td align="left" rowspan="1" colspan="1">Prospective, double-blinded, randomized placebo-controlled trial; high dose pirfenidone (<italic>n</italic>= 174) vs. low dose pirfenidone (<italic>n</italic>= 87) vs. placebo (<italic>n</italic>= 174)</td>
              <td align="left" rowspan="1" colspan="1">&#x394;FVC at 72 weeks</td>
              <td align="left" rowspan="1" colspan="1">Significant reduction in FVC decline in pirfenidone groups</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;Imatinib mesylate (Gleevec)</td>
              <td align="left" rowspan="1" colspan="1">See text</td>
              <td align="left" rowspan="1" colspan="1">
                <xref ref-type="bibr" rid="b54">Daniels <italic>et al</italic>. (2010)</xref>
              </td>
              <td align="left" rowspan="1" colspan="1">Prospective, double-blinded, randomized placebo-controlled trial; imatinib (<italic>n</italic>= 60) vs. placebo (n-61)</td>
              <td align="left" rowspan="1" colspan="1">Primary end point: time to disease progression (&gt;10% decline in % pred FVC) or death over 92 weeks</td>
              <td align="left" rowspan="1" colspan="1">No change in primary end point between treatment and placebo</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;FG-3019</td>
              <td align="left" rowspan="1" colspan="1">See text</td>
              <td align="left" rowspan="1" colspan="1">Fibrogen, USA</td>
              <td align="left" rowspan="1" colspan="1">Phase I open label study; <italic>n</italic>= 21</td>
              <td align="left" rowspan="1" colspan="1">1&#x2013;12 months</td>
              <td align="left" rowspan="1" colspan="1">FG-3019 is safe and well-tolerated. Future trials will assess therapeutic potential</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;Zileuton</td>
              <td align="left" rowspan="1" colspan="1">See text</td>
              <td align="left" rowspan="1" colspan="1">Investigator led (University of Michigan)</td>
              <td align="left" rowspan="1" colspan="1">Randomized, open label, active control, parallel assignment Phase II study; <italic>n</italic>= 140</td>
              <td align="left" rowspan="1" colspan="1">Primary end point: &#x394;[LTB<sub>4</sub>] in BALF at 6 monthsSecondary end points include progression free survival and change in physiology</td>
              <td align="left" rowspan="1" colspan="1">Results awaited</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;Iloprost</td>
              <td align="left" rowspan="1" colspan="1">See text</td>
              <td align="left" rowspan="1" colspan="1">
                <xref ref-type="bibr" rid="b140">Krowka <italic>et al</italic>. (2007)</xref>
              </td>
              <td align="left" rowspan="1" colspan="1">Prospective, double-blinded, randomized placebo-controlled Phase II study; iloprost (<italic>n</italic>= 26) vs. placebo (<italic>n</italic>= 25); recruited patients with IPF and elevated pulmonary arterial pressures</td>
              <td align="left" rowspan="1" colspan="1">Primary end point: safetySecondary end points included dyspnoea (Borg Scale) and 6MWD at 12 weeks</td>
              <td align="left" rowspan="1" colspan="1">Patients diagnosed with IPF and PAH.Iloprost was well tolerated though no significant differences observed in secondary end points'</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;Anti-IL-13 antibody (QAX576)</td>
              <td align="left" rowspan="1" colspan="1">See text</td>
              <td align="left" rowspan="1" colspan="1">Novartis, Switzerland</td>
              <td align="left" rowspan="1" colspan="1">Open label Phase II study; <italic>n</italic>= 50</td>
              <td align="left" rowspan="1" colspan="1">Primary end point: IL13 serum levelsSecondary end point: change in designated serum biomarkers over time with treatment for 4 weeks</td>
              <td align="left" rowspan="1" colspan="1">Results awaited</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;IFN&#x3B3;1b</td>
              <td align="left" rowspan="1" colspan="1">See text</td>
              <td align="left" rowspan="1" colspan="1">
                <xref ref-type="bibr" rid="b130">King <italic>et al</italic>. (2009)</xref>
              </td>
              <td align="left" rowspan="1" colspan="1">Prospective, double-blinded, randomized placebo-controlled trial; interferon (<italic>n</italic>= 551) vs. placebo (<italic>n</italic>= 275)</td>
              <td align="left" rowspan="1" colspan="1">Primary end point: survival from time of randomizationPrimary end points: safety and tolerability</td>
              <td align="left" rowspan="1" colspan="1">Trial ended prematurely as overall survival had crossed predefined boundary at planned interim stage analysis (64 weeks); however, no difference between treatment and placebo arms</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1">National Centre for Research Resources, USA</td>
              <td align="left" rowspan="1" colspan="1">Non-randomized open label single interventional study with nebulized interferon-&#x3B3;Recruiting patients, planned <italic>n</italic>= 12</td>
              <td align="left" rowspan="1" colspan="1">Secondary end points: lung function trends and BALF [IFN-&#x3B3;] at 1 year</td>
              <td align="left" rowspan="1" colspan="1">Results awaited</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Endothelin antagonists</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;Bosentan (dual ET-1 receptor antagonist)</td>
              <td align="left" rowspan="1" colspan="1">See text</td>
              <td align="left" rowspan="1" colspan="1">
                <xref ref-type="bibr" rid="b129">King <italic>et al</italic>. (2008)</xref>
              </td>
              <td align="left" rowspan="1" colspan="1">Prospective, double-blinded, randomized placebo-controlled trial; bosentan (<italic>n</italic>= 74) vs. placebo (<italic>n</italic>= 84)</td>
              <td align="left" rowspan="1" colspan="1">Primary end point: 6MWD at 12 months</td>
              <td align="left" rowspan="1" colspan="1">No effect on primary outcome between treatments arms; <italic>post hoc</italic> analysis demonstrated trend in delayed time to disease progression or death in the bosentan arm of IPF patients who had undergone lung biopsy</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1">BUILD-3 (Actelion, Switzerland)</td>
              <td align="left" rowspan="1" colspan="1">Prospective, double-blinded, randomized placebo-controlled trial; total <italic>n</italic>= 616, bosentan : placebo 2:1 recruitment complete;</td>
              <td align="left" rowspan="1" colspan="1">Primary end points: time to disease progression or death over 8&#x2013;32 months</td>
              <td align="left" rowspan="1" colspan="1">BUILD-3 trial designed to evaluate efficacy of bosentan in the subgroup of patients with IPF diagnosed at lung biopsy</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;Ambrisentan (selective ET-1<sub>A</sub> receptor antagonist)</td>
              <td align="left" rowspan="1" colspan="1">See text</td>
              <td align="left" rowspan="1" colspan="1">ARTEMIS-IPF (Gilead, USA)</td>
              <td align="left" rowspan="1" colspan="1">Prospective, double-blinded randomized placebo-controlled trial; ambrisentan vs. placebo, currently recruiting, total planned <italic>n</italic>= 600</td>
              <td align="left" rowspan="1" colspan="1">Primary end points: time to disease progression or death, event driven over 4 years</td>
              <td align="left" rowspan="1" colspan="1">Terminated at interim analysis stage due to lack of efficacy</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;Macicentan</td>
              <td align="left" rowspan="1" colspan="1">See text</td>
              <td align="left" rowspan="1" colspan="1">MUSIC (Actelion, Switzerland)</td>
              <td align="left" rowspan="1" colspan="1">Prospective, double-blinded randomized placebo-controlled trial; total <italic>n</italic>= 178; macicentan vs. placebo, recruitment complete</td>
              <td align="left" rowspan="1" colspan="1">&#x394;FVC over 12 months</td>
              <td align="left" rowspan="1" colspan="1">Results awaited</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;AII antagonists (Losartan)</td>
              <td align="left" rowspan="1" colspan="1">See text and refer to sildenafil below</td>
              <td align="left" rowspan="1" colspan="1">Losartan in Treating Patients with IPF (National Cancer Institute, USA)</td>
              <td align="left" rowspan="1" colspan="1">Open label interventional study; recruiting patients; planned <italic>n</italic>= 25</td>
              <td align="left" rowspan="1" colspan="1">Primary end point: FVC response at 1 year</td>
              <td align="left" rowspan="1" colspan="1">Results awaited</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1">Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis (University of Iowa, USA)</td>
              <td align="left" rowspan="1" colspan="1">Prospective, double-blinded, randomized placebo-controlled trial; currently recruiting; planned total <italic>n</italic>= 40</td>
              <td align="left" rowspan="1" colspan="1">Primary end points: 6MWD and QoL score</td>
              <td align="left" rowspan="1" colspan="1">This trial is designed to evaluate the effect of losartan &#xB1; sildenafil on exercise-induced oxygen desaturation in IPF patients</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;Minocycline</td>
              <td align="left" rowspan="1" colspan="1">See text</td>
              <td align="left" rowspan="1" colspan="1">Investigator led &#x2013; University of California, USA</td>
              <td align="left" rowspan="1" colspan="1">Prospective, double-blinded, randomized placebo-controlled trial; patient numbers not disclosed</td>
              <td align="left" rowspan="1" colspan="1">Primary end points: safety and efficacy</td>
              <td align="left" rowspan="1" colspan="1">Results awaited</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;Angiokinase inhibitor (BIBF 1120)</td>
              <td align="left" rowspan="1" colspan="1">See text</td>
              <td align="left" rowspan="1" colspan="1">Boehringer Ingelheim Pharmaceuticals, UK</td>
              <td align="left" rowspan="1" colspan="1">Prospective, double-blinded, randomized placebo-controlled Phase II study; BIBF1120 vs. placebo; total <italic>n</italic>= 400; recruitment complete</td>
              <td align="left" rowspan="1" colspan="1">Primary end point: &#x394;FVC over 1 year</td>
              <td align="left" rowspan="1" colspan="1">Results awaited</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;Tetrathiomolybdate</td>
              <td align="left" rowspan="1" colspan="1">See text</td>
              <td align="left" rowspan="1" colspan="1">Investigator led &#x2013; University of Michigan, USA</td>
              <td align="left" rowspan="1" colspan="1">Non-randomized, open label, uncontrolled, single group assignment Phase I/II; <italic>n</italic>= 20</td>
              <td align="left" rowspan="1" colspan="1">Primary end point: safetySecondary end points: &#x394;lung function tests</td>
              <td align="left" rowspan="1" colspan="1">Results awaited</td>
            </tr>
            <tr>
              <td align="left" colspan="6" rowspan="1">Antioxidant</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;N-acetylcysteine (NAC)</td>
              <td align="left" rowspan="1" colspan="1">See text</td>
              <td align="left" rowspan="1" colspan="1">
                <xref ref-type="bibr" rid="b57">Demedts <italic>et al</italic>. (2005)</xref>
              </td>
              <td align="left" rowspan="1" colspan="1">Prospective, double-blinded, randomized placebo-controlled trial; NAC + azathioprine + prednisolone (<italic>n</italic>= 92) vs. placebo + azathioprine + prednisolone (<italic>n</italic>= 90)</td>
              <td align="left" rowspan="1" colspan="1">Primary end points: absolute &#x394;FVC and DL<sub>co</sub> at 12 months</td>
              <td align="left" rowspan="1" colspan="1">Reduction in FVC and DL<sub>co</sub> decline over 1 year in NAC arm, though no change in mortality</td>
            </tr>
            <tr>
              <td align="left" colspan="6" rowspan="1">Anti-coagulation/pro-fibrinolytic</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;Warfarin</td>
              <td align="left" rowspan="1" colspan="1">See text</td>
              <td align="left" rowspan="1" colspan="1">
                <xref ref-type="bibr" rid="b141">Kubo <italic>et al</italic>. (2005)</xref>
              </td>
              <td align="left" rowspan="1" colspan="1">Randomized open label trial; prednisolone + warfarin/low molecular weight heparin(<italic>n</italic>= 31) vs. prednisolone + placebo (<italic>n</italic>= 33);</td>
              <td align="left" rowspan="1" colspan="1">Primary end points: time to death and hospitalization-free time over 1 year</td>
              <td align="left" rowspan="1" colspan="1">Anti-coagulant therapy resulted in a significant increase in survival of patients with IPF and a significant improvement in survival associated with acute exacerbations of IPF</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1">See text</td>
              <td align="left" rowspan="1" colspan="1">NHLBI &#x2013; Duke University, USA</td>
              <td align="left" rowspan="1" colspan="1">Prospective, double-blinded, randomized placebo-controlled trial; warfarin vs. placebo; currently recruiting, planned total <italic>n</italic>= 256</td>
              <td align="left" rowspan="1" colspan="1">Primary end points: time to death or disease progression over 48 weeks</td>
              <td align="left" rowspan="1" colspan="1">Results awaited</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;Heparin</td>
              <td align="left" rowspan="1" colspan="1">See text</td>
              <td align="left" rowspan="1" colspan="1">
                <xref ref-type="bibr" rid="b168">Markart <italic>et al</italic>. (2010)</xref>
              </td>
              <td align="left" rowspan="1" colspan="1">Open label exploratory study evaluating safety of nebulized heparin in IPF; <italic>n</italic>= 21</td>
              <td align="left" rowspan="1" colspan="1">Study designed to assess safety and tolerability</td>
              <td align="left" rowspan="1" colspan="1">Adequate local anticoagulation achieved with no significant adverse effects. Future trials planned to evaluate efficacy.</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Other</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;Sildenafil</td>
              <td align="left" rowspan="1" colspan="1">Phosphodiesterase 5 inhibitor. Causes vasorelaxation by stabilizing cGMP</td>
              <td align="left" rowspan="1" colspan="1">IPF Clinical Research Network, USA (<xref ref-type="bibr" rid="b285">Zisman <italic>et al</italic>., 2010</xref>)</td>
              <td align="left" rowspan="1" colspan="1">Prospective, double-blinded, randomized placebo-controlled trial :sildenafil (<italic>n</italic>= 89) vs. placebo (<italic>n</italic>= 91)</td>
              <td align="left" rowspan="1" colspan="1">Primary end points: 6MWDDouble-blinded over initial 12 weeks, followed by open label extension for 12 weeks with all patients receiving sildenafil</td>
              <td align="left" rowspan="1" colspan="1">This trial enrolled patients with advanced IPFNo significant improvement in primary end point in treatment arm, but significant improvement in secondary end points in sildenafil arm, including DL<sub>co</sub> and quality of life score</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;Anti-CCL2 antibody (CNTO 888)</td>
              <td align="left" rowspan="1" colspan="1">See text</td>
              <td align="left" rowspan="1" colspan="1">Centocor, USA</td>
              <td align="left" rowspan="1" colspan="1">Prospective, double-blinded, randomized placebo-controlled Phase II trial; CNTO 888 &#xB1; usual therapy vs. placebo &#xB1; usual therapy; currently recruiting patients, planned total <italic>n</italic>= 120</td>
              <td align="left" rowspan="1" colspan="1">Primary end points: safety and performance at lung function tests</td>
              <td align="left" rowspan="1" colspan="1">Results awaited</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;Somatostatin analogues</td>
              <td align="left" rowspan="1" colspan="1">See text</td>
              <td align="left" rowspan="1" colspan="1">Institut National de la Sant&#xE9; Et de la Recherche M&#xE9;dicale, France</td>
              <td align="left" rowspan="1" colspan="1">Non-randomized open label single interventional study with octreotide; <italic>n</italic>= 25</td>
              <td align="left" rowspan="1" colspan="1">Monitoring of FVC; DL<sub>co</sub>; HRCT fibrosis score; 6MWD over 48 weeks</td>
              <td align="left" rowspan="1" colspan="1">Results awaited</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#x2003;Thalidomide</td>
              <td align="left" rowspan="1" colspan="1">See text</td>
              <td align="left" rowspan="1" colspan="1">Investigator led &#x2013; John Hopkins University, USA</td>
              <td align="left" rowspan="1" colspan="1">Non-randomized open label single interventional study designed for patients who have failed or are unsuitable for immunosuppressive therapy; currently recruiting, planned total <italic>n</italic>= 19</td>
              <td align="left" rowspan="1" colspan="1">Primary end point: safetySecondary end points: &#x394;lung function over 1 year</td>
              <td align="left" rowspan="1" colspan="1">Results awaited</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p>A-a, alveolar:arterial; BALF, bronchoalveolar lavage fluid; CRP, clinical-radiographic-physiological; DL<sub>co</sub>, carbon monoxide transfer factor; pred, predicted; FVC, forced vital capacity; HRCT, high resolution computer tomography; IL-13, interleukin 13; IFN-&#x3B3;, interferon-gamma; LTB<sub>4</sub>, leukotriene B<sub>4</sub>; 6MWD, 6 min walk test distance; QoL, quality of life.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <fig id="fig02" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Key mediators in the pathogenesis of IPF. The pathobiological mechanisms underlying the development of IPF are highly complex. Recurring damage to the epithelium (possibly due to reactive oxygen species, endoplasmic reticulum stress or viral infection) results in an abnormal wound healing response characterized by dysregulated epithelial&#x2013;mesenchymal crosstalk and the accumulation of myofibroblasts (the key effector cells in IPF fibrogenesis). The proposed cellular origin of these cells includes resident fibroblasts, epithelial/endothelial&#x2013;mesenchymal transition or the recruitment of circulating fibrocytes. The fibrotic micro-environment may be skewed towards a pro-angiogenic and Th2-oriented profile, where multiple cytokines, growth factors and signalling pathways mediate the pro-fibrotic responses. Some of the potential anti-fibrotic strategies (shown in red) are highlighted and these are described further in the text.</p>
        </caption>
        <graphic xlink:href="bph0163-0141-f2"/>
      </fig>
    </sec>
    <sec sec-type="">
      <title>Inflammation in IPF: clinically, an unresolved issue</title>
      <p>Early hypotheses embraced the concept that pulmonary fibrosis represents the end stage of an inflammatory cascade initiated following alveolar injury, and that fibrogenesis following such alveolitis was mediated by a number of inflammatory and fibrogenic mediators derived from recruited inflammatory cells. However, the lack of efficacy of anti-inflammatory/immunosuppressive therapy in concert with experimental evidence suggesting that inflammation is not necessary for the progression to fibrosis has brought this hypothesis into question. Crucially, overexpression of the potent pro-fibrotic mediator, TGF-&#x3B2;1, leads to progressive fibrosis in mice, without any significant inflammatory component (<xref ref-type="bibr" rid="b234">Sime <italic>et al</italic>., 1997</xref>). Conversely, it has been argued that despite the lack of clinical benefit observed following anti-inflammatory treatment in established disease, a pathogenic role for inflammation cannot be excluded in the early initiating (subclinical) stages of the disease (<xref ref-type="bibr" rid="b239">Strieter, 2005</xref>). In fact, the forced vital capacity (FVC) of most patients is already significantly reduced by the time of presentation (<xref ref-type="bibr" rid="b128">King <italic>et al</italic>., 2001</xref>) indicating that fibrosis is already present. Recent work has demonstrated a potential role for the adaptive immune response to injury in fibrogenesis: peripheral CD4+ cells from IPF patients have increased effector functions (<xref ref-type="bibr" rid="b70">Feghali-Bostwick <italic>et al</italic>., 2007</xref>), and CD4+ cells from the lymph nodes of IPF patients proliferate in co-culture with autologous lung extract, suggesting an autoimmune component to the pathogenesis of IPF (<xref ref-type="bibr" rid="b70">Feghali-Bostwick <italic>et al</italic>., 2007</xref>). Indeed, interactions between T cells and antigen-presenting dendritic cells, critical to the development of an adaptive immune response, have recently been observed in IPF lung, in the form of tertiary lymphoid follicles, composed of reactivated T cells, B cells and locally maturing dendritic cells (<xref ref-type="bibr" rid="b166">Marchal-Somme <italic>et al</italic>., 2007</xref>). Finally, recent gene microarray studies have demonstrated that, in addition to the expected increase in gene expression of proteins associated with ECM turnover, expression of genes traditionally associated with inflammatory processes such as cytokines and chemokines (<xref ref-type="bibr" rid="b286">Zuo <italic>et al</italic>., 2002</xref>) is increased in IPF. These recent data have reinvigorated the argument that perhaps a more focused anti-inflammatory strategy may be of benefit in IPF.</p>
      <p>In reality, the question of whether or not current anti-inflammatory/immunosuppressive therapy is of benefit to IPF patients remains unanswered. To date, there has only been a single completed randomized, double-blinded placebo-controlled trial evaluating the efficacy of such treatment (<xref ref-type="bibr" rid="b210">Raghu <italic>et al</italic>., 1991</xref>), which demonstrated a marginal long-term survival benefit over a 9 year follow up in patients treated with azathioprine and prednisolone, compared with prednisolone alone. Beneficial responses to such therapy have been reported in a number of prospective non-randomized trials (<xref ref-type="bibr" rid="b229">Selman <italic>et al</italic>., 1998</xref>; <xref ref-type="bibr" rid="b284">Zisman <italic>et al</italic>., 2000</xref>; <xref ref-type="bibr" rid="b73">Flaherty <italic>et al</italic>., 2001</xref>; <xref ref-type="bibr" rid="b137">Kondoh <italic>et al</italic>., 2005</xref>), as well as several retrospective case series (<xref ref-type="bibr" rid="b250">Turner-Warwick <italic>et al</italic>., 1980</xref>; <xref ref-type="bibr" rid="b64">Douglas <italic>et al</italic>., 1997</xref>; <xref ref-type="bibr" rid="b65">2000</xref>; <xref ref-type="bibr" rid="b132">Kolb <italic>et al</italic>., 1998</xref>; <xref ref-type="bibr" rid="b49">Collard <italic>et al</italic>., 2004</xref>). However, difficulty in interpreting such data is further compounded by low patient numbers and diagnostic heterogeneity. With these crucial caveats in mind, and given the lack of any detrimental effect on survival or lung function, the American Thoracic Society (ATS)/European Respiratory Society (ERS) consensus statement on the management of IPF published in 2000 (<xref ref-type="bibr" rid="b12">ATS/ERS, 2000</xref>) suggested combined anti-inflammatory therapy with prednisolone plus azathioprine in patients with active disease. Considering the lack of strong data to wholeheartedly support this statement, two trials are currently recruiting patients to hopefully clarify this issue. The AZAPRED trial (Thorax National Institute, Chile) is a randomized double-blinded placebo-controlled trial evaluating the efficacy of azathioprine/prednisolone, while the PANTHER trial (NHLBI, USA) will assess the efficacy of the current recommended &#x2018;gold-standard triple therapy&#x2019; of azathioprine/prednisolone/N-acetylcysteine (NAC) as compared with NAC alone or placebo. While such therapy may not represent a novel advance in therapeutics in the true sense, data derived from these trials will go someway to advancing our understanding of whether the current therapy is beneficial.</p>
      <p>The observation that steroid use may actually enhance alveolar epithelial damage by promoting apoptosis (<xref ref-type="bibr" rid="b63">Dorscheid <italic>et al</italic>., 2001</xref>) highlights the greater importance of identifying disequilibrium in particular molecular pathways over broadly classifying IPF as a purely inflammatory condition. To this end, recent work has highlighted the potential importance of inflammasome activation, by danger signals released following lung injury, in promoting lung fibrosis. In a murine model of lung injury, mice deficient in the NALP-3 inflammasome develop an attenuated early inflammatory response to bleomycin, as well as a reduction in subsequent fibrosis, compared with wild-type controls (<xref ref-type="bibr" rid="b75">Gasse <italic>et al</italic>., 2009</xref>); a major role for uric acid as the danger signal to the NALP-3 inflammasome following experimental lung injury has been described and the prophylactic administration of allopurinol or uricase, strategies aimed at reducing uric acid levels, attenuated bleomycin-induced fibrosis in this model (<xref ref-type="bibr" rid="b75">Gasse <italic>et al</italic>., 2009</xref>). Moreover, the potential importance of this pathway in human disease is supported by the observation of elevated levels of uric acid in IPF lung compared with non-fibrotic control lung (<xref ref-type="bibr" rid="b167">Markart <italic>et al</italic>., 2009</xref>). As such, selective modulation of key inflammatory pathways, such as targeting inflammasome activation by endogenous injury-induced danger signals, may be worth consideration for therapeutic development in IPF rather than a broad-based anti-inflammatory strategy.</p>
    </sec>
    <sec sec-type="">
      <title>Dysregulated epithelial &#x2013; mesenchymal crosstalk in IPF</title>
      <p>Irrespective of the current uncertainty regarding the precise contribution of inflammation to the initiation and/or progression of IPF, the more recent hypothesis that IPF arises as a result of a highly aberrant wound healing response following repetitive epithelial injury in susceptible individuals (<xref ref-type="bibr" rid="b228">Selman and Pardo, 2002</xref>) is gaining increasing recognition. According to this hypothesis, IPF is an &#x2018;epithelial-fibroblastic disease&#x2019;, that is, a fibroproliferative disorder preceded by alveolar epithelial injury and activation, with fibrotic foci representing the primary sites of injury and aberrant repair. The underlying mechanisms leading to the emergence of fibrotic foci are still unclear; current evidence suggests roles for local proliferation and differentiation of resident fibroblasts, recruitment of circulating stem cells and epithelial&#x2013;mesenchymal transition (EMT), with a prominent role identified for the overlying, highly reactive and hyperplastic epithelium. These notions will be explored in greater detail below. Myofibroblasts in turn provoke basement membrane disruption and alveolar epithelial cell (AEC) apoptosis, perpetuating the damage and preventing appropriate re-epithelialization. The final result is the excessive deposition of ECM proteins with the destruction of the alveolar-capillary units and the formation of cystic fibrotic spaces or honeycombing. Unravelling the molecular basis for this aberrant epithelial&#x2013;mesenchymal crosstalk in IPF is currently an area of intense investigation. This effort has heralded major advances in disease understanding with much current interest focused on elucidating the pathways involved in myofibroblast accumulation and differentiation in the hope that this might lead to the identification of novel molecular targets for therapeutic intervention.</p>
    </sec>
    <sec sec-type="">
      <title>The epithelium in IPF</title>
      <p>Crucial to normal wound healing following injury is the re-establishment of an intact epithelium. Recruitment and activation of mesenchymal cells to the site of injury initiates limited deposition of ECM into the wound space &#x2013; this provisional matrix acts as a scaffold for normal tissue repair. Subsequent contraction of activated fibroblasts/myofibroblasts within this matrix approximates the epithelial margins to allow re-epithelialization and wound closure.</p>
      <p>An early and consistent feature of pulmonary fibrosis in humans is a change in the phenotype of the AEC, suggesting that ongoing AEC injury is a critical step in the pathogenesis of pulmonary fibrosis (<xref ref-type="bibr" rid="b115">Kasper and Haroske, 1996</xref>; <xref ref-type="bibr" rid="b42">Chilosi <italic>et al</italic>., 2002</xref>). These changes include apoptosis (<xref ref-type="bibr" rid="b143">Kuwano <italic>et al</italic>., 1996</xref>; <xref ref-type="bibr" rid="b208">Plataki <italic>et al</italic>., 2005</xref>), regenerative hyperplasia (<xref ref-type="bibr" rid="b50">Corrin <italic>et al</italic>., 1985</xref>), bronchiolarization (<xref ref-type="bibr" rid="b243">Sutinen <italic>et al</italic>., 1980</xref>; <xref ref-type="bibr" rid="b118">Kawanami <italic>et al</italic>., 1982</xref>) and proliferation (<xref ref-type="bibr" rid="b116">Katzenstein, 1985</xref>). AEC apoptosis is a well-recognized histological finding in IPF (<xref ref-type="bibr" rid="b143">Kuwano <italic>et al</italic>., 1996</xref>; <xref ref-type="bibr" rid="b251">Uhal <italic>et al</italic>., 1998</xref>; <xref ref-type="bibr" rid="b15">Barbas-Filho <italic>et al</italic>., 2001</xref>; <xref ref-type="bibr" rid="b162">Maeyama <italic>et al</italic>., 2001</xref>; <xref ref-type="bibr" rid="b208">Plataki <italic>et al</italic>., 2005</xref>). The underlying mechanisms involved are unclear, but numerous mediators/mechanisms have been proposed, including TGF-&#x3B2; (<xref ref-type="bibr" rid="b151">Lee <italic>et al</italic>., 2004</xref>), Fas activation (<xref ref-type="bibr" rid="b162">Maeyama <italic>et al</italic>., 2001</xref>), angiotensin II (ANGII) and reactive oxygen species (<xref ref-type="bibr" rid="b254">Waghray <italic>et al</italic>., 2005</xref>). More recently, the alveolar epithelium of patients with IPF has been shown to express markers of endoplasmic reticulum stress and the unfolded protein response (<xref ref-type="bibr" rid="b139">Korfei <italic>et al</italic>., 2008</xref>; <xref ref-type="bibr" rid="b148">Lawson <italic>et al</italic>., 2008</xref>). Activation of these pathways may result from altered surfactant protein processing or chronic herpesvirus infection. The persistent apoptosis and dysregulated proliferation of epithelial cells impairs adequate epithelial reconstitution, and also drives the inappropriate crosstalk between the epithelium and mesenchyme. For instance, the injured epithelium can contribute to fibrogenesis through the generation of pro-fibrotic cytokines such as TGF-&#x3B2; (<xref ref-type="bibr" rid="b270">Xu <italic>et al</italic>., 2003</xref>), and the targeting of such epithelial-derived mediators as potential therapeutic strategies in IPF will be discussed in later sections.</p>
    </sec>
    <sec sec-type="">
      <title>The myofibroblast response in IPF</title>
      <p>The myofibroblast has long been regarded as a major cell type involved in normal wound healing, and as the key effector cell in fibrogenesis. Myofibroblasts are highly synthetic for collagen and other ECM components, and are characterized by the <italic>de novo</italic> expression of &#x3B1;-smooth muscle actin (&#x3B1;-SMA) [reviewed in (<xref ref-type="bibr" rid="b225">Scotton and Chambers, 2007</xref>)]. The presence of myofibroblasts in fibrotic lesions in animal models of fibrosis correlates with the development of active fibrosis, and their persistence and localization to fibrotic foci in human disease is associated with disease progression (<xref ref-type="bibr" rid="b142">Kuhn and McDonald, 1991</xref>; <xref ref-type="bibr" rid="b276">Zhang <italic>et al</italic>., 1994a</xref>). Myofibroblasts isolated from the lungs of IPF patients also exhibit an enhanced migratory phenotype (<xref ref-type="bibr" rid="b242">Suganuma <italic>et al</italic>., 1995</xref>) and are capable of releasing numerous pro-fibrotic mediators (<xref ref-type="bibr" rid="b178">Moodley <italic>et al</italic>., 2003</xref>). In addition, when cultured <italic>ex vivo</italic> they are more resistant to apoptosis (<xref ref-type="bibr" rid="b214">Ramos <italic>et al</italic>., 2001</xref>; <xref ref-type="bibr" rid="b179">Moodley <italic>et al</italic>., 2004</xref>) &#x2013; this failure of apoptosis may explain the persistence of these highly activated cells at sites of injury.</p>
      <p>Originally thought to be derived from the local proliferation and differentiation of resident fibroblasts in the presence of a highly pro-fibrotic cytokine milieu (<xref ref-type="bibr" rid="b277">Zhang <italic>et al</italic>., 1994b</xref>; <xref ref-type="bibr" rid="b203">Phan, 2002</xref>), recent pioneering research demonstrated that myofibroblasts in pulmonary fibrosis can be derived from several other cellular sources. First, there is now growing evidence that myofibroblasts can be derived from the epithelium via EMT. During this process, epithelial cells lose their characteristic markers (e.g. E-cadherin and zona occludens-1) and acquire mesenchymal markers (e.g. fibroblast-specific protein-1 and &#x3B1;-SMA) (<xref ref-type="bibr" rid="b83">Grunert <italic>et al</italic>., 2003</xref>). The concept of EMT has been recognized for over 20 years, and evidence is now accumulating to support a role for EMT in IPF. AECs <italic>in vitro</italic> undergo EMT in response to prolonged exposure to major fibrogenic mediators (e.g. TGF-&#x3B2;1) when cultured on a provisional wound matrix (<xref ref-type="bibr" rid="b263">Willis <italic>et al</italic>., 2005</xref>). Elegant lineage tracing studies have also provided strong support for EMT as a potential source of myofibroblasts during lung fibrogenesis (<xref ref-type="bibr" rid="b126">Kim <italic>et al</italic>., 2006</xref>; <xref ref-type="bibr" rid="b127">2009</xref>;). In terms of human disease evidence, the notion of EMT is supported by the observation that cells in IPF biopsy samples co-express epithelial and mesenchymal markers (<xref ref-type="bibr" rid="b127">Kim <italic>et al</italic>., 2009</xref>) although this was not a universal finding (<xref ref-type="bibr" rid="b272">Yamada <italic>et al</italic>., 2008</xref>). The molecular pathways underlying the development of EMT are coming to light and may present novel avenues for therapeutic intervention. Current evidence suggests key roles for TGF-&#x3B2;1, Wnt and Notch signalling pathways. This will be explored in greater detail in future sections.</p>
      <p>A second hypothesis regarding the origin of (myo)fibroblasts in lung fibrosis proposes that these cells may be derived from circulating fibrocytes (<xref ref-type="bibr" rid="b145">Lama and Phan, 2006</xref>). Fibrocytes were originally identified as collagen I + /CD34+/CD45RO+ cells that are likely derived from hematopoietic stem cells (<xref ref-type="bibr" rid="b36">Bucala <italic>et al</italic>., 1994</xref>). Support for a pathogenic role for fibrocytes in lung fibrosis has been provided from studies showing that blockade of fibrocyte recruitment is protective following experimental lung injury in rodents (<xref ref-type="bibr" rid="b205">Phillips <italic>et al</italic>., 2004</xref>; <xref ref-type="bibr" rid="b180">Moore <italic>et al</italic>., 2005</xref>). A major role has been identified for the CXCR4/CXCL12 axis in the recruitment of fibrocytes (<xref ref-type="bibr" rid="b205">Phillips <italic>et al</italic>., 2004</xref>) although several chemokines have been shown to be capable of recruiting fibrocytes <italic>in vivo</italic>. Whether fibrocyte-derived fibroblasts are capable of differentiating into fully activated myofibroblasts, especially in patients with IPF, remains the subject of an interesting debate, although recent evidence suggests that about 10% of fibrocytes express &#x3B1;-SMA in the bleomycin model (<xref ref-type="bibr" rid="b171">Mehrad <italic>et al</italic>., 2009</xref>). Moreover, CXCL12 levels are increased in both plasma and bronchoalveolar lavage fluid (BALF) from patients with IPF and CXCR4/fibrocyte/mesenchymal marker co-expression studies support the notion that circulating fibrocytes may contribute to the expansion of the fibroblast/myofibroblast population in IPF (<xref ref-type="bibr" rid="b5">Andersson-Sjoland <italic>et al</italic>., 2008</xref>) Finally, a recent report has shown that a &gt;5% blood fibrocyte count is associated with poor survival in IPF (<xref ref-type="bibr" rid="b175">Moeller <italic>et al</italic>., 2009</xref>).</p>
      <p>In addition to the above cellular sources, there is very recent experimental evidence that lung capillary endothelial cells may also give rise to fibroblasts through endothelial&#x2013;mesenchymal transition in a bleomycin-induced lung fibrosis model (<xref ref-type="bibr" rid="b91">Hashimoto <italic>et al</italic>., 2010</xref>). Finally, myofibroblasts can also be derived from pericytes. In the liver, pericytes, or hepatic stellate cells, are the principal collagen-producing cell in hepatic fibrosis [reviewed in (<xref ref-type="bibr" rid="b81">Gressner and Weiskirchen, 2006</xref>)]. In animal studies of skin and kidney fibrosis (<xref ref-type="bibr" rid="b103">Humphreys <italic>et al</italic>., 2010</xref>; <xref ref-type="bibr" rid="b158">Liu <italic>et al</italic>., 2010b</xref>), pericytes have also been shown to represent a source of myofibroblasts. However, despite the suggestion that the pericyte may contribute to the myofibroblast population in lung fibrosis (<xref ref-type="bibr" rid="b1">Adler <italic>et al</italic>., 1989</xref>), the role of this cell type in IPF remains uncertain.</p>
      <p>Although the relative contribution of each of these potential cellular sources of fibroblasts/myofibroblasts to fibrogenesis in IPF remains unclear, the realization that fibrogenic cells may be derived from multiple cellular sources, in addition to resident fibroblasts, has opened up a myriad of new possibilities for therapeutic intervention. Molecules felt to be important in this regard will be addressed in subsequent sections.</p>
    </sec>
    <sec sec-type="">
      <title>Recently completed major placebo-controlled phase III trials in IPF</title>
      <sec>
        <title>IFN&#x3B3;1b</title>
        <p>Interferon (IFN)-&#x3B3; is an immunoregulatory cytokine that is crucial in both the innate and acquired immune responses. It is predominantly generated by natural killer cells and activated T-helper (Th) 1 cells (<xref ref-type="bibr" rid="b183">Murphy <italic>et al</italic>., 2000</xref>), which led to the suggestion that it may have a therapeutic benefit in IPF by redressing the perceived dominance of Th2 cytokines in this disease (<xref ref-type="bibr" rid="b266">Wynn, 2004</xref>). However, IFN-&#x3B3; also plays a role in counter-regulating TGF-&#x3B2; expression and signalling responses (<xref ref-type="bibr" rid="b253">Ulloa <italic>et al</italic>., 1999</xref>). Moreover, IFN-&#x3B3; limits fibroblast proliferation and collagen synthesis directly (<xref ref-type="bibr" rid="b219">Rosenbloom <italic>et al</italic>., 1986</xref>; <xref ref-type="bibr" rid="b66">Elias <italic>et al</italic>., 1987</xref>; <xref ref-type="bibr" rid="b67">1990</xref>;) and IFN-&#x3B3; administration attenuates bleomycin-induced fibrosis in mice (<xref ref-type="bibr" rid="b86">Gurujeyalakshmi and Giri, 1995</xref>). IFN-&#x3B3; has been extensively investigated as a novel therapy for IPF following an initial preliminary trial suggesting that lung function improved in patients with IPF treated with IFN-&#x3B3; (<xref ref-type="bibr" rid="b283">Ziesche <italic>et al</italic>., 1999</xref>). <italic>Post hoc</italic> analysis of a second, similarly designed trial (<xref ref-type="bibr" rid="b211">Raghu <italic>et al</italic>., 2004</xref>), suggested that patients with relatively well-preserved lung function may have a survival benefit with IFN-&#x3B3; treatment. The most recent trial investigating the efficacy of IFN-&#x3B3; (Intermune, USA) used overall survival time from randomization as its primary end point (<xref ref-type="bibr" rid="b130">King <italic>et al</italic>., 2009</xref>). However, this study was terminated prematurely at a planned interim analysis stage. Results showed that overall survival had crossed the predefined boundary for lack of benefit; in fact, among the randomized patients, there was no significant difference between treatment arms in overall mortality. Interest persists in IFN-&#x3B3; as a potential therapeutic agent in IPF. To this end, a phase I pilot study is currently recruiting patients to evaluate the safety and efficacy of nebulized IFN-&#x3B3; in IPF, which may help address concerns about the most appropriate mode of administration of this cytokine in this condition.</p>
      </sec>
      <sec>
        <title>Pirfenidone</title>
        <p>Pirfenidone is an orally available pyridine derivative that has recently received much interest in IPF in view of its anti-fibrotic (<xref ref-type="bibr" rid="b87">Gurujeyalakshmi <italic>et al</italic>., 1999</xref>; <xref ref-type="bibr" rid="b106">Iyer <italic>et al</italic>., 1999</xref>; <xref ref-type="bibr" rid="b97">Hewitson <italic>et al</italic>., 2001</xref>; <xref ref-type="bibr" rid="b60">Di Sario <italic>et al</italic>., 2002</xref>), anti-inflammatory (<xref ref-type="bibr" rid="b107">Iyer <italic>et al</italic>., 2000</xref>; <xref ref-type="bibr" rid="b88">Hale <italic>et al</italic>., 2002</xref>; <xref ref-type="bibr" rid="b186">Nakazato <italic>et al</italic>., 2002</xref>; <xref ref-type="bibr" rid="b190">Oku <italic>et al</italic>., 2002</xref>) and antioxidant properties (<xref ref-type="bibr" rid="b78">Giri <italic>et al</italic>., 1999</xref>). Its potential role in this disease is the subject of an excellent review by Maher (<xref ref-type="bibr" rid="b163">Maher, 2010</xref>). Briefly, pirfenidone has been shown to inhibit fibroblast proliferation and collagen synthesis <italic>in vitro</italic> (<xref ref-type="bibr" rid="b97">Hewitson <italic>et al</italic>., 2001</xref>; <xref ref-type="bibr" rid="b60">Di Sario <italic>et al</italic>., 2002</xref>) as well as inhibiting TGF-&#x3B2; induced heat shock protein HSP47 expression, a molecular chaperone of collagen, the synthesis of which is known to correlate with fibroblast ECM deposition. <italic>In vivo</italic> pirfenidone attenuates bleomycin-induced lung fibrosis when dosed either prophylactically or therapeutically (<xref ref-type="bibr" rid="b105">Iyer <italic>et al</italic>., 1995</xref>; <xref ref-type="bibr" rid="b112">Kakugawa <italic>et al</italic>., 2004</xref>), and this attenuation is associated with a reduction in lung platelet derived growth factor (PDGF) and TGF-&#x3B2; levels (<xref ref-type="bibr" rid="b87">Gurujeyalakshmi <italic>et al</italic>., 1999</xref>; <xref ref-type="bibr" rid="b106">Iyer <italic>et al</italic>., 1999</xref>). Its anti-inflammatory properties are manifested by an attenuation in TNF-&#x3B1; and IFN-&#x3B3; levels in experimental models of inflammation (<xref ref-type="bibr" rid="b107">Iyer <italic>et al</italic>., 2000</xref>; <xref ref-type="bibr" rid="b186">Nakazato <italic>et al</italic>., 2002</xref>; <xref ref-type="bibr" rid="b190">Oku <italic>et al</italic>., 2002</xref>). However, the precise molecular mechanism of action of pirfenidone remains unknown. Nonetheless, in light of promising data derived from animal models of fibrosis, pirfenidone has been the subject of a number of trials in IPF. The most recently published of these, a randomized double-blinded, placebo-controlled trial (Shionogi, Japan) demonstrated a significant reduction in decline in vital capacity in the treatment arm compared with the placebo arm (<xref ref-type="bibr" rid="b248">Taniguchi <italic>et al</italic>., 2010</xref>). However, the change in end point during the course of the trial has been highlighted as problematic in terms of drawing any firm conclusions regarding the use of pirfenidone in IPF patients (<xref ref-type="bibr" rid="b48">Collard, 2010</xref>). The results of two other Phase III trials (Intermune, USA) have, to date, been presented in abstract form only at international meetings and as such the results have yet to be subjected to rigorous peer review. Briefly, however, it appears from the presented data that pirfenidone treatment resulted in a significant reduction in FVC decline compared with placebo in the CAPACITY 2 trial at 72 weeks, although no such significance was reached in the CAPACITY 1 trial. Clearly, pirfenidone represents a potentially important advance in IPF therapy, and we look forward to the publication of data derived from these studies.</p>
      </sec>
      <sec>
        <title>Etanercept</title>
        <p>The long-standing interest in TNF-&#x3B1; as a target in IPF reflects no shortage of evidence indicating that expression of this master cytokine is increased in the lungs of patients with lung fibrosis (<xref ref-type="bibr" rid="b187">Nash <italic>et al</italic>., 1993</xref>; <xref ref-type="bibr" rid="b207">Piguet <italic>et al</italic>., 1993</xref>; <xref ref-type="bibr" rid="b282">Ziegenhagen <italic>et al</italic>., 1998</xref>), with expression localizing in particular to epithelial cells and macrophages. Moreover, functional polymorphisms of TNF-&#x3B1; are associated with an increased risk of developing IPF (<xref ref-type="bibr" rid="b260">Whyte <italic>et al</italic>., 2000</xref>). A causative role for TNF-&#x3B1; in the pathogenesis of pulmonary fibrosis is suggested by observations that blocking TNF-&#x3B1; signalling attenuates bleomycin-induced fibrosis (<xref ref-type="bibr" rid="b206">Piguet <italic>et al</italic>., 1989</xref>; <xref ref-type="bibr" rid="b278">Zhang <italic>et al</italic>., 1997</xref>; <xref ref-type="bibr" rid="b192">Ortiz <italic>et al</italic>., 1998</xref>; <xref ref-type="bibr" rid="b189">Oikonomou <italic>et al</italic>., 2006</xref>). Furthermore, local pulmonary overexpression of TNF-&#x3B1; results in fibroblast accumulation and increased deposition of ECM proteins in the pulmonary interstitium (<xref ref-type="bibr" rid="b172">Miyazaki <italic>et al</italic>., 1995</xref>; <xref ref-type="bibr" rid="b235">Sime <italic>et al</italic>., 1998</xref>). More recently, the importance of soluble TNF-&#x3B1; in mediating the transition from bleomycin-induced inflammation to fibrosis, a transition accompanied by lymphocyte recruitment, has been demonstrated in mice (<xref ref-type="bibr" rid="b189">Oikonomou <italic>et al</italic>., 2006</xref>). This latter observation highlights the potential importance of TNF-&#x3B1; in influencing the adaptive immune system [reviewed in (<xref ref-type="bibr" rid="b133">Kollias <italic>et al</italic>., 1999</xref>)] and potentially, the polarization of the Th immune response to lung injury. However, in contrast to these promising preclinical studies, the soluble TNF-&#x3B1; receptor antagonist Etanercept proved disappointing in a subsequent randomized, double-blinded, placebo-controlled trial (Wyeth, USA) in IPF patients with no significant improvement in lung function parameters observed (<xref ref-type="bibr" rid="b212">Raghu <italic>et al</italic>., 2008</xref>). However, a non-significant trend towards improvement in a composite of these indices was noted following secondary analysis.</p>
      </sec>
      <sec>
        <title>Imatinib</title>
        <p>There has been long-standing interest in the potent fibroblast mitogen and chemoattractant, PDGF, as a target in fibrosis, including lung fibrosis (<xref ref-type="bibr" rid="b6">Antoniades <italic>et al</italic>., 1990</xref>). Although PDGF has been shown to induce procollagen production by fibroblasts <italic>in vitro</italic> (<xref ref-type="bibr" rid="b152">Lepisto <italic>et al</italic>., 1995</xref>), it may play a greater role in expanding the fibroblast accumulation at sites of injury (<xref ref-type="bibr" rid="b46">Clark <italic>et al</italic>., 1993</xref>). Most attention has been focused on the two PDGF isoforms, PDGF-A and &#x2013;B, which homo- and heterodimerize, and stimulate tyrosine kinase signalling via interaction with the PDGF-&#x3B1; or -&#x3B2; receptors. The tyrosine kinase inhibitor, Imatinib mesylate (Novartis, Switzerland) has activity against the PDGF receptor, but the anti-fibrotic potential of this drug may reflect multiple potential modes of action. For example, imatinib inhibits signalling pathways directly downstream of TGF-&#x3B2;, in part through inhibition of c-Abl tyrosine phosphorylation (<xref ref-type="bibr" rid="b53">Daniels <italic>et al</italic>., 2004</xref>). It also inhibits the stem cell factor/c-kit axis (<xref ref-type="bibr" rid="b258">Wang <italic>et al</italic>., 2000b</xref>) and collagen-induced Discoidin Domain Receptor-1 activation (<xref ref-type="bibr" rid="b56">Day <italic>et al</italic>., 2008</xref>), two pathways recently implicated in the development of bleomycin-induced fibrosis in mice (<xref ref-type="bibr" rid="b13">Avivi-Green <italic>et al</italic>., 2006</xref>; <xref ref-type="bibr" rid="b61">Ding <italic>et al</italic>., 2010</xref>).</p>
        <p>Preclinical studies demonstrated that imatinib reduces collagen deposition and mesenchymal cell proliferation in the bleomycin model when dosed prophylactically (<xref ref-type="bibr" rid="b53">Daniels <italic>et al</italic>., 2004</xref>; <xref ref-type="bibr" rid="b8">Aono <italic>et al</italic>., 2005</xref>), but this was not the case when imatinib was administered in a therapeutic schedule (day 14 post bleomycin onwards) (<xref ref-type="bibr" rid="b8">Aono <italic>et al</italic>., 2005</xref>). In a recent multi-centre, randomized, placebo-controlled trial (Novartis, Switzerland) of patients with mild to moderate IPF followed for 96 weeks (<xref ref-type="bibr" rid="b54">Daniels <italic>et al</italic>., 2010</xref>) imatinib did not affect survival or lung function. The use of other tyrosine kinase inhibitors will be discussed in brief in later sections.</p>
      </sec>
      <sec>
        <title>Endothelin receptor antagonists</title>
        <p>Endothelin-1 (ET-1) expression is up-regulated in IPF (<xref ref-type="bibr" rid="b77">Giaid <italic>et al</italic>., 1993</xref>; <xref ref-type="bibr" rid="b223">Saleh <italic>et al</italic>., 1997b</xref>). Aside from promoting fibroblast proliferation (<xref ref-type="bibr" rid="b199">Peacock <italic>et al</italic>., 1992</xref>; <xref ref-type="bibr" rid="b231">Shahar <italic>et al</italic>., 1999</xref>), collagen synthesis (<xref ref-type="bibr" rid="b269">Xu <italic>et al</italic>., 1998</xref>) and differentiation into myofibroblasts (<xref ref-type="bibr" rid="b231">Shahar <italic>et al</italic>., 1999</xref>; <xref ref-type="bibr" rid="b233">Shi-Wen <italic>et al</italic>., 2004</xref>), it is an extremely potent mitogen for endothelial cells (<xref ref-type="bibr" rid="b201">Pedram <italic>et al</italic>., 1997</xref>) and vascular smooth muscle cells (<xref ref-type="bibr" rid="b136">Komuro <italic>et al</italic>., 1988</xref>), thus potentially contributing to neovascularization. In a rodent model of fibrosis, the administration of bosentan, a non-selective ET-1(A) and ET-1(B) receptor antagonist, attenuates bleomycin-induced fibrosis (<xref ref-type="bibr" rid="b198">Park <italic>et al</italic>., 1997</xref>), although this was not a universal finding (<xref ref-type="bibr" rid="b185">Mutsaers <italic>et al</italic>., 1998</xref>). The BUILD-1 trial (Actelion, Switzerland) evaluated the effect of bosentan administration in patients with IPF but no evidence of severe pulmonary hypertension (PHT) (<xref ref-type="bibr" rid="b129">King <italic>et al</italic>., 2008</xref>). Although no significant difference between the bosentan and placebo arms was observed in the primary end point of 6 minute walk test distance, a trend in favour of bosentan was observed in the secondary end point of time to death or disease progression. <italic>Post hoc</italic> analysis of data pertaining to these secondary end points, however, did demonstrate a significant benefit in the bosentan arm in those IPF patients who had undergone a lung biopsy to reach a diagnosis of IPF. The BUILD-3 trial (Actelion, Switzerland), which has finished recruiting patients, is a randomized double-blinded placebo-controlled trial, designed to explore the effect of bosentan on disease progression in this subset of patients. The ET-1(A) receptor antagonist, ambrisentan, is Food and Drug Administration approved for the treatment of PHT, and its potential in delaying disease progression in IPF patients without PHT was recently the subject of a prospective, double-blinded randomized placebo-controlled trial (ARTEMIS-IPF; Gilead, USA). Unfortunately, this trial was terminated at an interim analysis stage due to lack of efficacy. An additional trial investigating the efficacy of endothelin antagonists in IPF is currently ongoing: the MUSIC trial (Actelion, Switzerland) is a randomized double-blinded placebo-controlled trial designed to examine the effect of the dual endothelin receptor antagonist, macicentan, on FVC, and has finished recruiting patients.</p>
      </sec>
      <sec>
        <title>NAC</title>
        <p>Under normal conditions, lung epithelial cells are protected from damage by reactive oxidative species (ROS) by antioxidants, such as glutathione (<xref ref-type="bibr" rid="b215">Reddy <italic>et al</italic>., 2007</xref>). However, these defences may be inadequate in the face of excessive ROS generation. Oxidative stress is a feature of the IPF lung (<xref ref-type="bibr" rid="b108">Jack <italic>et al</italic>., 1996</xref>; <xref ref-type="bibr" rid="b177">Montuschi <italic>et al</italic>., 1998</xref>) and extracellular (<xref ref-type="bibr" rid="b38">Cantin <italic>et al</italic>., 1989</xref>; <xref ref-type="bibr" rid="b20">Behr <italic>et al</italic>., 1995</xref>; <xref ref-type="bibr" rid="b18">Beeh <italic>et al</italic>., 2002</xref>; <xref ref-type="bibr" rid="b176">Montaldo <italic>et al</italic>., 2002</xref>) and intracellular (<xref ref-type="bibr" rid="b21">Behr <italic>et al</italic>., 2002</xref>) glutathione levels are reduced in IPF. Aside from being directly injurious to epithelial cell macromolecules and DNA, excess ROS can influence several pro-fibrotic cellular processes; for instance, myofibroblasts derived from IPF lung generate hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), which may serve as a paracrine signal inducing apoptosis in the overlying epithelial cells (<xref ref-type="bibr" rid="b254">Waghray <italic>et al</italic>., 2005</xref>).</p>
        <p>NAC, a derivative of cysteine, augments the synthesis of glutathione both <italic>in vitro</italic> (<xref ref-type="bibr" rid="b204">Phelps <italic>et al</italic>., 1992</xref>) and <italic>in vivo</italic> (<xref ref-type="bibr" rid="b30">Borok <italic>et al</italic>., 1991a</xref>), thus contributing to the replenishment of glutathione stores and bolstering epithelial cell antioxidant defence. NAC is one of the few agents whose success in attenuating experimentally-induced fibrosis in animal models (<xref ref-type="bibr" rid="b232">Shahzeidi <italic>et al</italic>., 1991</xref>) has been translated, to some degree at least, into a clinical benefit in IPF (<xref ref-type="bibr" rid="b57">Demedts <italic>et al</italic>., 2005</xref>). The IFIGENIA trial (ZambonSpA, Italy) demonstrated a significant reduction in the rate of decline of FVC and transfer factor (DL<sub>co</sub>) in the NAC treatment arm, although this effect did not translate into increased survival at one year. These data have supported the recent addition of NAC to standard therapy in IPF, despite a number of concerns regarding the trial that have been highlighted elsewhere (<xref ref-type="bibr" rid="b19">Behr and Noble, 2009</xref>). In particular, as the treatment and placebo arms of the trial were add-on therapies to prednisolone and azathioprine, it is difficult to be sure that the beneficial effect of NAC is only observed in those patients on such therapy. The results of the PANTHER trial, outlined earlier, should help clarify these questions.</p>
      </sec>
    </sec>
    <sec sec-type="">
      <title>Current drug targets in IPF</title>
      <sec>
        <title>TGF&#x3B2;1</title>
        <p>TGF-&#x3B2; exists as one of three isoforms in humans, TGF-&#x3B2;1&#x2013;3, and there continues to be overwhelming evidence that, of these isoforms, TGF-&#x3B2;1 plays a major mechanistic role in fibrogenesis in numerous fibrotic disorders, including IPF. Although all isoforms are potent stimulators of lung fibroblast procollagen production <italic>in vitro</italic>, only TGF-&#x3B2;1 gene expression is increased in murine lung following bleomycin challenge (<xref ref-type="bibr" rid="b47">Coker <italic>et al</italic>., 1997</xref>), and immunohistochemical analysis of lungs from patients with pulmonary fibrosis demonstrates strong immunoreactivity for TGF-&#x3B2;1, but not for TGF-&#x3B2;2/3 (<xref ref-type="bibr" rid="b124">Khalil <italic>et al</italic>., 1996</xref>). Transient overexpression of TGF-&#x3B2;3 in rat lungs is capable of inducing a fibrotic response, but this is less severe and progressive than that which results from TGF-&#x3B2;1 overexpression (<xref ref-type="bibr" rid="b10">Ask <italic>et al</italic>., 2008</xref>). Paradoxically, in other models of fibrosis, including dermal and liver fibrosis, TGF-&#x3B2;3 appears to be anti-fibrotic (<xref ref-type="bibr" rid="b230">Shah <italic>et al</italic>., 1995</xref>; <xref ref-type="bibr" rid="b280">Zhang <italic>et al</italic>., 2010</xref>), and recombinant TGF-&#x3B2;3 is currently being evaluated in Phase II trials as a tool to promote scar-free healing following skin injury. The exact mechanism of action remains unclear, although modulation of macrophage infiltration (<xref ref-type="bibr" rid="b230">Shah <italic>et al</italic>., 1995</xref>) and the promotion of an MMP-dominant microenvironment (<xref ref-type="bibr" rid="b280">Zhang <italic>et al</italic>., 2010</xref>) have been postulated. However, no such data currently exist to demonstrate a similar effect in lung fibrosis, and the remainder of this section will focus on strategies targeting TGF-&#x3B2;1 signalling.</p>
        <p>TGF-&#x3B2;1 is the most potent inducer of fibroblast ECM production characterized to date (<xref ref-type="bibr" rid="b209">Raghow <italic>et al</italic>., 1987</xref>; <xref ref-type="bibr" rid="b194">Overall <italic>et al</italic>., 1989</xref>; <xref ref-type="bibr" rid="b160">McAnulty <italic>et al</italic>., 1991</xref>), and promotes fibroblast to myofibroblast differentiation (<xref ref-type="bibr" rid="b41">Chambers <italic>et al</italic>., 2003</xref>; <xref ref-type="bibr" rid="b240">Subramanian <italic>et al</italic>., 2004</xref>). Overexpression of TGF-&#x3B2;1 is sufficient to drive progressive fibrosis in mice (<xref ref-type="bibr" rid="b234">Sime <italic>et al</italic>., 1997</xref>) and TGF-&#x3B2;1 has more recently been shown to drive either epithelial cell apoptosis (<xref ref-type="bibr" rid="b273">Yanagisawa <italic>et al</italic>., 1998</xref>) or EMT (<xref ref-type="bibr" rid="b127">Kim <italic>et al</italic>., 2009</xref>) (<xref ref-type="bibr" rid="b263">Willis <italic>et al</italic>., 2005</xref>), depending on the composition of the ECM. A number of strategies aimed at interfering with TGF-&#x3B2;1-induced cellular responses have been developed, although there remains concern that TGF-&#x3B2;1 plays essential roles in regulating inflammation and acts as a tumour suppressor in certain contexts. If these strategies interfere with TGF-&#x3B2;1's homeostatic roles, this may carry the liability of highly undesirable side effects; especially in light of the fact that many IPF patients will have a previous smoking history and will already be at heightened risk of developing lung cancer (<xref ref-type="bibr" rid="b195">Ozawa <italic>et al</italic>., 2009</xref>).</p>
      </sec>
      <sec>
        <title>TGF-&#x3B2; inhibition</title>
        <p>Both pan-TGF-&#x3B2; and TGF-&#x3B2;1, -&#x3B2;2 and -&#x3B2;3 isoform-specific antibodies are in development for multiple indications, including IPF. Cambridge Antibody Technology (UK) and Genzyme (UK) have recently completed a Phase I clinical trial in IPF patients with GC1008 &#x2013; a neutralizing antibody that targets all three mammalian isoforms. We await the publication of the results of this study with interest.</p>
      </sec>
      <sec>
        <title>Inhibition of TGF-&#x3B2; signalling</title>
        <p>Approaches aimed at inhibiting active TGF-&#x3B2; signalling have also been intensely investigated in several disease indications with much of this effort focused on the development of inhibitors of the high-affinity serine/threonine kinase receptor TGF-&#x3B2;RI (activin-like kinase receptor-5). Orally active activin-like kinase receptor-5 kinase inhibitors, e.g. SB-525334 (GlaxoSmithKline, UK) have been shown to attenuate bleomycin-induced pulmonary fibrosis (<xref ref-type="bibr" rid="b98">Higashiyama <italic>et al</italic>., 2007</xref>) and have also been shown to be effective in blocking fibrotic progression in TGF-&#x3B2;1 lung overexpression studies (SD-208; Scios Inc., USA) (<xref ref-type="bibr" rid="b27">Bonniaud <italic>et al</italic>., 2005</xref>).</p>
      </sec>
      <sec>
        <title>Blockade of TGF-&#x3B2; activation</title>
        <p>As mentioned above, direct TGF-&#x3B2; blocking strategies may carry high liabilities with respect to interfering with key homeostatic functions of TGF-&#x3B2;. Another approach that has gained much favour is to develop strategies aimed at blocking TGF-&#x3B2; at the level of activation. TGF-&#x3B2; bioactivity is controlled on a number of levels, with latent TGF-&#x3B2; activation representing one of the key rate-limiting steps. This is dependent on the dissociation of TGF-&#x3B2; from the TGF-&#x3B2; latency-associated peptide (LAP). Depending on cell type, TGF-&#x3B2; activation is mediated by proteolytic cleavage or by the proteolytic-independent interaction of LAP with integrins or the matrix glycoprotein thrombospondin-1 (reviewed in [<xref ref-type="bibr" rid="b184">Murphy-Ullrich and Poczatek, 2000</xref>; <xref ref-type="bibr" rid="b264">Wipff and Hinz, 2008</xref>)]. In the context of lung fibrosis, integrin-dependent mechanisms are felt to be particularly important. Integrins <italic>&#x3B1;</italic>v<italic>&#x3B2;</italic>6, <italic>&#x3B1;</italic>v<italic>&#x3B2;</italic>5, <italic>&#x3B1;</italic>v<italic>&#x3B2;</italic>3, and an as yet unidentified <italic>&#x3B2;</italic>1 integrin have been shown to activate latent TGF-<italic>&#x3B2;</italic>1 independently from any proteolytic activity &#x2013; they all recognize the RGD sequence of LAP-TGF-<italic>&#x3B2;</italic>1 as part of the ECM-bound large latent complex. When the large latent complex is covalently bound to a mechanically resistant ECM (as would be the case in fibrosis), cell traction forces exerted on LAP-TGF<italic>&#x3B2;</italic>1 result in a conformational change of the latent complex and liberates active TGF-<italic>&#x3B2;</italic>1 [reviewed in (<xref ref-type="bibr" rid="b264">Wipff and Hinz, 2008</xref>)]. There is strong <italic>in vitro</italic>, experimental animal and IPF patient immunohistochemistry data to support a key role for the epithelial-restricted integrin, &#x3B1;v&#x3B2;6, in the activation of TGF-&#x3B2;1 (<xref ref-type="bibr" rid="b182">Munger <italic>et al</italic>., 1999</xref>; <xref ref-type="bibr" rid="b110">Jenkins <italic>et al</italic>., 2006</xref>). Expression of this integrin is low in normal epithelial tissues and is significantly up-regulated in injured and inflamed epithelia (<xref ref-type="bibr" rid="b33">Breuss <italic>et al</italic>., 1995</xref>) including the activated epithelium in IPF (<xref ref-type="bibr" rid="b100">Horan <italic>et al</italic>., 2008</xref>). Targeting this integrin therefore reduces the theoretical possibility of interfering with wider TGF-&#x3B2; homeostatic roles. Partial inhibition of the &#x3B1;v&#x3B2;6 integrin by antibody blockade has been shown to prevent pulmonary fibrosis without exacerbating inflammation (<xref ref-type="bibr" rid="b100">Horan <italic>et al</italic>., 2008</xref>). A humanized monoclonal antibody (STX-100) has recently been evaluated in a completed Phase I clinical trial (Stromedix, USA) &#x2013; phase II trials are planned and this molecule has recently been granted orphan drug status in the USA.</p>
        <p>In addition to the epithelial integrin &#x3B1;v&#x3B2;6, the more widely expressed &#x3B1;v&#x3B2;5 integrin has also received much recent attention in the context of TGF-&#x3B2; activation by myofibroblasts in fibrosis [reviewed in (<xref ref-type="bibr" rid="b264">Wipff and Hinz, 2008</xref>)]. We have recently shown that this integrin is co-expressed by &#x3B1;-SMA positive myofibroblasts within IPF fibrotic foci (<xref ref-type="bibr" rid="b227">Scotton <italic>et al</italic>., 2009</xref>) but &#x3B1;v&#x3B2;5 staining was weak or absent on hyperplastic epithelial cells within the same tissue samples. This raises the possibility that this integrin may play a role in the activation of TGF-&#x3B2; within fibrotic foci while the <italic>&#x3B1;</italic>v<italic>&#x3B2;</italic>6 integrin is involved in the activation of TGF-&#x3B2; by the activated epithelium. Although dual &#x3B2;3 and &#x3B2;5 integrin deficient mice have recently been reported not to be protected from developing bleomycin-induced lung fibrosis (<xref ref-type="bibr" rid="b11">Atabai <italic>et al</italic>., 2009</xref>) it is worth bearing in mind that this model does not usually lead to the development of the typical fibrotic foci seen in patients with IPF.</p>
      </sec>
      <sec>
        <title>Other strategies to inhibit TGF-&#x3B2; signalling</title>
        <p>Of the three known human isoforms of TGF-&#x3B2;, TGF-&#x3B2;1 is thought to be the most important in human fibrotic lung disease (<xref ref-type="bibr" rid="b124">Khalil <italic>et al</italic>., 1996</xref>), and strategies to modulate TGF-&#x3B2;-mediated process have reflected this. However, therapies to influence TGF-&#x3B2;2 activity have resulted in clinical benefits to patients with pathologies in which this isoform is perhaps more dominant. These include the use of antisense oligonucleotides to block TGF-&#x3B2;2 expression in patients with high grade gliomas (<xref ref-type="bibr" rid="b224">Schlingensiepen <italic>et al</italic>., 2008</xref>) and it is conceivable that such strategies may be applicable to the TGF-&#x3B2;1 isoform in the future. Synthetically derived peptides have also been used to inhibit the TGF-&#x3B2; pathway. P144 (DigNA Biotech, Spain) is one such 14 mer peptide derived from the TGF-&#x3B2;1R3 sequence, which blocks binding of TGF-&#x3B2;1 to TGF-&#x3B2;R1 and has been demonstrated to attenuate experimentally induced liver fibrosis in rats (<xref ref-type="bibr" rid="b69">Ezquerro <italic>et al</italic>., 2003</xref>). A Phase II clinical study for the treatment of skin fibrosis in systemic sclerosis with topical application of P144 is currently recruiting patients.</p>
      </sec>
      <sec>
        <title>Connective tissue growth factor (CTGF)</title>
        <p>There has been a long-standing interest in the role of CTGF, a prototypic member of the CCN protein family, as a potential target in fibrosis, including lung fibrosis. CTGF was originally thought to be a specific downstream mediator of the pro-fibrotic effects of TGF-&#x3B2;, with a particular role in stimulating fibroblast matrix production and myofibroblast differentiation (<xref ref-type="bibr" rid="b150">Leask and Abraham, 2003</xref>). Its cell surface receptor and downstream signalling pathways have yet to be fully determined and there is now increasing support for the notion that CTGF may not act as a classical autocrine growth factor. In addition, it is now clear that CTGF is induced by a number of other pro-fibrotic mediators, including thrombin (<xref ref-type="bibr" rid="b40">Chambers <italic>et al</italic>., 2000</xref>). Despite the uncertainties about mechanisms of action, CTGF remains an interesting target in the context of a number of fibrotic disorders, including systemic sclerosis and IPF [reviewed in (<xref ref-type="bibr" rid="b149">Leask, 2009</xref>)]. CTGF expression is increased in IPF (<xref ref-type="bibr" rid="b4">Allen <italic>et al</italic>., 1999</xref>), and although adenoviral overexpression induces only mild and transient fibrosis in rats (<xref ref-type="bibr" rid="b25">Bonniaud <italic>et al</italic>., 2003</xref>), overexpression in mice confers susceptibility to bleomycin-induced fibrosis in the fibrosis-resistant Balb/c mouse strain (<xref ref-type="bibr" rid="b26">Bonniaud <italic>et al</italic>., 2004</xref>). Moreover, selective expression of CTGF in fibroblasts <italic>in vivo</italic> has recently been shown to promote systemic tissue fibrosis, including in the lung (<xref ref-type="bibr" rid="b237">Sonnylal <italic>et al</italic>., 2010</xref>). A Phase I clinical trial assessing a neutralizing antibody directed against CTGF (FG-3019; FibroGen, USA) was recently completed; the results demonstrate that this antibody is safe and well-tolerated. Further studies are required to assess potential therapeutic benefits of this antibody in IPF.</p>
      </sec>
      <sec>
        <title>IL-13</title>
        <p>There is growing evidence that the cytokine and chemokine response to an inciting agent determines whether the injury response is resolved or progresses to fibrosis. The Th hypothesis of fibrosis proposes that progressive pulmonary fibrosis results from a maladaptive immune response, dominated by Th2 cytokines, such as interleukin (IL)-13, to a persistent inciting agent [reviewed in (<xref ref-type="bibr" rid="b266">Wynn, 2004</xref>)]. Therapies aimed at redressing this imbalance may represent attractive anti-fibrotic strategies.</p>
        <p>IL-13 is the most extensively studied Th2 cytokine in the context of several fibroproliferative diseases, including IPF. IL-13 levels are increased in BALF from patients with pulmonary fibrosis (<xref ref-type="bibr" rid="b90">Hancock <italic>et al</italic>., 1998</xref>) and IL-13 promotes fibroblast collagen production (<xref ref-type="bibr" rid="b191">Oriente <italic>et al</italic>., 2000</xref>; <xref ref-type="bibr" rid="b221">Saito <italic>et al</italic>., 2003</xref>) and fibroblast to myofibroblast differentiation (<xref ref-type="bibr" rid="b221">Saito <italic>et al</italic>., 2003</xref>) <italic>in vitro</italic>. These effects may be direct or dependent on secondary mediators such as TGF-&#x3B2; (<xref ref-type="bibr" rid="b71">Fichtner-Feigl <italic>et al</italic>., 2006</xref>) and/or Found in Inflammatory Zone-1 (<xref ref-type="bibr" rid="b156">Liu <italic>et al</italic>., 2004</xref>). Mice deficient for IL-13 are protected from fluorescein isothiocyanate-induced lung fibrosis (<xref ref-type="bibr" rid="b135">Kolodsick <italic>et al</italic>., 2004</xref>) and IL-13 targeted therapies have proved successful in attenuating bleomycin-induced fibrosis in mice (<xref ref-type="bibr" rid="b22">Belperio <italic>et al</italic>., 2002</xref>; <xref ref-type="bibr" rid="b109">Jakubzick <italic>et al</italic>., 2003</xref>). More recently, IL-13 has also been shown to promote epithelial cell apoptosis <italic>in vitro</italic> (<xref ref-type="bibr" rid="b32">Borowski <italic>et al</italic>., 2008</xref>) and may therefore play a role in the abnormal epithelial&#x2013;mesenchymal crosstalk in IPF. Taken together, these observations support the notion that IL-13 may represent an attractive target for therapeutic intervention in IPF and other fibrotic lung diseases. An open label, non-randomized phase II trial investigating the effect of an anti-IL13 antibody (QAX576; Novartis, Switzerland) on IL-13 production in IPF has recently been concluded. Publication of the results is eagerly anticipated.</p>
      </sec>
      <sec>
        <title>CCL2</title>
        <p>There has long-standing interest in the major monocyte chemoattractant, CCL2/MCP-1, in pulmonary fibrosis based on the observation that this chemokine is elevated in BALF from IPF patients (<xref ref-type="bibr" rid="b14">Baran <italic>et al</italic>., 2007</xref>). Moreover, serum CCL2 levels may correlate with the clinical course of IPF (<xref ref-type="bibr" rid="b241">Suga <italic>et al</italic>., 1999</xref>). CCR2 knockout mouse studies (<xref ref-type="bibr" rid="b180">Moore <italic>et al</italic>., 2005</xref>) and CCL12 neutralizing antibody studies (<xref ref-type="bibr" rid="b181">Moore <italic>et al</italic>., 2006</xref>) in wild-type mice support a causal role for this chemokine axis in animal models of fibrosis. As well as being a potent chemoattractant for T cells, immature dendritic cells, mononuclear cells (<xref ref-type="bibr" rid="b218">Rose <italic>et al</italic>., 2003</xref>) and fibrocytes (<xref ref-type="bibr" rid="b180">Moore <italic>et al</italic>., 2005</xref>), CCL2 signalling may also promote fibrosis by inducing the expression of TGF-&#x3B2; (<xref ref-type="bibr" rid="b76">Gharaee-Kermani <italic>et al</italic>., 1996</xref>). In terms of the immune response to injury, CCL2 also exerts immunomodulatory effects, which in turn may contribute to the development of a Th2 cytokine dominated phenotype (<xref ref-type="bibr" rid="b114">Karpus <italic>et al</italic>., 1997</xref>; <xref ref-type="bibr" rid="b99">Hogaboam <italic>et al</italic>., 1998</xref>; <xref ref-type="bibr" rid="b84">Gu <italic>et al</italic>., 2000</xref>). A randomized double-blinded placebo-controlled trial to evaluate the safety and efficacy of the anti-CCL2 antibody, CNTO 888 (Centocor Inc, USA) is currently recruiting. Patients will be maintained on their current therapy and the primary end point is performance at lung function testing.</p>
      </sec>
    </sec>
    <sec sec-type="">
      <title>CXCR4 and CXCL12</title>
      <p>As outlined earlier, there has been much recent interest in the role of chemokines in recruiting fibrocytes to the injured lung. Although both the CCR2/CCL12 and CXCL12/CXCR4 axes have been shown to play important roles in murine models, in human IPF greater focus has been placed on the CXCL12/CXCR4 axis (<xref ref-type="bibr" rid="b205">Phillips <italic>et al</italic>., 2004</xref>). As such, there has been much interest in the development of CXCR4 antagonists for a number of indications, including cancer. Such agents may also be worth considering in the context of IPF. Alternative strategies targeting this axis include inhibition of CXCR4 expression &#x2013; hypoxia- and growth factor-induced CXCR4 expression in fibrocytes is attenuated by inhibition of mTOR, and administration of the mTOR inhibitor rapamycin to rodents significantly inhibited bleomycin-induced lung collagen deposition (<xref ref-type="bibr" rid="b236">Simler <italic>et al</italic>., 2002</xref>; <xref ref-type="bibr" rid="b171">Mehrad <italic>et al</italic>., 2009</xref>).</p>
    </sec>
    <sec sec-type="">
      <title>Angiotensin converting enzyme (ACE) and angiotensin II (ANG II)</title>
      <p>Angiotensin II is derived from the conversion of angiotensinogen (AGT) by ACE. ANG II is a potent inducer of epithelial apoptosis (<xref ref-type="bibr" rid="b256">Wang <italic>et al</italic>., 1999</xref>) and there is <italic>in vitro</italic> and <italic>in vivo</italic> evidence that these effects are mediated by the ANGII receptor subtype, AT(1) (<xref ref-type="bibr" rid="b153">Li <italic>et al</italic>., 2003a</xref>,<xref ref-type="bibr" rid="b154">b</xref>;). ANG II is also a potent inducer of procollagen production by human lung fibroblasts, at least in part via the autocrine action of TGF-&#x3B2; (<xref ref-type="bibr" rid="b170">Marshall <italic>et al</italic>., 2004</xref>). Recent studies have also provided evidence for the existence of an ANGII/TGF-&#x3B2;&#x2018;autocrine loop&#x2019;: human lung myofibroblasts derived from human IPF lung constitutively express more AGT and active TGF-&#x3B2; than control fibroblasts; in turn, induction of fibroblast to myofibroblast differentiation by TGF-&#x3B2; is associated with increased AGT expression (<xref ref-type="bibr" rid="b252">Uhal <italic>et al</italic>., 2007</xref>).</p>
      <p>ACE inhibitors such as captopril (<xref ref-type="bibr" rid="b257">Wang <italic>et al</italic>., 2000a</xref>), and AT(1) receptor antagonists such as losartan (<xref ref-type="bibr" rid="b170">Marshall <italic>et al</italic>., 2004</xref>) attenuate bleomycin-induced lung fibrosis. This response is associated with a reduction in epithelial cell apoptosis (<xref ref-type="bibr" rid="b257">Wang <italic>et al</italic>., 2000a</xref>; <xref ref-type="bibr" rid="b153">Li <italic>et al</italic>., 2003a</xref>) and TGF-&#x3B2; expression (<xref ref-type="bibr" rid="b193">Otsuka <italic>et al</italic>., 2004</xref>).</p>
      <p>In human disease, increased levels of ANGII are observed in IPF lung compared with non-fibrotic controls, localizing to apoptosing epithelial cells and myofibroblasts in fibrotic foci (<xref ref-type="bibr" rid="b155">Li <italic>et al</italic>., 2006</xref>), Moreover, ACE insertion/deletion polymorphisms are associated with susceptibility and outcome in acute respiratory distress syndrome (<xref ref-type="bibr" rid="b169">Marshall <italic>et al</italic>., 2002</xref>).</p>
      <p>In light of these observations, two trials to evaluate the efficacy of losartan in IPF are currently recruiting. The first will focus on vascular reactivity in IPF and is beyond the scope of this review. The second trial is a pilot intervention study (University of South Florida) evaluating the FVC response to losartan after 12 months treatment. The estimated completion date for this study is March 2012.</p>
    </sec>
    <sec sec-type="">
      <title>Targeting the coagulation cascade</title>
      <p>There is compelling evidence for a role for the coagulation cascade in driving the fibroproliferative response to lung injury [reviewed in (<xref ref-type="bibr" rid="b39">Chambers, 2008</xref>)]. Tissue factor is highly expressed on the hyperplastic epithelium in IPF (<xref ref-type="bibr" rid="b104">Imokawa <italic>et al</italic>., 1997</xref>) and thrombin levels are increased in BALF from patients with fibrotic lung disease (<xref ref-type="bibr" rid="b96">Hernandez-Rodriguez <italic>et al</italic>., 1995</xref>). Moreover, we have provided evidence that the upstream coagulation zymogen, factor X, is locally produced and activated in the intra-alveolar compartment of patients with IPF and in the bleomycin model (<xref ref-type="bibr" rid="b227">Scotton <italic>et al</italic>., 2009</xref>). Anticoagulants are highly effective in attenuating fibrosis in experimental animal models when given either prophylactically (<xref ref-type="bibr" rid="b101">Howell <italic>et al</italic>., 2001</xref>; <xref ref-type="bibr" rid="b227">Scotton <italic>et al</italic>., 2009</xref>) or therapeutically (<xref ref-type="bibr" rid="b85">Gunther <italic>et al</italic>., 2003</xref>).</p>
      <p>While the coagulation cascade may contribute to pulmonary fibrosis by promoting the deposition and persistence of fibrin, current evidence suggests that the direct receptor-mediated cellular effects elicited by activation of the major high-affinity thrombin receptor, proteinase-activated receptor (PAR)-1) may play a central role [reviewed in (<xref ref-type="bibr" rid="b39">Chambers, 2008</xref>)]. Recent work has also highlighted a potentially key role for PAR-2 in pulmonary fibrosis (<xref ref-type="bibr" rid="b28">Borensztajn <italic>et al</italic>., 2010</xref>).</p>
      <p>PAR-1 is expressed by numerous cell types, including fibroblasts, epithelial cells and macrophages; and activation of this receptor leads to the release of potent pro-inflammatory and pro-fibrotic mediators [reviewed in (<xref ref-type="bibr" rid="b39">Chambers, 2008</xref>)]. In terms of pro-fibrotic responses, PAR-1 signalling in fibroblasts promotes their proliferation via the autocrine production of PDGF (<xref ref-type="bibr" rid="b24">Blanc-Brude <italic>et al</italic>., 2005</xref>) and drives their differentiation into myofibroblasts via &#x3B1;v&#x3B2;5-dependent TGF-&#x3B2; activation (<xref ref-type="bibr" rid="b227">Scotton <italic>et al</italic>., 2009</xref>). On epithelial cells, PAR-1 activation similarly leads to TGF-&#x3B2; activation but this is mediated via the epithelial-restricted &#x3B1;v&#x3B2;6 integrin (<xref ref-type="bibr" rid="b110">Jenkins <italic>et al</italic>., 2006</xref>). PAR-1 signalling also induces the production and release of CTGF by lung fibroblasts (<xref ref-type="bibr" rid="b40">Chambers <italic>et al</italic>., 2000</xref>) and thrombin up-regulates the expression of the fibrinolysis inhibitor, plasminogen activator inhibitor-1 in this cell type (<xref ref-type="bibr" rid="b93">Hayakawa <italic>et al</italic>., 1995</xref>). Finally, studies in our laboratory with PAR-1 knockout mice provide strong support for a role for this receptor in mediating inflammatory and fibrotic responses to lung injury (<xref ref-type="bibr" rid="b102">Howell <italic>et al</italic>., 2005</xref>).</p>
      <p>In terms of demonstrating a causal role for the coagulation cascade in human disease, a recently completed trial investigating the effect of anticoagulation in IPF provided some support for this notion (<xref ref-type="bibr" rid="b141">Kubo <italic>et al</italic>., 2005</xref>). In this non-blinded prospective randomized trial, patients with IPF who were admitted to hospital were randomly assigned to receive prednisolone or prednisolone and anticoagulation in the form of heparin or warfarin. Increased survival at 3 years was observed in the anticoagulation arm compared with the non-anticoagulation arm (63% vs. 25% respectively). Furthermore, mortality associated with acute exacerbations of IPF was reduced in the anticoagulation arm compared with those treated with prednisolone alone. Despite these promising data, concerns about the non-blinded nature of the trial as well as the diagnostic criteria used to confirm the diagnosis of IPF mean that the role of anticoagulation in IPF remains unclear. However, the AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis (ACE-IPF) trial (NHLBI, USA), currently recruiting patients, will hopefully shed important light on this issue. This double-blinded randomized placebo-controlled study will evaluate the efficacy of warfarin treatment on time to death or disease progression in IPF, and the results are eagerly awaited. It has also been proposed that nebulized administration of anticoagulant to patients might represent a means of achieving local anticoagulation without undesired systemic effects, and a recent open label exploratory study demonstrated that nebulized heparin was safe and well-tolerated in IPF patients (<xref ref-type="bibr" rid="b168">Markart <italic>et al</italic>., 2010</xref>). Finally, PAR-1 antagonists are currently being developed as novel anti-thrombotic agents and several large-scale trials have recently been completed in the setting of cardiovascular disease. The scientific rationale for testing such antagonists in the setting of lung fibrosis is gaining strength.</p>
    </sec>
    <sec sec-type="">
      <title>Eicosanoid imbalance</title>
      <p>There is good experimental evidence that re-establishing an intact epithelium following injury may serve to suppress excessive fibroblast activation. Because fibrosis may result from an imbalance in the relative levels of pro- and anti- fibrotic mediators, there has been much interest in the potential anti-fibrotic role of the cyclooxygenase (COX)-2 dependent prostanoid, prostaglandin E<sub>2</sub> (PGE<sub>2</sub>). PGE<sub>2</sub> is the main prostanoid produced in the lung and is secreted by several cell types, including fibroblasts and epithelial cells (<xref ref-type="bibr" rid="b164">Maher <italic>et al</italic>., 2010a</xref>). PGE<sub>2</sub> exerts major anti-fibrotic effects by suppressing fibroblast responses, including proliferation (<xref ref-type="bibr" rid="b23">Bitterman <italic>et al</italic>., 1986</xref>; <xref ref-type="bibr" rid="b144">Lama <italic>et al</italic>., 2002</xref>), differentiation into myofibroblasts (<xref ref-type="bibr" rid="b134">Kolodsick <italic>et al</italic>., 2003</xref>) and collagen synthesis (<xref ref-type="bibr" rid="b80">Goldstein and Polgar, 1982</xref>). In support of an anti-fibrotic role for COX-2 in lung fibrosis, COX-2-deficient mice develop increased fibrosis following bleomycin-induced injury (<xref ref-type="bibr" rid="b122">Keerthisingam <italic>et al</italic>., 2001</xref>). These findings are supported by the observation that PGE<sub>2</sub> levels are decreased in IPF lung, whereas levels of leukotrienes derived from the 5-lipooxygenase pathway, including LTB<sub>4</sub>, are increased (<xref ref-type="bibr" rid="b31">Borok <italic>et al</italic>., 1991b</xref>; <xref ref-type="bibr" rid="b262">Wilborn <italic>et al</italic>., 1996</xref>). Several groups have shown that primary lung fibroblasts derived from patients with IPF are unable to up-regulate COX-2 in response to pro-inflammatory and pro-fibrotic mediator activation, including TGF-&#x3B2; (<xref ref-type="bibr" rid="b122">Keerthisingam <italic>et al</italic>., 2001</xref>) (<xref ref-type="bibr" rid="b261">Wilborn <italic>et al</italic>., 1995</xref>; <xref ref-type="bibr" rid="b268">Xaubet <italic>et al</italic>., 2004</xref>).</p>
      <p>Aside from exerting major anti-fibrotic effects, PGE2 has recently been implicated as playing a central role in promoting the &#x2018;apoptosis paradox&#x2019; of IPF. According to this paradox, IPF is characterized by (and possibly the result of) excessive epithelial cell apoptosis and (myo)fibroblast resistance to apoptosis. Recent studies from our centre have shown that the lack of PGE<sub>2</sub> may provide a mechanistic explanation for increased resistance of myofibroblasts to apoptosis, in comparison with increased epithelial cell apoptosis (<xref ref-type="bibr" rid="b164">Maher <italic>et al</italic>., 2010a</xref>). PGE<sub>2</sub> has also been shown to play a central role in mediating the anti-fibrotic effects of plasminogen activation (<xref ref-type="bibr" rid="b17">Bauman <italic>et al</italic>., 2010</xref>). The EP receptors involved in mediating the anti-fibrotic and apoptotic responses of PGE<sub>2</sub> are coming to light with roles identified for both EP2 (<xref ref-type="bibr" rid="b134">Kolodsick <italic>et al</italic>., 2003</xref>) and EP4 (<xref ref-type="bibr" rid="b165">Maher <italic>et al</italic>., 2010b</xref>). Activation of these receptors with selective agonists (e.g. butaprost, ONO-A1-329) may offer promise as novel anti-fibrotic agents.</p>
      <p>Further evidence to suggest that an eicosanoid imbalance contributes to a pro-fibrotic microenvironment stems from the observation that 5-LO knockout mice are protected from bleomycin-induced fibrosis (<xref ref-type="bibr" rid="b202">Peters-Golden <italic>et al</italic>., 2002</xref>). In light of these data, a recent study has completed recruitment of IPF patients. This trial is an open label phase II trial (University of Michigan) comparing the 5-LO inhibitor, zileuton, to azathioprine and prednisolone: the primary end point is BALF LTB<sub>4</sub> levels, but secondary end points include performance at lung function testing and progression free survival.</p>
      <p>Prostacyclin (PGI<sub>2</sub>) is another arachidonic acid metabolite derived via the COX-2 pathway. Similar to PGE2, PGI<sub>2</sub> possess a number of anti-fibrotic properties, and COX-2 derived PGI<sub>2</sub> has been shown to play an important role in limiting the development of bleomycin-induced lung fibrosis (<xref ref-type="bibr" rid="b159">Lovgren <italic>et al</italic>., 2006</xref>). Recent work has demonstrated that intraperitoneal administration of iloprost, a PGI<sub>2</sub> analogue, attenuates the fibrosis seen in this model (<xref ref-type="bibr" rid="b281">Zhu <italic>et al</italic>., 2010</xref>). The use of this drug in a nebulized form in PHT suggests that further investigation in IPF might be warranted.</p>
    </sec>
    <sec sec-type="">
      <title>Targeting the redox equilibrium</title>
      <p>The recent addition of NAC to prednisolone and azathioprine as an adjunct therapy for IPF reflects the growing belief that targeting the increased oxidative burden in IPF (<xref ref-type="bibr" rid="b161">MacNee and Rahman, 1995</xref>; <xref ref-type="bibr" rid="b213">Rahman <italic>et al</italic>., 1999</xref>) will result in a clinical benefit for these patients.</p>
      <p>However, recent work has demonstrated that similar benefits may be observed when redressing this redox imbalance from the opposite side of the equation: NADPH oxidase (NOX)-4 catalyses the reduction of O<sub>2</sub> to ROS, and genetic and pharmacological targeting of NOX-4 attenuates experimentally induced fibrosis, possibly by interfering with TGF-&#x3B2; induced myofibroblast activity (<xref ref-type="bibr" rid="b94">Hecker <italic>et al</italic>., 2009</xref>). Moreover, in addition to ROS there is evidence for nitric-oxide driven nitrosative stress in IPF (<xref ref-type="bibr" rid="b222">Saleh <italic>et al</italic>., 1997a</xref>) and the administration of aminoguanidine, a specific inhibitor of inducible nitric oxide synthase, attenuates bleomycin-induced fibrosis in mice (<xref ref-type="bibr" rid="b79">Giri <italic>et al</italic>., 2002</xref>). The development of such agents, as well as other novel antioxidant therapies such as superoxide dismutase mimetics, which inactivate ROS, may offer alternative therapeutic strategies to redress this redox imbalance, although the successful translation of these latter agents from animal to human studies has yet to be realized. Moreover, the identification of the redox-sensitive transcription factor Nrf2 as a regulator of antioxidant enzyme and defence protein genes [reviewed in (<xref ref-type="bibr" rid="b255">Walters <italic>et al</italic>., 2008</xref>)], together with evidence of increased susceptibility of Nrf2 knockout mice to bleomycin-induced fibrosis (<xref ref-type="bibr" rid="b44">Cho <italic>et al</italic>., 2004</xref>), may help identify further molecular targets and pathways for therapeutic modulation in IPF.</p>
    </sec>
    <sec sec-type="">
      <title>Epithelial mitogens</title>
      <p>As mentioned previously, appropriate epithelial cell migration, proliferation and differentiation in response to injury is central to successful wound healing and tissue repair. There is accumulating evidence that such processes are impaired in the context of abnormal fibroproliferative responses to injury (<xref ref-type="bibr" rid="b72">Finch <italic>et al</italic>., 1989</xref>; <xref ref-type="bibr" rid="b220">Rubin <italic>et al</italic>., 1989</xref>; <xref ref-type="bibr" rid="b58">Deterding <italic>et al</italic>., 1996</xref>). Intratracheal administration of the epithelial mitogen, keratinocyte growth factor (KGF) before bleomycin instillation attenuates the subsequent fibrotic response (<xref ref-type="bibr" rid="b59">Deterding <italic>et al</italic>., 1997</xref>) while TGF-&#x3B2; blocks KGF-induced proliferation of alveolar pneumocytes <italic>in vitro</italic> (<xref ref-type="bibr" rid="b279">Zhang <italic>et al</italic>., 2004</xref>). In addition, bone marrow transplantation of haematopoietic stem cells expressing KGF significantly reduces bleomycin-induced lung injury, possibly by promoting AEC II proliferation (<xref ref-type="bibr" rid="b2">Aguilar <italic>et al</italic>., 2009</xref>). Administration of the epithelial mitogen, hepatocyte growth factor (HGF) similarly attenuates lung collagen accumulation in animal models of pulmonary fibrosis (<xref ref-type="bibr" rid="b62">Dohi <italic>et al</italic>., 2000</xref>), and HGF further exerts a pro-apoptotic effect on myofibroblasts via the c-Met receptor (<xref ref-type="bibr" rid="b173">Mizuno <italic>et al</italic>., 2005</xref>). Although this raises the possibility that activation of the HGF/c-Met system in fibrotic lungs may represent a potential target in IPF, this receptor system is frequently activated in a broad spectrum of human cancers &#x2013; because IPF patients are at a heightened risk of developing lung cancer (<xref ref-type="bibr" rid="b195">Ozawa <italic>et al</italic>., 2009</xref>), the potential role of the HGF/c-Met axis in driving epithelial tumours in IPF would need to be fully explored and understood before this approach could be deemed viable.</p>
    </sec>
    <sec sec-type="">
      <title>Angiogenesis</title>
      <p>Despite the first observation of microvascular systemic-pulmonary anastamoses in IPF lung over 40 years ago (<xref ref-type="bibr" rid="b249">Turner-Warwick, 1963</xref>), the role of aberrant angiogenesis in the pathogenesis of this condition remains unclear. The key issue remains whether neovascularization represents a critical pathogenetic mechanism contributing to progressive fibrosis or a compensatory mechanism to promote alveolar repair.</p>
      <p>In line with human studies, aberrant vascular remodelling has been observed in the lungs of bleomycin-challenged rats (<xref ref-type="bibr" rid="b200">Peao <italic>et al</italic>., 1994</xref>) suggesting a pro-angiogenic microenvironment in this model. Evidence to suggest that an imbalance between angiogenic and angiostatic chemokines is of mechanistic importance in this model stems from observations that levels of the angiostatic chemokine CXCL10 are lower in bleomycin-challenged mice compared with control lungs (<xref ref-type="bibr" rid="b120">Keane <italic>et al</italic>., 1999</xref>). Moreover, administration of both CXCL10 and CXCL11, another angiostatic chemokine, attenuate bleomycin-induced fibrosis with a concomitant reduction in angiogenesis (<xref ref-type="bibr" rid="b120">Keane <italic>et al</italic>., 1999</xref>; <xref ref-type="bibr" rid="b37">Burdick <italic>et al</italic>., 2005</xref>). In humans, increased levels of the angiogenic chemokines CXCL8 and CXCL5 have been reported in IPF lung (<xref ref-type="bibr" rid="b119">Keane <italic>et al</italic>., 1997</xref>; <xref ref-type="bibr" rid="b121">2001</xref>;), while IPF-derived fibroblasts constitutively express more CXCL8 than their non-fibrotic counterparts (<xref ref-type="bibr" rid="b119">Keane <italic>et al</italic>., 1997</xref>); depletion of these chemokines from lung tissue reduced the tissue-derived angiogenic activity (<xref ref-type="bibr" rid="b119">Keane <italic>et al</italic>., 1997</xref>; <xref ref-type="bibr" rid="b121">2001</xref>;).</p>
      <p>It seems therefore that targeting the pro-angiogenic micro-environment may provide a further therapeutic avenue for IPF patients. A more global approach to achieving an angiostatic environment may be achieved using agents such as tetrathiomolybdate (TM) and minocycline. TM is a copper-chelating agent that possesses anti-angiogenic properties <italic>in vivo</italic> (<xref ref-type="bibr" rid="b196">Pan <italic>et al</italic>., 2002</xref>), which may be related to transcriptional down-regulation of angiogenic growth factors such as vascular endothelial growth factor (VEGF) (<xref ref-type="bibr" rid="b35">Brewer <italic>et al</italic>., 2004</xref>). TM administration attenuated bleomycin-induced fibrosis in mice (<xref ref-type="bibr" rid="b34">Brewer <italic>et al</italic>., 2003</xref>) and a non-randomized control trial (University of Michigan) investigating the safety of TM in IPF has recently been completed. The secondary end point in this trial was performance at lung function testing, and we await the results with interest. Minocycline is also known to possess anti-angiogenic properties (<xref ref-type="bibr" rid="b246">Tamargo <italic>et al</italic>., 1991</xref>) and its efficacy in treating IPF is the subject of a Phase III trial (University of California) &#x2013; this trial has finished recruiting and the results are awaited. The targeting of VEGF, along with PDGF and fibroblast growth factor signalling pathways is an area of active research in tumour biology. Optimism that BIBF 1120 [Boehringer Ingelheim Pharmaceuticals (BIP), UK], an inhibitor of their respective receptor kinases, fuelled by the observation that anti-VEGF gene therapy attenuates experimentally induced fibrosis (<xref ref-type="bibr" rid="b89">Hamada <italic>et al</italic>., 2005</xref>), could prove an effective anti-angiogenic drug in this field prompted the initiation of a double-blinded, placebo-controlled trial (BIP, UK) to evaluate the safety and efficacy of this drug in IPF. The results are currently pending.</p>
      <p>However, recent work suggests a decrease in the extent of anastamoses (<xref ref-type="bibr" rid="b217">Renzoni <italic>et al</italic>., 2003</xref>) between the pulmonary and systemic vasculature within the fibroblastic foci of IPF, highlighting the lack of clarity regarding the role of neovascularization in IPF &#x2013; to this end, it has been proposed that aberrant neovascularization in areas of less fibrosis may represent a compensatory mechanism to the vascular ablation reported in the aforementioned work, and necessary for regeneration of alveolar septae (<xref ref-type="bibr" rid="b216">Renzoni, 2004</xref>). Further investigation is therefore required to elucidate the role of neovascularization in the pathogenesis of IPF to enable a rational interpretation of data derived from the aforementioned trials.</p>
    </sec>
    <sec sec-type="">
      <title>Ongoing trials of other agents in IPF</title>
      <sec>
        <title>Somatostatin</title>
        <p>Aside from the broad and overlapping therapeutic categories discussed above, a number of other novel targets potentially important in the pathogenesis of IPF have recently been identified. For example, recent work has demonstrated that expression of the somatostatin receptor, sst2, is increased in mice following bleomycin challenge (<xref ref-type="bibr" rid="b29">Borie <italic>et al</italic>., 2008</xref>). Subcutaneous administration of a somatostatin analogue, SOM230 (Novartis, Switzerland), in this model attenuates bleomycin-induced fibrosis, and this attenuation is associated with reduced expression of TGF-&#x3B2; and CTGF (<xref ref-type="bibr" rid="b29">Borie <italic>et al</italic>., 2008</xref>). The anti-fibrotic mechanism of action of somatostatin analogues remains unclear, although it may relate to inhibition of fibroblast proliferation (<xref ref-type="bibr" rid="b29">Borie <italic>et al</italic>., 2008</xref>). Increased expression of the sst2 receptor is also observed in the lungs of patients with IPF (<xref ref-type="bibr" rid="b7">Antoniu, 2008</xref>), and these data prompted the initiation of a proof of concept, non-randomized open label study (Institut National de la Sant&#xE9; Et de la Recherche M&#xE9;dicale, France) to evaluate the efficacy of octreotide, a somatostatin analogue, in IPF. This study has been completed, although the results are yet to be reported.</p>
      </sec>
      <sec>
        <title>Thalidomide</title>
        <p>Thalidomide is a drug originally introduced as a sedative. Despite its well-known teratogenic effects, it has proven efficacious in treating a wide variety of conditions including multiple myeloma. Thalidomide possesses anti-inflammatory (<xref ref-type="bibr" rid="b131">Koch, 1985</xref>), immunomodulatory (<xref ref-type="bibr" rid="b92">Haslett <italic>et al</italic>., 1998</xref>) and anti-angiogenic properties (<xref ref-type="bibr" rid="b52">D'Amato <italic>et al</italic>., 1994</xref>), and has been demonstrated to attenuate bleomycin-induced fibrosis in mice (<xref ref-type="bibr" rid="b244">Tabata <italic>et al</italic>., 2007</xref>). Its precise mechanism of action remains unclear, although the observed attenuation in fibrosis following experimental lung injury is accompanied by a reduction in VEGF expression (<xref ref-type="bibr" rid="b244">Tabata <italic>et al</italic>., 2007</xref>), suggesting that inhibition of neovascularization might represent a potential mechanism. IL-6 expression has also been shown to be reduced in this model suggesting multiple possible modes of action (<xref ref-type="bibr" rid="b244">Tabata <italic>et al</italic>., 2007</xref>). In light of these data, a non-randomized open label study (John Hopkins University) designed to evaluate the safety and efficacy of thalidomide in patients with IPF has been completed, but the results are not yet published.</p>
      </sec>
    </sec>
    <sec sec-type="">
      <title>Recent advances in the identification of novel targets and pathways</title>
      <sec>
        <title>Lysophosphatidic acid</title>
        <p>Recent work has identified the bioactive phospholipid derivative lysophosphaditic acid (LPA), acting via stimulation of its multiple G-protein-coupled receptors LPA<sub>1&#x2013;5</sub>, as an important mediator in wound repair and tissue fibrogenesis (<xref ref-type="bibr" rid="b259">Watterson <italic>et al</italic>., 2007</xref>). The potential significance of this mediator in lung fibrosis has been highlighted by studies demonstrating a critical role for LPA<sub>1</sub> activation in fibroblast recruitment and vascular leak following experimentally induced lung injury in mice (<xref ref-type="bibr" rid="b245">Tager <italic>et al</italic>., 2008</xref>). In addition, LPA induces &#x3B1;v&#x3B2;6-mediated TGF-&#x3B2; activation in lung epithelial cells (<xref ref-type="bibr" rid="b271">Xu <italic>et al</italic>., 2009</xref>) via RhoA and Rho kinase, following interaction with the LPA<sub>2</sub> receptor, findings consistent with previous observations that LPA is capable of mediating cellular contraction in a number of different cell types (<xref ref-type="bibr" rid="b45">Chrzanowska-Wodnicka and Burridge, 1996</xref>). In support of a role for LPA in human disease, BALF LPA levels and LPA<sub>2</sub> immunoreactivity are significantly increased in IPF patients compared with non-fibrotic control samples (<xref ref-type="bibr" rid="b245">Tager <italic>et al</italic>., 2008</xref>; <xref ref-type="bibr" rid="b271">Xu <italic>et al</italic>., 2009</xref>), suggesting that LPA may represent a novel therapeutic target in pulmonary fibrosis. Indeed, the success of prophylactic administration of a LPA<sub>1</sub> receptor antagonist, in attenuating bleomycin-induced lung fibrosis in mice, has prompted the initiation of a phase I clinical study using AM152 (Amira, USA), an alternative LPA<sub>1</sub> antagonist, in healthy subjects, with a view to evaluating its anti-fibrotic efficacy in IPF in the future.</p>
      </sec>
      <sec>
        <title>Wnt signalling</title>
        <p>The Wnt signalling pathway plays a crucial role in lung development, regulating both epithelial and mesenchymal development via autocrine and paracrine signals. A detailed discussion of this signalling pathway is beyond the scope of this article and has been recently reviewed (<xref ref-type="bibr" rid="b125">Kikuchi <italic>et al</italic>., 2007</xref>). In brief, Wnt proteins bind to Frizzled cell surface receptors or low-density lipoprotein co-receptors. The inhibition of glycogen synthase kinase 3&#x3B2; results in the hypophosphorylation of &#x3B2;-catenin that allows translocation of this cytoskeletal protein into the nucleus. Subsequent binding of &#x3B2;-catenin to the LEC/TCF family of transcription factors converts them from transcriptional repressors to activators.</p>
        <p>Support for the potential involvement of this pathway in IPF comes from observations in humans and animal models. Strong nuclear &#x3B2;-catenin immunoreactivity is observed in the lungs of IPF patients, localizing to fibroblasts within fibrotic foci and to proliferative bronchiolar lesions, a finding not observed in non-IPF lung (<xref ref-type="bibr" rid="b43">Chilosi <italic>et al</italic>., 2003</xref>). &#x3B2;-catenin and WNT-1-inducible signalling protein (WISP-1) have been shown to promote EMT <italic>in vitro</italic> suggesting that dysregulated activation of &#x3B2;-catenin associated transcription factors could promote an expansion of the myofibroblast population in IPF (<xref ref-type="bibr" rid="b43">Chilosi <italic>et al</italic>., 2003</xref>) (<xref ref-type="bibr" rid="b138">Konigshoff <italic>et al</italic>., 2009</xref>). Further support for the importance of the Wnt signalling pathway in the pathogenesis of IPF stems from the observation that mice deficient in matrilysin (MMP-7), a target gene of the &#x3B2;-catenin-LEF1 signalling pathway, are protected from bleomycin-induced fibrosis, and interestingly expression of MMP7 is significantly increased in IPF lung (<xref ref-type="bibr" rid="b286">Zuo <italic>et al</italic>., 2002</xref>)., WISP-1 is up-regulated in humans with IPF and mediates pulmonary fibrosis in mice (<xref ref-type="bibr" rid="b138">Konigshoff <italic>et al</italic>., 2009</xref>) and pharmacological inhibition of Wnt/beta-catenin/CREB binding protein signalling reverses experimentally-induced pulmonary fibrosis (<xref ref-type="bibr" rid="b138">Konigshoff <italic>et al</italic>., 2009</xref>; <xref ref-type="bibr" rid="b95">Henderson <italic>et al</italic>., 2010</xref>) The scientific rationale for interfering with Wnt signalling in IPF is therefore rapidly gaining strength.</p>
      </sec>
      <sec>
        <title>Jagged/Notch pathway</title>
        <p>As highlighted previously, it is increasingly recognized that in the context of a pro-fibrogenic cytokine milieu, EMT may promote the development of a myofibroblast population that significantly contributes to fibrogenesis. While TGF-&#x3B2; is seen as the principle driving force for EMT, recent studies have demonstrated the potential importance of integration of TGF-&#x3B2; and Jagged ligand/Notch receptor signalling pathways in EMT &#x2013; these pathways are highly evolutionary conserved cell signalling systems that regulate cell fate specification, and siRNA targeting of components of the Notch pathway has previously been shown to block TGF-&#x3B2; induced EMT in kidney tubule epithelial cells (<xref ref-type="bibr" rid="b275">Zavadil <italic>et al</italic>., 2004</xref>). Recent work has demonstrated that Notch signalling plays a role in EMT both upstream and downstream of TGF-&#x3B2; in rat AECs <italic>in vitro</italic>, and that inhibition of Notch receptor activation attenuates TGF-&#x3B2;&#x2013; induced &#x3B1;-SMA expression (<xref ref-type="bibr" rid="b9">Aoyagi-Ikeda <italic>et al</italic>., 2010</xref>), a finding seen also in kidney tubule epithelial cells (<xref ref-type="bibr" rid="b188">Nyhan <italic>et al</italic>., 2010</xref>). Furthermore, Notch1 co-localizes with &#x3B1;-SMA in bleomycin-induced pulmonary fibrosis and in patients with pulmonary fibrosis (<xref ref-type="bibr" rid="b9">Aoyagi-Ikeda <italic>et al</italic>., 2010</xref>). These exciting data suggest that inhibition of the Notch signalling pathway may offer a further therapeutic opportunity to tackle pulmonary fibrosis, one that may bypass the potential problems of a more global anti-TGF-&#x3B2; strategy.</p>
      </sec>
      <sec>
        <title>Lysyl oxidase-2</title>
        <p>Lysyl oxidase-2 (LOXL2) belongs to a family of five enzymes that play essential roles during the biogenesis of connective tissue by catalysing the first step in the formation of cross links in collagens and elastin (<xref ref-type="bibr" rid="b111">Kagan and Li, 2003</xref>). Recent studies have highlighted a novel role for LOXL2 in the creation and maintenance of the pathologic micro-environment of cancer and fibrotic diseases (<xref ref-type="bibr" rid="b3">Akiri <italic>et al</italic>., 2003</xref>; <xref ref-type="bibr" rid="b68">Erler <italic>et al</italic>., 2006</xref>). This enzyme is up-regulated in IPF and administration of a monoclonal anti-LOXL2 antibody (AB0023; Arresto BioSciences, USA) dosed either prophylactically or therapeutically, significantly attenuated bleomycin-induced fibrosis in mice (<xref ref-type="bibr" rid="b16">Barry-Hamilton <italic>et al</italic>., 2010</xref>). This attenuation was associated with a decrease in the number of &#x3B1;-SMA + fibroblasts as well as a considerable improvement in cross-linked fibrillar collagen abundance and a reduction in TGF-&#x3B2; signalling (<xref ref-type="bibr" rid="b16">Barry-Hamilton <italic>et al</italic>., 2010</xref>). LOXL2 could therefore potentially mediate fibroblast activation <italic>in vivo</italic> by enzymatically catalysing the cross-linking of fibrillar collagen with a corresponding increase in local matrix tension (<xref ref-type="bibr" rid="b265">Wipff <italic>et al</italic>., 2007</xref>) resulting in activation of TGF-&#x3B2;1 signalling from the latent complex as outlined earlier. LOXL2 expression is relatively low in normal tissues so therapeutic targeting of this enzyme may represent an attractive target for therapeutic intervention in several fibrotic conditions, including pulmonary fibrosis.</p>
      </sec>
      <sec>
        <title>microRNA</title>
        <p>microRNAs (miRNAs) are short (20&#x2013;24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression by affecting both the stability and translation of mRNA. They are known to play critical roles in organogenesis (<xref ref-type="bibr" rid="b238">Stefani and Slack, 2008</xref>), and dysregulation of miRNAs is increasingly implicated in a variety of disease processes. Recent microRNA microarray studies in IPF showed that a number of miRNAs are differentially expressed in IPF compared with non-fibrotic control lungs. Notable examples include the miRNA, let-7d, which is down-regulated in the IPF lung, as well as in response to TGF-&#x3B2; signalling. The down-regulation of let-7d in IPF and the pro-fibrotic effects of this down-regulation <italic>in vitro</italic> and <italic>in vivo</italic> suggest a key regulatory role for this microRNA in preventing lung fibrosis (<xref ref-type="bibr" rid="b197">Pandit <italic>et al</italic>., 2010</xref>). In contrast, a second study focused on miR-21 &#x2013; this is up-regulated in human IPF lung specimens, as well as in the murine bleomycin model (<xref ref-type="bibr" rid="b157">Liu <italic>et al</italic>., 2010a</xref>). In this study, miR-21 was found to exert/promote pro-fibrotic responses, potentially by amplifying the fibrogenic effects of TGF-&#x3B2; by regulating the expression of an inhibitory Smad, Smad7. Administration of miR-21 antisense probes diminished the severity of experimental lung fibrosis in mice, even when treatment was started 5&#x2013;7 days after initiation of bleomycin injury. This study raises the tantalizing possibility that future developments in miRNA therapeutics may open up novel opportunities for treating clinically refractory fibrotic diseases, such as IPF.</p>
      </sec>
    </sec>
    <sec sec-type="">
      <title>Conclusions and future directions</title>
      <p>Idiopathic pulmonary fibrosis is a devastating and progressive condition with an appalling prognosis. It is clear that the fibroproliferative response to injury seen in this condition reflects an extremely complex interplay between a number of different cellular and signalling mechanisms, with an unknown degree of redundancy. Furthermore, it is increasingly appreciated that the targeting of one particular pathway only, may not have any effect on fibrosis secondary to injury; rather, lung fibrosis may be a consequence of disequilibrium in a number of different processes &#x2013; epithelial and endothelial injury; inflammation and the immune response to injury; myofibroblast expansion; hypercoagulation; angiogenesis and aberrant wound repair mechanisms. The relative importance of these pathways, which share the final common pathway of fibrogenesis, may further vary across individuals, highlighting the importance of identifying subgroups of phenotypes, which may be more responsive to particular therapies.</p>
      <p>The bleomycin model of fibrosis in mice is a useful model to delineate the relative importance to pathogenesis of these pathways but, as has been well documented, is by no means an accurate representation of all the features of IPF (<xref ref-type="bibr" rid="b226">Scotton and Chambers, 2010</xref>). Aside from pirfenidone and NAC, optimism that targets derived from attenuation of experimentally induced fibrosis would translate into a clinical benefit in IPF has not yet been realized. In terms of the clinical predictability of the bleomycin model to IPF, therapeutic rather than prophylactic dosing is recommended in order to avoid interfering with the inflammatory response rather than the fibrotic response to injury (<xref ref-type="bibr" rid="b174">Moeller <italic>et al</italic>., 2008</xref>; <xref ref-type="bibr" rid="b226">Scotton and Chambers, 2010</xref>).</p>
      <p>The use of high-throughput gene expression profiling technology may be of particular benefit in understanding the complex interplays seen in pulmonary fibrosis. Microarray analysis of RNA expression in human disease samples can reveal regulatory networks and expression profiles, which underlie disease progression (see (<xref ref-type="bibr" rid="b113">Kaminski and Rosas, 2006</xref>) for review), but as yet, no targets identified by this means have been trialled in IPF.</p>
      <p>Aside from challenges to understanding pathogenetic mechanisms in IPF, advances in therapeutics have been limited by a number of other factors. Importantly, the intrinsic nature of the disease, a slow burning process reflecting years of dysregulated remodelling, means that identifying patients before end-stage fibrosis has developed is problematic &#x2013; it is by no means certain that an adult lung has the capacity to remodel and regain functionality from established fibrosis, and a halt to disease progression may be all that can achieved. The design of clinical trials to evaluate therapeutic strategies in IPF can also be beset by problems. For instance, selection bias and diagnostic uncertainty in this heterogeneous condition may result in patients with varying degrees of baseline disease, and therefore varying degrees of sensitivity to treatment, being inappropriately enrolled into the same trial. In addition, there remains no clear consensus as to the most appropriate end point to study in interventional studies. Clearly, mortality is the most robust outcome but large numbers of patients are required to be maintained within a trial for long periods. A 10% decline in FVC over 1 year is a widely used parameter of disease progression and increased risk of mortality (<xref ref-type="bibr" rid="b128">King <italic>et al</italic>., 2001</xref>; <xref ref-type="bibr" rid="b74">Flaherty <italic>et al</italic>., 2003</xref>; <xref ref-type="bibr" rid="b146">Latsi <italic>et al</italic>., 2003</xref>), although recent work suggests that smaller changes may be of clinical significance in IPF (<xref ref-type="bibr" rid="b274">Zappala <italic>et al</italic>., 2010</xref>) and while composite indices of lung function can predict mortality, their use has not been adopted into the design of recent clinical trials. The recent demonstration, however, that large well-conducted trials can be performed to evaluate drug treatments in IPF, together with the realization that the therapeutic targeting of multiple pro-fibrotic pathways is likely to be more successful than focusing on single pathways, offers more hope than ever before to sufferers of this devastating condition.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>The authors are grateful to the following grant agencies for funding for research into the pathogenesis of pulmonary fibrosis: Wellcome Trust (A.D. Clinical Research Training Fellowship 084382/Z/07/Z), MRC (C.J.S. Career Development Award G0800340; R.C.C. CASE Award 2009&#x2013;12), European Commission (R.C.C Framework 7 Programme HEALTH-F2-2007-2224; European IPF Network) and BBSRC (CASE Award BB/I532702/1).</p>
    </ack>
    <sec>
      <title>Conflicts of interest</title>
      <p>R.C.C has/is acting as a consultant for the following companies: Centocor, Sanofi-Aventis and GlaxoSmithKline and is currently the recipient of research funding from GlaxoSmithKline and Novartis. C.J.S. has acted as a consultant for GlaxoSmithKline and is currently the recipient of research funding from GlaxoSmithKline.</p>
    </sec>
    <ref-list>
      <title>References</title>
      <ref id="b1">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Adler</surname>
              <given-names>KB</given-names>
            </name>
            <name>
              <surname>Low</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Leslie</surname>
              <given-names>KO</given-names>
            </name>
            <name>
              <surname>Mitchell</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>JN</given-names>
            </name>
          </person-group>
          <article-title>Contractile cells in normal and fibrotic lung</article-title>
          <source>Lab Invest</source>
          <year>1989</year>
          <volume>60</volume>
          <fpage>473</fpage>
          <lpage>485</lpage>
          <pub-id pub-id-type="pmid">2651799</pub-id>
        </element-citation>
      </ref>
      <ref id="b2">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aguilar</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Scotton</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>McNulty</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nye</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Stamp</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Laurent</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Bone marrow stem cells expressing keratinocyte growth factor via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis</article-title>
          <source>PloS ONE</source>
          <year>2009</year>
          <volume>4</volume>
          <fpage>e8013</fpage>
          <pub-id pub-id-type="pmid">19956603</pub-id>
        </element-citation>
      </ref>
      <ref id="b3">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Akiri</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sabo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Dafni</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Vadasz</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Kartvelishvily</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Gan</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Lysyl oxidase-related protein-1 promotes tumor fibrosis and tumor progression in vivo</article-title>
          <source>Cancer Res</source>
          <year>2003</year>
          <volume>63</volume>
          <fpage>1657</fpage>
          <lpage>1666</lpage>
          <pub-id pub-id-type="pmid">12670920</pub-id>
        </element-citation>
      </ref>
      <ref id="b4">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Allen</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Knight</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Bloor</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Spiteri</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Enhanced insulin-like growth factor binding protein-related protein 2 (Connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis</article-title>
          <source>Am J Respir Cell Mol Biol</source>
          <year>1999</year>
          <volume>21</volume>
          <fpage>693</fpage>
          <lpage>700</lpage>
          <pub-id pub-id-type="pmid">10572066</pub-id>
        </element-citation>
      </ref>
      <ref id="b5">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andersson-Sjoland</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>de Alba</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Nihlberg</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Becerril</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ramirez</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Pardo</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis</article-title>
          <source>Int J Biochem Cell Biol</source>
          <year>2008</year>
          <volume>40</volume>
          <fpage>2129</fpage>
          <lpage>2140</lpage>
          <pub-id pub-id-type="pmid">18374622</pub-id>
        </element-citation>
      </ref>
      <ref id="b6">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Antoniades</surname>
              <given-names>HN</given-names>
            </name>
            <name>
              <surname>Bravo</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Avila</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Galanopoulos</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Neville-Golden</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Maxwell</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Platelet-derived growth factor in idiopathic pulmonary fibrosis</article-title>
          <source>J Clin Invest</source>
          <year>1990</year>
          <volume>86</volume>
          <fpage>1055</fpage>
          <lpage>1064</lpage>
          <pub-id pub-id-type="pmid">2170444</pub-id>
        </element-citation>
      </ref>
      <ref id="b7">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Antoniu</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
          <article-title>Somatostatin analogs for idiopathic pulmonary fibrosis therapy</article-title>
          <source>Expert Opin Investig Drugs</source>
          <year>2008</year>
          <volume>17</volume>
          <fpage>1137</fpage>
          <lpage>1140</lpage>
        </element-citation>
      </ref>
      <ref id="b8">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aono</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Nishioka</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Inayama</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ugai</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kishi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Uehara</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2005</year>
          <volume>171</volume>
          <fpage>1279</fpage>
          <lpage>1285</lpage>
          <pub-id pub-id-type="pmid">15735062</pub-id>
        </element-citation>
      </ref>
      <ref id="b9">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aoyagi-Ikeda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Maeno</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Matsui</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ueno</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hara</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Aoki</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Notch Induces myofibroblast differentiation of alveolar epithelial cells via TGF-ss/Smad3 pathway</article-title>
          <source>Am J Respir Cell Mol Biol</source>
          <year>2010</year>
          <comment>in press</comment>
        </element-citation>
      </ref>
      <ref id="b10">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ask</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bonniaud</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Maass</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Eickelberg</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Margetts</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Warburton</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Progressive pulmonary fibrosis is mediated by TGF-beta isoform 1 but not TGF-beta3</article-title>
          <source>Int J Biochem Cell Biol</source>
          <year>2008</year>
          <volume>40</volume>
          <fpage>484</fpage>
          <lpage>495</lpage>
          <pub-id pub-id-type="pmid">17931953</pub-id>
        </element-citation>
      </ref>
      <ref id="b11">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Atabai</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Jame</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Azhar</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kuo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lam</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>McKleroy</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mfge8 diminishes the severity of tissue fibrosis in mice by binding and targeting collagen for uptake by macrophages</article-title>
          <source>J Clin Invest</source>
          <year>2009</year>
          <volume>119</volume>
          <fpage>3713</fpage>
          <lpage>3722</lpage>
          <pub-id pub-id-type="pmid">19884654</pub-id>
        </element-citation>
      </ref>
      <ref id="b12">
        <element-citation publication-type="journal">
          <collab>ATS/ERS</collab>
          <article-title>American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2000</year>
          <volume>161</volume>
          <fpage>646</fpage>
          <lpage>664</lpage>
          <pub-id pub-id-type="pmid">10673212</pub-id>
        </element-citation>
      </ref>
      <ref id="b13">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Avivi-Green</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Singal</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Vogel</surname>
              <given-names>WF</given-names>
            </name>
          </person-group>
          <article-title>Discoidin domain receptor 1-deficient mice are resistant to bleomycin-induced lung fibrosis</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2006</year>
          <volume>174</volume>
          <fpage>420</fpage>
          <lpage>427</lpage>
          <pub-id pub-id-type="pmid">16690978</pub-id>
        </element-citation>
      </ref>
      <ref id="b14">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baran</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Opalek</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>McMaken</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Newland</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>O'Brien</surname>
              <given-names>JM</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Hunter</surname>
              <given-names>MG</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Important roles for macrophage colony-stimulating factor, CC chemokine ligand 2, and mononuclear phagocytes in the pathogenesis of pulmonary fibrosis</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2007</year>
          <volume>176</volume>
          <fpage>78</fpage>
          <lpage>89</lpage>
          <pub-id pub-id-type="pmid">17431224</pub-id>
        </element-citation>
      </ref>
      <ref id="b15">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barbas-Filho</surname>
              <given-names>JV</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Sesso</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kairalla</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Carvalho</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Capelozzi</surname>
              <given-names>VL</given-names>
            </name>
          </person-group>
          <article-title>Evidence of type II pneumocyte apoptosis in the pathogenesis of idiopathic pulmonary fibrosis (IFP)/usual interstitial pneumonia (UIP)</article-title>
          <source>J Clin Pathol</source>
          <year>2001</year>
          <volume>54</volume>
          <fpage>132</fpage>
          <lpage>138</lpage>
          <pub-id pub-id-type="pmid">11215282</pub-id>
        </element-citation>
      </ref>
      <ref id="b16">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barry-Hamilton</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Spangler</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Marshall</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>McCauley</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rodriguez</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Oyasu</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment</article-title>
          <source>Nat Med</source>
          <year>2010</year>
          <volume>16</volume>
          <fpage>1009</fpage>
          <lpage>1017</lpage>
          <pub-id pub-id-type="pmid">20818376</pub-id>
        </element-citation>
      </ref>
      <ref id="b17">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bauman</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Wettlaufer</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Okunishi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Vannella</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Stoolman</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>SK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice</article-title>
          <source>J Clin Invest</source>
          <year>2010</year>
          <volume>120</volume>
          <fpage>1950</fpage>
          <lpage>1960</lpage>
          <pub-id pub-id-type="pmid">20501949</pub-id>
        </element-citation>
      </ref>
      <ref id="b18">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beeh</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Beier</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Haas</surname>
              <given-names>IC</given-names>
            </name>
            <name>
              <surname>Kornmann</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Micke</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Buhl</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Glutathione deficiency of the lower respiratory tract in patients with idiopathic pulmonary fibrosis</article-title>
          <source>Eur Respir J</source>
          <year>2002</year>
          <volume>19</volume>
          <fpage>1119</fpage>
          <lpage>1123</lpage>
          <pub-id pub-id-type="pmid">12108866</pub-id>
        </element-citation>
      </ref>
      <ref id="b19">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Behr</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Noble</surname>
              <given-names>PW</given-names>
            </name>
          </person-group>
          <article-title>Clinical trials in interstitial lung disease</article-title>
          <source>European Respiratory Soc Monograph</source>
          <year>2009</year>
          <volume>46</volume>
          <fpage>67</fpage>
          <lpage>84</lpage>
        </element-citation>
      </ref>
      <ref id="b20">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Behr</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Degenkolb</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Maier</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Braun</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Beinert</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Krombach</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Increased oxidation of extracellular glutathione by bronchoalveolar inflammatory cells in diffuse fibrosing alveolitis</article-title>
          <source>Eur Respir J</source>
          <year>1995</year>
          <volume>8</volume>
          <fpage>1286</fpage>
          <lpage>1292</lpage>
          <pub-id pub-id-type="pmid">7489792</pub-id>
        </element-citation>
      </ref>
      <ref id="b21">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Behr</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Degenkolb</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Krombach</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Vogelmeier</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Intracellular glutathione and bronchoalveolar cells in fibrosing alveolitis: effects of N-acetylcysteine</article-title>
          <source>Eur Respir J</source>
          <year>2002</year>
          <volume>19</volume>
          <fpage>906</fpage>
          <lpage>911</lpage>
          <pub-id pub-id-type="pmid">12030732</pub-id>
        </element-citation>
      </ref>
      <ref id="b22">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Belperio</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Dy</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Burdick</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Xue</surname>
              <given-names>YY</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Elias</surname>
              <given-names>JA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis</article-title>
          <source>Am J Respir Cell Mol Biol</source>
          <year>2002</year>
          <volume>27</volume>
          <fpage>419</fpage>
          <lpage>427</lpage>
          <pub-id pub-id-type="pmid">12356575</pub-id>
        </element-citation>
      </ref>
      <ref id="b23">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bitterman</surname>
              <given-names>PB</given-names>
            </name>
            <name>
              <surname>Wewers</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Rennard</surname>
              <given-names>SI</given-names>
            </name>
            <name>
              <surname>Adelberg</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Crystal</surname>
              <given-names>RG</given-names>
            </name>
          </person-group>
          <article-title>Modulation of alveolar macrophage-driven fibroblast proliferation by alternative macrophage mediators</article-title>
          <source>J Clin Invest</source>
          <year>1986</year>
          <volume>77</volume>
          <fpage>700</fpage>
          <lpage>708</lpage>
          <pub-id pub-id-type="pmid">3081573</pub-id>
        </element-citation>
      </ref>
      <ref id="b24">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blanc-Brude</surname>
              <given-names>OP</given-names>
            </name>
            <name>
              <surname>Archer</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Leoni</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Derian</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bolsover</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Laurent</surname>
              <given-names>GJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Factor Xa stimulates fibroblast procollagen production, proliferation, and calcium signaling via PAR1 activation</article-title>
          <source>Exp Cell Res</source>
          <year>2005</year>
          <volume>304</volume>
          <fpage>16</fpage>
          <lpage>27</lpage>
          <pub-id pub-id-type="pmid">15707570</pub-id>
        </element-citation>
      </ref>
      <ref id="b25">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bonniaud</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Margetts</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Kolb</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Haberberger</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kelly</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Robertson</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Adenoviral gene transfer of connective tissue growth factor in the lung induces transient fibrosis</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2003</year>
          <volume>168</volume>
          <fpage>770</fpage>
          <lpage>778</lpage>
          <pub-id pub-id-type="pmid">12816739</pub-id>
        </element-citation>
      </ref>
      <ref id="b26">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bonniaud</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Margetts</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Ask</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Robertson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gauldie</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Connective tissue growth factor is crucial to inducing a profibrotic environment in &#x2018;fibrosis-resistant&#x2019; BALB/c mouse lungs</article-title>
          <source>Am J Respir Cell Mol Biol</source>
          <year>2004</year>
          <volume>31</volume>
          <fpage>510</fpage>
          <lpage>516</lpage>
          <pub-id pub-id-type="pmid">15256388</pub-id>
        </element-citation>
      </ref>
      <ref id="b27">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bonniaud</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Margetts</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Kolb</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schroeder</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Kapoun</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Damm</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2005</year>
          <volume>171</volume>
          <fpage>889</fpage>
          <lpage>898</lpage>
          <pub-id pub-id-type="pmid">15563636</pub-id>
        </element-citation>
      </ref>
      <ref id="b28">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Borensztajn</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bresser</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>van der Loos</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bot</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>van den Blink</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>den Bakker</surname>
              <given-names>MA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Protease-activated receptor-2 induces myofibroblast differentiation and tissue factor up-regulation during bleomycin-induced lung injury. Potential role in pulmonary fibrosis</article-title>
          <source>Am J Pathol</source>
          <year>2010</year>
          <volume>177</volume>
          <fpage>2753</fpage>
          <lpage>2764</lpage>
          <pub-id pub-id-type="pmid">20971733</pub-id>
        </element-citation>
      </ref>
      <ref id="b29">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Borie</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fabre</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Prost</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Marchal-Somme</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lebtahi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Marchand-Adam</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Activation of somatostatin receptors attenuates pulmonary fibrosis</article-title>
          <source>Thorax</source>
          <year>2008</year>
          <volume>63</volume>
          <fpage>251</fpage>
          <lpage>258</lpage>
          <pub-id pub-id-type="pmid">17951277</pub-id>
        </element-citation>
      </ref>
      <ref id="b30">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Borok</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Buhl</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Grimes</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Bokser</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Hubbard</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Holroyd</surname>
              <given-names>KJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effect of glutathione aerosol on oxidant-antioxidant imbalance in idiopathic pulmonary fibrosis</article-title>
          <source>Lancet</source>
          <year>1991a</year>
          <volume>338</volume>
          <fpage>215</fpage>
          <lpage>216</lpage>
          <pub-id pub-id-type="pmid">1676780</pub-id>
        </element-citation>
      </ref>
      <ref id="b31">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Borok</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Gillissen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Buhl</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hoyt</surname>
              <given-names>RF</given-names>
            </name>
            <name>
              <surname>Hubbard</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Ozaki</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Augmentation of functional prostaglandin E levels on the respiratory epithelial surface by aerosol administration of prostaglandin E</article-title>
          <source>Am Rev Respir Dis</source>
          <year>1991b</year>
          <volume>144</volume>
          <fpage>1080</fpage>
          <lpage>1084</lpage>
          <pub-id pub-id-type="pmid">1952435</pub-id>
        </element-citation>
      </ref>
      <ref id="b32">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Borowski</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kuepper</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Horn</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Knupfer</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Zissel</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hohne</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Interleukin-13 acts as an apoptotic effector on lung epithelial cells and induces pro-fibrotic gene expression in lung fibroblasts</article-title>
          <source>Clin Exp Allergy</source>
          <year>2008</year>
          <volume>38</volume>
          <fpage>619</fpage>
          <lpage>628</lpage>
          <pub-id pub-id-type="pmid">18266877</pub-id>
        </element-citation>
      </ref>
      <ref id="b33">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Breuss</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Gallo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>DeLisser</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Klimanskaya</surname>
              <given-names>IV</given-names>
            </name>
            <name>
              <surname>Folkesson</surname>
              <given-names>HG</given-names>
            </name>
            <name>
              <surname>Pittet</surname>
              <given-names>JF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling</article-title>
          <source>J Cell Sci</source>
          <year>1995</year>
          <volume>108</volume>
          <fpage>2241</fpage>
          <lpage>2251</lpage>
          <pub-id pub-id-type="pmid">7673344</pub-id>
        </element-citation>
      </ref>
      <ref id="b34">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brewer</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Ullenbruch</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Dick</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Olivarez</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Phan</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
          <article-title>Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice</article-title>
          <source>J Lab Clin Med</source>
          <year>2003</year>
          <volume>141</volume>
          <fpage>210</fpage>
          <lpage>216</lpage>
          <pub-id pub-id-type="pmid">12624602</pub-id>
        </element-citation>
      </ref>
      <ref id="b35">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brewer</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Dick</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ullenbruch</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Jin</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Phan</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis</article-title>
          <source>J Inorg Biochem</source>
          <year>2004</year>
          <volume>98</volume>
          <fpage>2160</fpage>
          <lpage>2167</lpage>
          <pub-id pub-id-type="pmid">15541506</pub-id>
        </element-citation>
      </ref>
      <ref id="b36">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bucala</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Spiegel</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Chesney</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hogan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cerami</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair</article-title>
          <source>Mol Med</source>
          <year>1994</year>
          <volume>1</volume>
          <fpage>71</fpage>
          <lpage>81</lpage>
          <pub-id pub-id-type="pmid">8790603</pub-id>
        </element-citation>
      </ref>
      <ref id="b37">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Burdick</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Keane</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Xue</surname>
              <given-names>YY</given-names>
            </name>
            <name>
              <surname>Zisman</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Belperio</surname>
              <given-names>JA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2005</year>
          <volume>171</volume>
          <fpage>261</fpage>
          <lpage>268</lpage>
          <pub-id pub-id-type="pmid">15502109</pub-id>
        </element-citation>
      </ref>
      <ref id="b38">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cantin</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Hubbard</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Crystal</surname>
              <given-names>RG</given-names>
            </name>
          </person-group>
          <article-title>Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis</article-title>
          <source>Am Rev Respir Dis</source>
          <year>1989</year>
          <volume>139</volume>
          <fpage>370</fpage>
          <lpage>372</lpage>
          <pub-id pub-id-type="pmid">2913886</pub-id>
        </element-citation>
      </ref>
      <ref id="b39">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chambers</surname>
              <given-names>RC</given-names>
            </name>
          </person-group>
          <article-title>Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention?</article-title>
          <source>Br J Pharmacol</source>
          <year>2008</year>
          <volume>153</volume>
          <issue>Suppl 1</issue>
          <fpage>S367</fpage>
          <lpage>S378</lpage>
          <pub-id pub-id-type="pmid">18223674</pub-id>
        </element-citation>
      </ref>
      <ref id="b40">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chambers</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Leoni</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Blanc-Brude</surname>
              <given-names>OP</given-names>
            </name>
            <name>
              <surname>Wembridge</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Laurent</surname>
              <given-names>GJ</given-names>
            </name>
          </person-group>
          <article-title>Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of protease-activated receptor-1</article-title>
          <source>J Biol Chem</source>
          <year>2000</year>
          <volume>275</volume>
          <fpage>35584</fpage>
          <lpage>35591</lpage>
          <pub-id pub-id-type="pmid">10952976</pub-id>
        </element-citation>
      </ref>
      <ref id="b41">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chambers</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Leoni</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kaminski</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Laurent</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Heller</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Global expression profiling of fibroblast responses to transforming growth factor-beta1 reveals the induction of inhibitor of differentiation-1 and provides evidence of smooth muscle cell phenotypic switching</article-title>
          <source>Am J Pathol</source>
          <year>2003</year>
          <volume>162</volume>
          <fpage>533</fpage>
          <lpage>546</lpage>
          <pub-id pub-id-type="pmid">12547711</pub-id>
        </element-citation>
      </ref>
      <ref id="b42">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chilosi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Poletti</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Murer</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Lestani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cancellieri</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Montagna</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Abnormal re-epithelialization and lung remodeling in idiopathic pulmonary fibrosis: the role of deltaN-p63</article-title>
          <source>Lab Invest</source>
          <year>2002</year>
          <volume>82</volume>
          <fpage>1335</fpage>
          <lpage>1345</lpage>
          <pub-id pub-id-type="pmid">12379768</pub-id>
        </element-citation>
      </ref>
      <ref id="b43">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chilosi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Poletti</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Zamo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lestani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Montagna</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Piccoli</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis</article-title>
          <source>Am J Pathol</source>
          <year>2003</year>
          <volume>162</volume>
          <fpage>1495</fpage>
          <lpage>1502</lpage>
          <pub-id pub-id-type="pmid">12707032</pub-id>
        </element-citation>
      </ref>
      <ref id="b44">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cho</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Reddy</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kleeberger</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
          <article-title>The transcription factor NRF2 protects against pulmonary fibrosis</article-title>
          <source>FASEB J</source>
          <year>2004</year>
          <volume>18</volume>
          <fpage>1258</fpage>
          <lpage>1260</lpage>
          <pub-id pub-id-type="pmid">15208274</pub-id>
        </element-citation>
      </ref>
      <ref id="b45">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chrzanowska-Wodnicka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Burridge</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Rho-stimulated contractility drives the formation of stress fibers and focal adhesions</article-title>
          <source>J Cell Biol</source>
          <year>1996</year>
          <volume>133</volume>
          <fpage>1403</fpage>
          <lpage>1415</lpage>
          <pub-id pub-id-type="pmid">8682874</pub-id>
        </element-citation>
      </ref>
      <ref id="b46">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Clark</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Madtes</surname>
              <given-names>DK</given-names>
            </name>
            <name>
              <surname>Raghu</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Effects of platelet-derived growth factor isoforms on human lung fibroblast proliferation and procollagen gene expression</article-title>
          <source>Exp Lung Res</source>
          <year>1993</year>
          <volume>19</volume>
          <fpage>327</fpage>
          <lpage>344</lpage>
          <pub-id pub-id-type="pmid">8319603</pub-id>
        </element-citation>
      </ref>
      <ref id="b47">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coker</surname>
              <given-names>RK</given-names>
            </name>
            <name>
              <surname>Laurent</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Shahzeidi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lympany</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>du Bois</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Jeffery</surname>
              <given-names>PK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Transforming growth factors-beta 1, -beta 2, and -beta 3 stimulate fibroblast procollagen production in vitro but are differentially expressed during bleomycin-induced lung fibrosis</article-title>
          <source>Am J Pathol</source>
          <year>1997</year>
          <volume>150</volume>
          <fpage>981</fpage>
          <lpage>991</lpage>
          <pub-id pub-id-type="pmid">9060836</pub-id>
        </element-citation>
      </ref>
      <ref id="b48">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Collard</surname>
              <given-names>HR</given-names>
            </name>
          </person-group>
          <article-title>Idiopathic pulmonary fibrosis and pirfenidone</article-title>
          <source>Eur Respir J</source>
          <year>2010</year>
          <volume>35</volume>
          <fpage>728</fpage>
          <lpage>729</lpage>
          <pub-id pub-id-type="pmid">20356985</pub-id>
        </element-citation>
      </ref>
      <ref id="b49">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Collard</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Ryu</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Douglas</surname>
              <given-names>WW</given-names>
            </name>
            <name>
              <surname>Schwarz</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Curran-Everett</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>King</surname>
              <given-names>TE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis</article-title>
          <source>Chest</source>
          <year>2004</year>
          <volume>125</volume>
          <fpage>2169</fpage>
          <lpage>2174</lpage>
          <pub-id pub-id-type="pmid">15189938</pub-id>
        </element-citation>
      </ref>
      <ref id="b50">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Corrin</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Dewar</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rodriguez-Roisin</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Turner-Warwick</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Fine structural changes in cryptogenic fibrosing alveolitis and asbestosis</article-title>
          <source>J Pathol</source>
          <year>1985</year>
          <volume>147</volume>
          <fpage>107</fpage>
          <lpage>119</lpage>
          <pub-id pub-id-type="pmid">4067730</pub-id>
        </element-citation>
      </ref>
      <ref id="b51">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coultas</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Zumwalt</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Black</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Sobonya</surname>
              <given-names>RE</given-names>
            </name>
          </person-group>
          <article-title>The epidemiology of interstitial lung diseases</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>1994</year>
          <volume>150</volume>
          <fpage>967</fpage>
          <lpage>972</lpage>
          <pub-id pub-id-type="pmid">7921471</pub-id>
        </element-citation>
      </ref>
      <ref id="b52">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>D'Amato</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Loughnan</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Flynn</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Folkman</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Thalidomide is an inhibitor of angiogenesis</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>1994</year>
          <volume>91</volume>
          <fpage>4082</fpage>
          <lpage>4085</lpage>
          <pub-id pub-id-type="pmid">7513432</pub-id>
        </element-citation>
      </ref>
      <ref id="b53">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Daniels</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Wilkes</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Edens</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kottom</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Limper</surname>
              <given-names>AH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis</article-title>
          <source>J Clin Invest</source>
          <year>2004</year>
          <volume>114</volume>
          <fpage>1308</fpage>
          <lpage>1316</lpage>
          <pub-id pub-id-type="pmid">15520863</pub-id>
        </element-citation>
      </ref>
      <ref id="b54">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Daniels</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Lasky</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Limper</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Mieras</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Gabor</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Schroeder</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
          <article-title>Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2010</year>
          <volume>181</volume>
          <fpage>604</fpage>
          <lpage>610</lpage>
          <pub-id pub-id-type="pmid">20007927</pub-id>
        </element-citation>
      </ref>
      <ref id="b55">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davies</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Richeldi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Walters</surname>
              <given-names>EH</given-names>
            </name>
          </person-group>
          <article-title>Immunomodulatory agents for idiopathic pulmonary fibrosis</article-title>
          <source>Cochrane Database Syst Rev</source>
          <year>2003</year>
          <issue>3</issue>
          <comment>CD003134</comment>
        </element-citation>
      </ref>
      <ref id="b56">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Day</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Waters</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Spiegel</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Alnadaf</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Manley</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Buchdunger</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib</article-title>
          <source>Eur J Pharmacol</source>
          <year>2008</year>
          <volume>599</volume>
          <fpage>44</fpage>
          <lpage>53</lpage>
          <pub-id pub-id-type="pmid">18938156</pub-id>
        </element-citation>
      </ref>
      <ref id="b57">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Demedts</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Behr</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Buhl</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Costabel</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Dekhuijzen</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jansen</surname>
              <given-names>HM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>High-dose acetylcysteine in idiopathic pulmonary fibrosis</article-title>
          <source>N Engl J Med</source>
          <year>2005</year>
          <volume>353</volume>
          <fpage>2229</fpage>
          <lpage>2242</lpage>
          <pub-id pub-id-type="pmid">16306520</pub-id>
        </element-citation>
      </ref>
      <ref id="b58">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Deterding</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Jacoby</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Shannon</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Acidic fibroblast growth factor and keratinocyte growth factor stimulate fetal rat pulmonary epithelial growth</article-title>
          <source>Am J Physiol</source>
          <year>1996</year>
          <volume>271</volume>
          <fpage>L495</fpage>
          <lpage>L505</lpage>
          <pub-id pub-id-type="pmid">8897895</pub-id>
        </element-citation>
      </ref>
      <ref id="b59">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Deterding</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Havill</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Yano</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Middleton</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Jacoby</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Shannon</surname>
              <given-names>JM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prevention of bleomycin-induced lung injury in rats by keratinocyte growth factor</article-title>
          <source>Proc Assoc Am Physicians</source>
          <year>1997</year>
          <volume>109</volume>
          <fpage>254</fpage>
          <lpage>268</lpage>
          <pub-id pub-id-type="pmid">9154642</pub-id>
        </element-citation>
      </ref>
      <ref id="b60">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Di Sario</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bendia</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Svegliati Baroni</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ridolfi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Casini</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ceni</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production</article-title>
          <source>J Hepatol</source>
          <year>2002</year>
          <volume>37</volume>
          <fpage>584</fpage>
          <lpage>591</lpage>
          <pub-id pub-id-type="pmid">12399223</pub-id>
        </element-citation>
      </ref>
      <ref id="b61">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ding</surname>
              <given-names>LW</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ullenbruch</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Phan</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Activation of stem cell factor/c-kit signaling pathway in pulmonary fibrosis</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2010</year>
          <volume>181</volume>
          <issue>Suppl.</issue>
          <fpage>A3536</fpage>
        </element-citation>
      </ref>
      <ref id="b62">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dohi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hasegawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Marshall</surname>
              <given-names>BC</given-names>
            </name>
          </person-group>
          <article-title>Hepatocyte growth factor attenuates collagen accumulation in a murine model of pulmonary fibrosis</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2000</year>
          <volume>162</volume>
          <fpage>2302</fpage>
          <lpage>2307</lpage>
          <pub-id pub-id-type="pmid">11112155</pub-id>
        </element-citation>
      </ref>
      <ref id="b63">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dorscheid</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Wojcik</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Marroquin</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
          <article-title>Apoptosis of airway epithelial cells induced by corticosteroids</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2001</year>
          <volume>164</volume>
          <fpage>1939</fpage>
          <lpage>1947</lpage>
          <pub-id pub-id-type="pmid">11734450</pub-id>
        </element-citation>
      </ref>
      <ref id="b64">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Douglas</surname>
              <given-names>WW</given-names>
            </name>
            <name>
              <surname>Ryu</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Bjoraker</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Schroeder</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Myers</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Tazelaar</surname>
              <given-names>HD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Colchicine versus prednisone as treatment of usual interstitial pneumonia</article-title>
          <source>Mayo Clin Proc</source>
          <year>1997</year>
          <volume>72</volume>
          <fpage>201</fpage>
          <lpage>209</lpage>
          <pub-id pub-id-type="pmid">9070193</pub-id>
        </element-citation>
      </ref>
      <ref id="b65">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Douglas</surname>
              <given-names>WW</given-names>
            </name>
            <name>
              <surname>Ryu</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Schroeder</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
          <article-title>Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2000</year>
          <volume>161</volume>
          <fpage>1172</fpage>
          <lpage>1178</lpage>
          <pub-id pub-id-type="pmid">10764308</pub-id>
        </element-citation>
      </ref>
      <ref id="b66">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Elias</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Jimenez</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Freundlich</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Recombinant gamma, alpha, and beta interferon regulation of human lung fibroblast proliferation</article-title>
          <source>Am Rev Respir Dis</source>
          <year>1987</year>
          <volume>135</volume>
          <fpage>62</fpage>
          <lpage>65</lpage>
          <pub-id pub-id-type="pmid">3099617</pub-id>
        </element-citation>
      </ref>
      <ref id="b67">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Elias</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Freundlich</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rosenbloom</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Regulation of human lung fibroblast collagen production by recombinant interleukin-1, tumor necrosis factor, and interferon-gamma</article-title>
          <source>Ann N Y Acad Sci</source>
          <year>1990</year>
          <volume>580</volume>
          <fpage>233</fpage>
          <lpage>244</lpage>
          <pub-id pub-id-type="pmid">2110794</pub-id>
        </element-citation>
      </ref>
      <ref id="b68">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Erler</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Bennewith</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Nicolau</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dornhofer</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kong</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Le</surname>
              <given-names>QT</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Lysyl oxidase is essential for hypoxia-induced metastasis</article-title>
          <source>Nature</source>
          <year>2006</year>
          <volume>440</volume>
          <fpage>1222</fpage>
          <lpage>1226</lpage>
          <pub-id pub-id-type="pmid">16642001</pub-id>
        </element-citation>
      </ref>
      <ref id="b69">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ezquerro</surname>
              <given-names>IJ</given-names>
            </name>
            <name>
              <surname>Lasarte</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Dotor</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Castilla-Cortazar</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Bustos</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Penuelas</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury</article-title>
          <source>Cytokine</source>
          <year>2003</year>
          <volume>22</volume>
          <fpage>12</fpage>
          <lpage>20</lpage>
          <pub-id pub-id-type="pmid">12946101</pub-id>
        </element-citation>
      </ref>
      <ref id="b70">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feghali-Bostwick</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Tsai</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Valentine</surname>
              <given-names>VG</given-names>
            </name>
            <name>
              <surname>Kantrow</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Stoner</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Pilewski</surname>
              <given-names>JM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis</article-title>
          <source>J Immunol</source>
          <year>2007</year>
          <volume>179</volume>
          <fpage>2592</fpage>
          <lpage>2599</lpage>
          <pub-id pub-id-type="pmid">17675522</pub-id>
        </element-citation>
      </ref>
      <ref id="b71">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fichtner-Feigl</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Strober</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Kawakami</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Puri</surname>
              <given-names>RK</given-names>
            </name>
            <name>
              <surname>Kitani</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis</article-title>
          <source>Nat Med</source>
          <year>2006</year>
          <volume>12</volume>
          <fpage>99</fpage>
          <lpage>106</lpage>
          <pub-id pub-id-type="pmid">16327802</pub-id>
        </element-citation>
      </ref>
      <ref id="b72">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Finch</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Rubin</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Miki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ron</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Aaronson</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
          <article-title>Human KGF is FGF-related with properties of a paracrine effector of epithelial cell growth</article-title>
          <source>Science</source>
          <year>1989</year>
          <volume>245</volume>
          <fpage>752</fpage>
          <lpage>755</lpage>
          <pub-id pub-id-type="pmid">2475908</pub-id>
        </element-citation>
      </ref>
      <ref id="b73">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Flaherty</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Toews</surname>
              <given-names>GB</given-names>
            </name>
            <name>
              <surname>Lynch</surname>
              <given-names>JP</given-names>
              <suffix>3rd</suffix>
            </name>
            <name>
              <surname>Kazerooni</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Gross</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>Strawderman</surname>
              <given-names>RL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival</article-title>
          <source>Am J Med</source>
          <year>2001</year>
          <volume>110</volume>
          <fpage>278</fpage>
          <lpage>282</lpage>
          <pub-id pub-id-type="pmid">11239846</pub-id>
        </element-citation>
      </ref>
      <ref id="b74">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Flaherty</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Mumford</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kazerooni</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Gross</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>Colby</surname>
              <given-names>TV</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2003</year>
          <volume>168</volume>
          <fpage>543</fpage>
          <lpage>548</lpage>
          <pub-id pub-id-type="pmid">12773329</pub-id>
        </element-citation>
      </ref>
      <ref id="b75">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gasse</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Riteau</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Charron</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Girre</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fick</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Petrilli</surname>
              <given-names>V</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2009</year>
          <volume>179</volume>
          <fpage>903</fpage>
          <lpage>913</lpage>
          <pub-id pub-id-type="pmid">19218193</pub-id>
        </element-citation>
      </ref>
      <ref id="b76">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gharaee-Kermani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Denholm</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Phan</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
          <article-title>Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors</article-title>
          <source>J Biol Chem</source>
          <year>1996</year>
          <volume>271</volume>
          <fpage>17779</fpage>
          <lpage>17784</lpage>
          <pub-id pub-id-type="pmid">8663511</pub-id>
        </element-citation>
      </ref>
      <ref id="b77">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Giaid</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Michel</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Stewart</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Sheppard</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Corrin</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Hamid</surname>
              <given-names>Q</given-names>
            </name>
          </person-group>
          <article-title>Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis</article-title>
          <source>Lancet</source>
          <year>1993</year>
          <volume>341</volume>
          <fpage>1550</fpage>
          <lpage>1554</lpage>
          <pub-id pub-id-type="pmid">8099638</pub-id>
        </element-citation>
      </ref>
      <ref id="b78">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Giri</surname>
              <given-names>SN</given-names>
            </name>
            <name>
              <surname>Leonard</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Shi</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Margolin</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Vallyathan</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Effects of pirfenidone on the generation of reactive oxygen species in vitro</article-title>
          <source>J Environ Pathol Toxicol Oncol</source>
          <year>1999</year>
          <volume>18</volume>
          <fpage>169</fpage>
          <lpage>177</lpage>
          <pub-id pub-id-type="pmid">15281229</pub-id>
        </element-citation>
      </ref>
      <ref id="b79">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Giri</surname>
              <given-names>SN</given-names>
            </name>
            <name>
              <surname>Biring</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Hyde</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <article-title>Abrogation of bleomycin-induced lung fibrosis by nitric oxide synthase inhibitor, aminoguanidine in mice</article-title>
          <source>Nitric Oxide</source>
          <year>2002</year>
          <volume>7</volume>
          <fpage>109</fpage>
          <lpage>118</lpage>
          <pub-id pub-id-type="pmid">12223180</pub-id>
        </element-citation>
      </ref>
      <ref id="b80">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goldstein</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Polgar</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>The effect and interaction of bradykinin and prostaglandins on protein and collagen production by lung fibroblasts</article-title>
          <source>J Biol Chem</source>
          <year>1982</year>
          <volume>257</volume>
          <fpage>8630</fpage>
          <lpage>8633</lpage>
          <pub-id pub-id-type="pmid">6954152</pub-id>
        </element-citation>
      </ref>
      <ref id="b81">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gressner</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Weiskirchen</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets</article-title>
          <source>J Cell Mol Med</source>
          <year>2006</year>
          <volume>10</volume>
          <fpage>76</fpage>
          <lpage>99</lpage>
          <pub-id pub-id-type="pmid">16563223</pub-id>
        </element-citation>
      </ref>
      <ref id="b82">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gribbin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hubbard</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Le Jeune</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>West</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Tata</surname>
              <given-names>LJ</given-names>
            </name>
          </person-group>
          <article-title>Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK</article-title>
          <source>Thorax</source>
          <year>2006</year>
          <volume>61</volume>
          <fpage>980</fpage>
          <lpage>985</lpage>
          <pub-id pub-id-type="pmid">16844727</pub-id>
        </element-citation>
      </ref>
      <ref id="b83">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grunert</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jechlinger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Beug</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis</article-title>
          <source>Nat Rev Mol Cell Biol</source>
          <year>2003</year>
          <volume>4</volume>
          <fpage>657</fpage>
          <lpage>665</lpage>
          <pub-id pub-id-type="pmid">12923528</pub-id>
        </element-citation>
      </ref>
      <ref id="b84">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gu</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Tseng</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Horner</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Tam</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Loda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rollins</surname>
              <given-names>BJ</given-names>
            </name>
          </person-group>
          <article-title>Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1</article-title>
          <source>Nature</source>
          <year>2000</year>
          <volume>404</volume>
          <fpage>407</fpage>
          <lpage>411</lpage>
          <pub-id pub-id-type="pmid">10746730</pub-id>
        </element-citation>
      </ref>
      <ref id="b85">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gunther</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lubke</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ermert</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schermuly</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Weissmann</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Breithecker</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2003</year>
          <volume>168</volume>
          <fpage>1358</fpage>
          <lpage>1365</lpage>
          <pub-id pub-id-type="pmid">14644925</pub-id>
        </element-citation>
      </ref>
      <ref id="b86">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gurujeyalakshmi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Giri</surname>
              <given-names>SN</given-names>
            </name>
          </person-group>
          <article-title>Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression</article-title>
          <source>Exp Lung Res</source>
          <year>1995</year>
          <volume>21</volume>
          <fpage>791</fpage>
          <lpage>808</lpage>
          <pub-id pub-id-type="pmid">8556994</pub-id>
        </element-citation>
      </ref>
      <ref id="b87">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gurujeyalakshmi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hollinger</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Giri</surname>
              <given-names>SN</given-names>
            </name>
          </person-group>
          <article-title>Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level</article-title>
          <source>Am J Physiol</source>
          <year>1999</year>
          <volume>276</volume>
          <fpage>L311</fpage>
          <lpage>L318</lpage>
          <pub-id pub-id-type="pmid">9950894</pub-id>
        </element-citation>
      </ref>
      <ref id="b88">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hale</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Margolin</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Krakauer</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Roy</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Stiles</surname>
              <given-names>BG</given-names>
            </name>
          </person-group>
          <article-title>Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin B</article-title>
          <source>Infect Immun</source>
          <year>2002</year>
          <volume>70</volume>
          <fpage>2989</fpage>
          <lpage>2994</lpage>
          <pub-id pub-id-type="pmid">12010989</pub-id>
        </element-citation>
      </ref>
      <ref id="b89">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hamada</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kuwano</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yamada</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hagimoto</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Hiasa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Egashira</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice</article-title>
          <source>J Immunol</source>
          <year>2005</year>
          <volume>175</volume>
          <fpage>1224</fpage>
          <lpage>1231</lpage>
          <pub-id pub-id-type="pmid">16002726</pub-id>
        </element-citation>
      </ref>
      <ref id="b90">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hancock</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Armstrong</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gama</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Millar</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung</article-title>
          <source>Am J Respir Cell Mol Biol</source>
          <year>1998</year>
          <volume>18</volume>
          <fpage>60</fpage>
          <lpage>65</lpage>
          <pub-id pub-id-type="pmid">9448046</pub-id>
        </element-citation>
      </ref>
      <ref id="b91">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hashimoto</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Phan</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Imaizumi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Matsuo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nakashima</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kawabe</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis</article-title>
          <source>Am J Respir Cell Mol Biol</source>
          <year>2010</year>
          <volume>43</volume>
          <fpage>161</fpage>
          <lpage>172</lpage>
          <pub-id pub-id-type="pmid">19767450</pub-id>
        </element-citation>
      </ref>
      <ref id="b92">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haslett</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Corral</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>Albert</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kaplan</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset</article-title>
          <source>J Exp Med</source>
          <year>1998</year>
          <volume>187</volume>
          <fpage>1885</fpage>
          <lpage>1892</lpage>
          <pub-id pub-id-type="pmid">9607928</pub-id>
        </element-citation>
      </ref>
      <ref id="b93">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hayakawa</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tazawa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ishikawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Niiya</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sakuragawa</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Transcriptional regulation of tissue- and urokinase-type plasminogen activator genes by thrombin in human fetal lung fibroblasts</article-title>
          <source>Thromb Haemost</source>
          <year>1995</year>
          <volume>74</volume>
          <fpage>704</fpage>
          <lpage>710</lpage>
          <pub-id pub-id-type="pmid">8585010</pub-id>
        </element-citation>
      </ref>
      <ref id="b94">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hecker</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Vittal</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Jagirdar</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Luckhardt</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Horowitz</surname>
              <given-names>JC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury</article-title>
          <source>Nat Med</source>
          <year>2009</year>
          <volume>15</volume>
          <fpage>1077</fpage>
          <lpage>1081</lpage>
          <pub-id pub-id-type="pmid">19701206</pub-id>
        </element-citation>
      </ref>
      <ref id="b95">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Henderson</surname>
              <given-names>WR</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Chi</surname>
              <given-names>EY</given-names>
            </name>
            <name>
              <surname>Ye</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Tien</surname>
              <given-names>YT</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>2010</year>
          <volume>107</volume>
          <fpage>14309</fpage>
          <lpage>14314</lpage>
          <pub-id pub-id-type="pmid">20660310</pub-id>
        </element-citation>
      </ref>
      <ref id="b96">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hernandez-Rodriguez</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Cambrey</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Harrison</surname>
              <given-names>NK</given-names>
            </name>
            <name>
              <surname>Chambers</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Gray</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Southcott</surname>
              <given-names>AM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Role of thrombin in pulmonary fibrosis</article-title>
          <source>Lancet</source>
          <year>1995</year>
          <volume>346</volume>
          <fpage>1071</fpage>
          <lpage>1073</lpage>
          <pub-id pub-id-type="pmid">7564789</pub-id>
        </element-citation>
      </ref>
      <ref id="b97">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hewitson</surname>
              <given-names>TD</given-names>
            </name>
            <name>
              <surname>Kelynack</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Tait</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Martic</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Margolin</surname>
              <given-names>SB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis</article-title>
          <source>J Nephrol</source>
          <year>2001</year>
          <volume>14</volume>
          <fpage>453</fpage>
          <lpage>460</lpage>
          <pub-id pub-id-type="pmid">11783601</pub-id>
        </element-citation>
      </ref>
      <ref id="b98">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Higashiyama</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yoshimoto</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kaise</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fujiwara</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kikkawa</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis</article-title>
          <source>Exp Mol Pathol</source>
          <year>2007</year>
          <volume>83</volume>
          <fpage>39</fpage>
          <lpage>46</lpage>
          <pub-id pub-id-type="pmid">17274978</pub-id>
        </element-citation>
      </ref>
      <ref id="b99">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hogaboam</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Lukacs</surname>
              <given-names>NW</given-names>
            </name>
            <name>
              <surname>Chensue</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Strieter</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Kunkel</surname>
              <given-names>SL</given-names>
            </name>
          </person-group>
          <article-title>Monocyte chemoattractant protein-1 synthesis by murine lung fibroblasts modulates CD4+ T cell activation</article-title>
          <source>J Immunol</source>
          <year>1998</year>
          <volume>160</volume>
          <fpage>4606</fpage>
          <lpage>4614</lpage>
          <pub-id pub-id-type="pmid">9574568</pub-id>
        </element-citation>
      </ref>
      <ref id="b100">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Horan</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ona</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Lukashev</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Weinreb</surname>
              <given-names>PH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2008</year>
          <volume>177</volume>
          <fpage>56</fpage>
          <lpage>65</lpage>
          <pub-id pub-id-type="pmid">17916809</pub-id>
        </element-citation>
      </ref>
      <ref id="b101">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Howell</surname>
              <given-names>DCJ</given-names>
            </name>
            <name>
              <surname>Goldsack</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>Marshall</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>McAnulty</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Starke</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Purdy</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mrna levels in bleomycin-induced pulmonary fibrosis</article-title>
          <source>Am J Pathol</source>
          <year>2001</year>
          <volume>159</volume>
          <fpage>1383</fpage>
          <lpage>1395</lpage>
          <pub-id pub-id-type="pmid">11583966</pub-id>
        </element-citation>
      </ref>
      <ref id="b102">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Howell</surname>
              <given-names>DCJ</given-names>
            </name>
            <name>
              <surname>Johns</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Lasky</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Shan</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Scotton</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Laurent</surname>
              <given-names>GJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis</article-title>
          <source>Am J Pathol</source>
          <year>2005</year>
          <volume>166</volume>
          <fpage>1353</fpage>
          <lpage>1365</lpage>
          <pub-id pub-id-type="pmid">15855637</pub-id>
        </element-citation>
      </ref>
      <ref id="b103">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Humphreys</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Kobayashi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hudson</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Nowlin</surname>
              <given-names>BT</given-names>
            </name>
            <name>
              <surname>Bonventre</surname>
              <given-names>JV</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis</article-title>
          <source>Am J Pathol</source>
          <year>2010</year>
          <volume>176</volume>
          <fpage>85</fpage>
          <lpage>97</lpage>
          <pub-id pub-id-type="pmid">20008127</pub-id>
        </element-citation>
      </ref>
      <ref id="b104">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Imokawa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hayakawa</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kotani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Urano</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Takada</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>1997</year>
          <volume>156</volume>
          <fpage>631</fpage>
          <lpage>636</lpage>
          <pub-id pub-id-type="pmid">9279250</pub-id>
        </element-citation>
      </ref>
      <ref id="b105">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iyer</surname>
              <given-names>SN</given-names>
            </name>
            <name>
              <surname>Wild</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Schiedt</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Hyde</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Margolin</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Giri</surname>
              <given-names>SN</given-names>
            </name>
          </person-group>
          <article-title>Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters</article-title>
          <source>J Lab Clin Med</source>
          <year>1995</year>
          <volume>125</volume>
          <fpage>779</fpage>
          <lpage>785</lpage>
          <pub-id pub-id-type="pmid">7539478</pub-id>
        </element-citation>
      </ref>
      <ref id="b106">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iyer</surname>
              <given-names>SN</given-names>
            </name>
            <name>
              <surname>Gurujeyalakshmi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Giri</surname>
              <given-names>SN</given-names>
            </name>
          </person-group>
          <article-title>Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis</article-title>
          <source>J Pharmacol Exp Ther</source>
          <year>1999</year>
          <volume>291</volume>
          <fpage>367</fpage>
          <lpage>373</lpage>
          <pub-id pub-id-type="pmid">10490926</pub-id>
        </element-citation>
      </ref>
      <ref id="b107">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iyer</surname>
              <given-names>SN</given-names>
            </name>
            <name>
              <surname>Hyde</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Giri</surname>
              <given-names>SN</given-names>
            </name>
          </person-group>
          <article-title>Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation</article-title>
          <source>Inflammation</source>
          <year>2000</year>
          <volume>24</volume>
          <fpage>477</fpage>
          <lpage>491</lpage>
          <pub-id pub-id-type="pmid">10921510</pub-id>
        </element-citation>
      </ref>
      <ref id="b108">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jack</surname>
              <given-names>CI</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Johnston</surname>
              <given-names>ID</given-names>
            </name>
            <name>
              <surname>Hind</surname>
              <given-names>CR</given-names>
            </name>
          </person-group>
          <article-title>Serum indicators of free radical activity in idiopathic pulmonary fibrosis</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>1996</year>
          <volume>153</volume>
          <fpage>1918</fpage>
          <lpage>1923</lpage>
          <pub-id pub-id-type="pmid">8665056</pub-id>
        </element-citation>
      </ref>
      <ref id="b109">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jakubzick</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Joshi</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>Keane</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Kunkel</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Puri</surname>
              <given-names>RK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4- and IL-13-responsive cells</article-title>
          <source>J Immunol</source>
          <year>2003</year>
          <volume>171</volume>
          <fpage>2684</fpage>
          <lpage>2693</lpage>
          <pub-id pub-id-type="pmid">12928422</pub-id>
        </element-citation>
      </ref>
      <ref id="b110">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jenkins</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Su</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Su</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Scotton</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Camerer</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Laurent</surname>
              <given-names>GJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ligation of protease-activated receptor 1 enhances alpha(v)beta6 integrin-dependent TGF-beta activation and promotes acute lung injury</article-title>
          <source>J Clin Invest</source>
          <year>2006</year>
          <volume>116</volume>
          <fpage>1606</fpage>
          <lpage>1614</lpage>
          <pub-id pub-id-type="pmid">16710477</pub-id>
        </element-citation>
      </ref>
      <ref id="b111">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kagan</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell</article-title>
          <source>J Cell Biochem</source>
          <year>2003</year>
          <volume>88</volume>
          <fpage>660</fpage>
          <lpage>672</lpage>
          <pub-id pub-id-type="pmid">12577300</pub-id>
        </element-citation>
      </ref>
      <ref id="b112">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kakugawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Mukae</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hayashi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ishii</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Abe</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Fujii</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis</article-title>
          <source>Eur Respir J</source>
          <year>2004</year>
          <volume>24</volume>
          <fpage>57</fpage>
          <lpage>65</lpage>
          <pub-id pub-id-type="pmid">15293605</pub-id>
        </element-citation>
      </ref>
      <ref id="b113">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaminski</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Rosas</surname>
              <given-names>IO</given-names>
            </name>
          </person-group>
          <article-title>Gene expression profiling as a window into idiopathic pulmonary fibrosis pathogenesis: can we identify the right target genes?</article-title>
          <source>Proc Am Thorac Soc</source>
          <year>2006</year>
          <volume>3</volume>
          <fpage>339</fpage>
          <lpage>344</lpage>
          <pub-id pub-id-type="pmid">16738198</pub-id>
        </element-citation>
      </ref>
      <ref id="b114">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Karpus</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Lukacs</surname>
              <given-names>NW</given-names>
            </name>
            <name>
              <surname>Kennedy</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>WS</given-names>
            </name>
            <name>
              <surname>Hurst</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Barrett</surname>
              <given-names>TA</given-names>
            </name>
          </person-group>
          <article-title>Differential CC chemokine-induced enhancement of T helper cell cytokine production</article-title>
          <source>J Immunol</source>
          <year>1997</year>
          <volume>158</volume>
          <fpage>4129</fpage>
          <lpage>4136</lpage>
          <pub-id pub-id-type="pmid">9126972</pub-id>
        </element-citation>
      </ref>
      <ref id="b115">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kasper</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Haroske</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Alterations in the alveolar epithelium after injury leading to pulmonary fibrosis</article-title>
          <source>Histol Histopathol</source>
          <year>1996</year>
          <volume>11</volume>
          <fpage>463</fpage>
          <lpage>483</lpage>
          <pub-id pub-id-type="pmid">8861769</pub-id>
        </element-citation>
      </ref>
      <ref id="b116">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Katzenstein</surname>
              <given-names>AL</given-names>
            </name>
          </person-group>
          <article-title>Pathogenesis of &#x2018;fibrosis&#x2019; in interstitial pneumonia: an electron microscopic study</article-title>
          <source>Hum Pathol</source>
          <year>1985</year>
          <volume>16</volume>
          <fpage>1015</fpage>
          <lpage>1024</lpage>
          <pub-id pub-id-type="pmid">4043950</pub-id>
        </element-citation>
      </ref>
      <ref id="b117">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Katzenstein</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Myers</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>1998</year>
          <volume>157</volume>
          <fpage>1301</fpage>
          <lpage>1315</lpage>
          <pub-id pub-id-type="pmid">9563754</pub-id>
        </element-citation>
      </ref>
      <ref id="b118">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kawanami</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Ferrans</surname>
              <given-names>VJ</given-names>
            </name>
            <name>
              <surname>Crystal</surname>
              <given-names>RG</given-names>
            </name>
          </person-group>
          <article-title>Structure of alveolar epithelial cells in patients with fibrotic lung disorders</article-title>
          <source>Lab Invest</source>
          <year>1982</year>
          <volume>46</volume>
          <fpage>39</fpage>
          <lpage>53</lpage>
          <pub-id pub-id-type="pmid">7054589</pub-id>
        </element-citation>
      </ref>
      <ref id="b119">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Keane</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Arenberg</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Lynch</surname>
              <given-names>JP</given-names>
              <suffix>3rd</suffix>
            </name>
            <name>
              <surname>Whyte</surname>
              <given-names>RI</given-names>
            </name>
            <name>
              <surname>Iannettoni</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Burdick</surname>
              <given-names>MD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis</article-title>
          <source>J Immunol</source>
          <year>1997</year>
          <volume>159</volume>
          <fpage>1437</fpage>
          <lpage>1443</lpage>
          <pub-id pub-id-type="pmid">9233641</pub-id>
        </element-citation>
      </ref>
      <ref id="b120">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Keane</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Belperio</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Arenberg</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Burdick</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>ZJ</given-names>
            </name>
            <name>
              <surname>Xue</surname>
              <given-names>YY</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis</article-title>
          <source>J Immunol</source>
          <year>1999</year>
          <volume>163</volume>
          <fpage>5686</fpage>
          <lpage>5692</lpage>
          <pub-id pub-id-type="pmid">10553099</pub-id>
        </element-citation>
      </ref>
      <ref id="b121">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Keane</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Belperio</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Burdick</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Lynch</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Fishbein</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Strieter</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>
          <article-title>ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2001</year>
          <volume>164</volume>
          <fpage>2239</fpage>
          <lpage>2242</lpage>
          <pub-id pub-id-type="pmid">11751193</pub-id>
        </element-citation>
      </ref>
      <ref id="b122">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Keerthisingam</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Jenkins</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Harrison</surname>
              <given-names>NK</given-names>
            </name>
            <name>
              <surname>Hernandez-Rodriguez</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Booth</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Laurent</surname>
              <given-names>GJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice</article-title>
          <source>Am J Pathol</source>
          <year>2001</year>
          <volume>158</volume>
          <fpage>1411</fpage>
          <lpage>1422</lpage>
          <pub-id pub-id-type="pmid">11290559</pub-id>
        </element-citation>
      </ref>
      <ref id="b123">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kelly</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Lok</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Hasleton</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Egan</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Stewart</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>A rearranged form of Epstein-Barr virus DNA is associated with idiopathic pulmonary fibrosis</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2002</year>
          <volume>166</volume>
          <fpage>510</fpage>
          <lpage>513</lpage>
          <pub-id pub-id-type="pmid">12186829</pub-id>
        </element-citation>
      </ref>
      <ref id="b124">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khalil</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>O'Connor</surname>
              <given-names>RN</given-names>
            </name>
            <name>
              <surname>Flanders</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Unruh</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>TGF-beta 1, but not TGF-beta 2 or TGF-beta 3, is differentially present in epithelial cells of advanced pulmonary fibrosis: an immunohistochemical study</article-title>
          <source>Am J Respir Cell Mol Biol</source>
          <year>1996</year>
          <volume>14</volume>
          <fpage>131</fpage>
          <lpage>138</lpage>
          <pub-id pub-id-type="pmid">8630262</pub-id>
        </element-citation>
      </ref>
      <ref id="b125">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kikuchi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kishida</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Multiplicity of the interactions of Wnt proteins and their receptors</article-title>
          <source>Cell Signal</source>
          <year>2007</year>
          <volume>19</volume>
          <fpage>659</fpage>
          <lpage>671</lpage>
          <pub-id pub-id-type="pmid">17188462</pub-id>
        </element-citation>
      </ref>
      <ref id="b126">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Kugler</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Wolters</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Robillard</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Galvez</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Brumwell</surname>
              <given-names>AN</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>2006</year>
          <volume>103</volume>
          <fpage>13180</fpage>
          <lpage>13185</lpage>
          <pub-id pub-id-type="pmid">16924102</pub-id>
        </element-citation>
      </ref>
      <ref id="b127">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Szekeres</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kugler</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Wolters</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Hill</surname>
              <given-names>ML</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Epithelial cell alpha3beta1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis</article-title>
          <source>J Clin Invest</source>
          <year>2009</year>
          <volume>119</volume>
          <fpage>213</fpage>
          <lpage>224</lpage>
          <pub-id pub-id-type="pmid">19104148</pub-id>
        </element-citation>
      </ref>
      <ref id="b128">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>King</surname>
              <given-names>TE</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Tooze</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Schwarz</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Cherniack</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>
          <article-title>Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2001</year>
          <volume>164</volume>
          <fpage>1171</fpage>
          <lpage>1181</lpage>
          <pub-id pub-id-type="pmid">11673205</pub-id>
        </element-citation>
      </ref>
      <ref id="b129">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>King</surname>
              <given-names>TE</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Behr</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>du Bois</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Lancaster</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>de Andrade</surname>
              <given-names>JA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2008</year>
          <volume>177</volume>
          <fpage>75</fpage>
          <lpage>81</lpage>
          <pub-id pub-id-type="pmid">17901413</pub-id>
        </element-citation>
      </ref>
      <ref id="b130">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>King</surname>
              <given-names>TE</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Albera</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bradford</surname>
              <given-names>WZ</given-names>
            </name>
            <name>
              <surname>Costabel</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Hormel</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lancaster</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial</article-title>
          <source>Lancet</source>
          <year>2009</year>
          <volume>374</volume>
          <fpage>222</fpage>
          <lpage>228</lpage>
          <pub-id pub-id-type="pmid">19570573</pub-id>
        </element-citation>
      </ref>
      <ref id="b131">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koch</surname>
              <given-names>HP</given-names>
            </name>
          </person-group>
          <article-title>Thalidomide and congeners as anti-inflammatory agents</article-title>
          <source>Prog Med Chem</source>
          <year>1985</year>
          <volume>22</volume>
          <fpage>165</fpage>
          <lpage>242</lpage>
          <pub-id pub-id-type="pmid">3915365</pub-id>
        </element-citation>
      </ref>
      <ref id="b132">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kolb</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kirschner</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Riedel</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Wirtz</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Cyclophosphamide pulse therapy in idiopathic pulmonary fibrosis</article-title>
          <source>Eur Respir J</source>
          <year>1998</year>
          <volume>12</volume>
          <fpage>1409</fpage>
          <lpage>1414</lpage>
          <pub-id pub-id-type="pmid">9877500</pub-id>
        </element-citation>
      </ref>
      <ref id="b133">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kollias</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Douni</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kassiotis</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kontoyiannis</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease</article-title>
          <source>Immunol Rev</source>
          <year>1999</year>
          <volume>169</volume>
          <fpage>175</fpage>
          <lpage>194</lpage>
          <pub-id pub-id-type="pmid">10450517</pub-id>
        </element-citation>
      </ref>
      <ref id="b134">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kolodsick</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Peters-Golden</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Larios</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Toews</surname>
              <given-names>GB</given-names>
            </name>
            <name>
              <surname>Thannickal</surname>
              <given-names>VJ</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>BB</given-names>
            </name>
          </person-group>
          <article-title>Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation</article-title>
          <source>Am J Respir Cell Mol Biol</source>
          <year>2003</year>
          <volume>29</volume>
          <fpage>537</fpage>
          <lpage>544</lpage>
          <pub-id pub-id-type="pmid">12738687</pub-id>
        </element-citation>
      </ref>
      <ref id="b135">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kolodsick</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Toews</surname>
              <given-names>GB</given-names>
            </name>
            <name>
              <surname>Jakubzick</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hogaboam</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>McKenzie</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts</article-title>
          <source>J Immunol</source>
          <year>2004</year>
          <volume>172</volume>
          <fpage>4068</fpage>
          <lpage>4076</lpage>
          <pub-id pub-id-type="pmid">15034018</pub-id>
        </element-citation>
      </ref>
      <ref id="b136">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Komuro</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Kurihara</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sugiyama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yoshizumi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Takaku</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Yazaki</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells</article-title>
          <source>FEBS Lett</source>
          <year>1988</year>
          <volume>238</volume>
          <fpage>249</fpage>
          <lpage>252</lpage>
          <pub-id pub-id-type="pmid">3139457</pub-id>
        </element-citation>
      </ref>
      <ref id="b137">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kondoh</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Taniguchi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yokoi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nishiyama</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Ohishi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia</article-title>
          <source>Eur Respir J</source>
          <year>2005</year>
          <volume>25</volume>
          <fpage>528</fpage>
          <lpage>533</lpage>
          <pub-id pub-id-type="pmid">15738299</pub-id>
        </element-citation>
      </ref>
      <ref id="b138">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Konigshoff</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kramer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Balsara</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Wilhelm</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Amarie</surname>
              <given-names>OV</given-names>
            </name>
            <name>
              <surname>Jahn</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis</article-title>
          <source>J Clin Invest</source>
          <year>2009</year>
          <volume>119</volume>
          <fpage>772</fpage>
          <lpage>787</lpage>
          <pub-id pub-id-type="pmid">19287097</pub-id>
        </element-citation>
      </ref>
      <ref id="b139">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Korfei</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ruppert</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mahavadi</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Henneke</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Markart</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Koch</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2008</year>
          <volume>178</volume>
          <fpage>838</fpage>
          <lpage>846</lpage>
          <pub-id pub-id-type="pmid">18635891</pub-id>
        </element-citation>
      </ref>
      <ref id="b140">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Krowka</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Ahmad</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>de Andrade</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Frost</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Glassberg</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lancaster</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A ranomized, double-blind trial, placebo-controlled study to evaluate the safety and efficacy of iloprost inhalation in adults with abnormal pulmonary arterial pressure and exercise limitation associated with idiopathic pulmonary fibrosis</article-title>
          <source>Chest (Suppl)</source>
          <year>2007</year>
          <volume>132</volume>
          <fpage>633a</fpage>
        </element-citation>
      </ref>
      <ref id="b141">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kubo</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nakayama</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yanai</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yamaya</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Watanabe</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Anticoagulant therapy for idiopathic pulmonary fibrosis</article-title>
          <source>Chest</source>
          <year>2005</year>
          <volume>128</volume>
          <fpage>1475</fpage>
          <lpage>1482</lpage>
          <pub-id pub-id-type="pmid">16162746</pub-id>
        </element-citation>
      </ref>
      <ref id="b142">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kuhn</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>McDonald</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis</article-title>
          <source>Am J Pathol</source>
          <year>1991</year>
          <volume>138</volume>
          <fpage>1257</fpage>
          <lpage>1265</lpage>
          <pub-id pub-id-type="pmid">2024710</pub-id>
        </element-citation>
      </ref>
      <ref id="b143">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kuwano</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kunitake</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kawasaki</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nomoto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hagimoto</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Nakanishi</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>P21Waf1/Cip1/Sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>1996</year>
          <volume>154</volume>
          <fpage>477</fpage>
          <lpage>483</lpage>
          <pub-id pub-id-type="pmid">8756825</pub-id>
        </element-citation>
      </ref>
      <ref id="b144">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lama</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Christensen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Toews</surname>
              <given-names>GB</given-names>
            </name>
            <name>
              <surname>Peters-Golden</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Prostaglandin E2 synthesis and suppression of fibroblast proliferation by alveolar epithelial cells is cyclooxygenase-2-dependent</article-title>
          <source>Am J Respir Cell Mol Biol</source>
          <year>2002</year>
          <volume>27</volume>
          <fpage>752</fpage>
          <lpage>758</lpage>
          <pub-id pub-id-type="pmid">12444036</pub-id>
        </element-citation>
      </ref>
      <ref id="b145">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lama</surname>
              <given-names>VN</given-names>
            </name>
            <name>
              <surname>Phan</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
          <article-title>The extrapulmonary origin of fibroblasts: stem/progenitor cells and beyond</article-title>
          <source>Proc Am Thorac Soc</source>
          <year>2006</year>
          <volume>3</volume>
          <fpage>373</fpage>
          <lpage>376</lpage>
          <pub-id pub-id-type="pmid">16738203</pub-id>
        </element-citation>
      </ref>
      <ref id="b146">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Latsi</surname>
              <given-names>PI</given-names>
            </name>
            <name>
              <surname>du Bois</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Nicholson</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Colby</surname>
              <given-names>TV</given-names>
            </name>
            <name>
              <surname>Bisirtzoglou</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Nikolakopoulou</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2003</year>
          <volume>168</volume>
          <fpage>531</fpage>
          <lpage>537</lpage>
          <pub-id pub-id-type="pmid">12791580</pub-id>
        </element-citation>
      </ref>
      <ref id="b147">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lawson</surname>
              <given-names>WE</given-names>
            </name>
            <name>
              <surname>Grant</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Ambrosini</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Womble</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Dawson</surname>
              <given-names>EP</given-names>
            </name>
            <name>
              <surname>Lane</surname>
              <given-names>KB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF</article-title>
          <source>Thorax</source>
          <year>2004</year>
          <volume>59</volume>
          <fpage>977</fpage>
          <lpage>980</lpage>
          <pub-id pub-id-type="pmid">15516475</pub-id>
        </element-citation>
      </ref>
      <ref id="b148">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lawson</surname>
              <given-names>WE</given-names>
            </name>
            <name>
              <surname>Crossno</surname>
              <given-names>PF</given-names>
            </name>
            <name>
              <surname>Polosukhin</surname>
              <given-names>VV</given-names>
            </name>
            <name>
              <surname>Roldan</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Lane</surname>
              <given-names>KB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection</article-title>
          <source>Am J Physiol Lung Cell Mol Physiol</source>
          <year>2008</year>
          <volume>294</volume>
          <fpage>L1119</fpage>
          <lpage>L1126</lpage>
          <pub-id pub-id-type="pmid">18390830</pub-id>
        </element-citation>
      </ref>
      <ref id="b149">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leask</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Signaling in fibrosis: targeting the TGF beta, endothelin-1 and CCN2 axis in scleroderma</article-title>
          <source>Front Biosci (Elite Ed)</source>
          <year>2009</year>
          <volume>1</volume>
          <fpage>115</fpage>
          <lpage>122</lpage>
          <pub-id pub-id-type="pmid">19482630</pub-id>
        </element-citation>
      </ref>
      <ref id="b150">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leask</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Abraham</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
          <article-title>The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology</article-title>
          <source>Biochem Cell Biol</source>
          <year>2003</year>
          <volume>81</volume>
          <fpage>355</fpage>
          <lpage>363</lpage>
          <pub-id pub-id-type="pmid">14663501</pub-id>
        </element-citation>
      </ref>
      <ref id="b151">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Cho</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Chapoval</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Noble</surname>
              <given-names>PW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Early growth response gene 1-mediated apoptosis is essential for transforming growth factor beta1-induced pulmonary fibrosis</article-title>
          <source>J Exp Med</source>
          <year>2004</year>
          <volume>200</volume>
          <fpage>377</fpage>
          <lpage>389</lpage>
          <pub-id pub-id-type="pmid">15289506</pub-id>
        </element-citation>
      </ref>
      <ref id="b152">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lepisto</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Peltonen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vaha-Kreula</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Niinikoski</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Laato</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Platelet-derived growth factor isoforms PDGF-AA, -AB and -BB exert specific effects on collagen gene expression and mitotic activity of cultured human wound fibroblasts</article-title>
          <source>Biochem Biophys Res Commun</source>
          <year>1995</year>
          <volume>209</volume>
          <fpage>393</fpage>
          <lpage>399</lpage>
          <pub-id pub-id-type="pmid">7733905</pub-id>
        </element-citation>
      </ref>
      <ref id="b153">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Rayford</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Uhal</surname>
              <given-names>BD</given-names>
            </name>
          </person-group>
          <article-title>Essential roles for angiotensin receptor AT1a in bleomycin-induced apoptosis and lung fibrosis in mice</article-title>
          <source>Am J Pathol</source>
          <year>2003a</year>
          <volume>163</volume>
          <fpage>2523</fpage>
          <lpage>2530</lpage>
          <pub-id pub-id-type="pmid">14633624</pub-id>
        </element-citation>
      </ref>
      <ref id="b154">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Soledad-Conrad</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Zhuang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Uhal</surname>
              <given-names>BD</given-names>
            </name>
          </person-group>
          <article-title>Bleomycin-induced apoptosis of alveolar epithelial cells requires angiotensin synthesis de novo</article-title>
          <source>Am J Physiol Lung Cell Mol Physiol</source>
          <year>2003b</year>
          <volume>284</volume>
          <fpage>L501</fpage>
          <lpage>L507</lpage>
          <pub-id pub-id-type="pmid">12573988</pub-id>
        </element-citation>
      </ref>
      <ref id="b155">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Molina-Molina</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Abdul-Hafez</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ramirez</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Serrano-Mollar</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Xaubet</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Extravascular sources of lung angiotensin peptide synthesis in idiopathic pulmonary fibrosis</article-title>
          <source>Am J Physiol Lung Cell Mol Physiol</source>
          <year>2006</year>
          <volume>291</volume>
          <fpage>L887</fpage>
          <lpage>L895</lpage>
          <pub-id pub-id-type="pmid">16844946</pub-id>
        </element-citation>
      </ref>
      <ref id="b156">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Jin</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ullenbruch</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Hashimoto</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Regulation of found in inflammatory zone 1 expression in bleomycin-induced lung fibrosis: role of IL-4/IL-13 and mediation via STAT-6</article-title>
          <source>J Immunol</source>
          <year>2004</year>
          <volume>173</volume>
          <fpage>3425</fpage>
          <lpage>3431</lpage>
          <pub-id pub-id-type="pmid">15322207</pub-id>
        </element-citation>
      </ref>
      <ref id="b157">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Friggeri</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Milosevic</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ding</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Thannickal</surname>
              <given-names>VJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis</article-title>
          <source>J Exp Med</source>
          <year>2010a</year>
          <volume>207</volume>
          <fpage>1589</fpage>
          <lpage>1597</lpage>
          <pub-id pub-id-type="pmid">20643828</pub-id>
        </element-citation>
      </ref>
      <ref id="b158">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Taghavi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Leask</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Connective tissue growth factor is induced in bleomycin-induced skin scleroderma</article-title>
          <source>J Cell Commun Signal</source>
          <year>2010b</year>
          <volume>4</volume>
          <fpage>25</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="pmid">19916059</pub-id>
        </element-citation>
      </ref>
      <ref id="b159">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lovgren</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Jania</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Hartney</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Parsons</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Audoly</surname>
              <given-names>LP</given-names>
            </name>
            <name>
              <surname>Fitzgerald</surname>
              <given-names>GA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>COX-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis</article-title>
          <source>Am J Physiol Lung Cell Mol Physiol</source>
          <year>2006</year>
          <volume>291</volume>
          <fpage>L144</fpage>
          <lpage>L156</lpage>
          <pub-id pub-id-type="pmid">16473862</pub-id>
        </element-citation>
      </ref>
      <ref id="b160">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McAnulty</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Campa</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Cambrey</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Laurent</surname>
              <given-names>GJ</given-names>
            </name>
          </person-group>
          <article-title>The effect of transforming growth factor beta on rates of procollagen synthesis and degradation in vitro</article-title>
          <source>Biochim Biophys Acta</source>
          <year>1991</year>
          <volume>1091</volume>
          <fpage>231</fpage>
          <lpage>235</lpage>
          <pub-id pub-id-type="pmid">1995081</pub-id>
        </element-citation>
      </ref>
      <ref id="b161">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>MacNee</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Rahman</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Oxidants/antioxidants in idiopathic pulmonary fibrosis</article-title>
          <source>Thorax</source>
          <year>1995</year>
          <volume>50</volume>
          <issue>Suppl 1</issue>
          <fpage>S53</fpage>
          <lpage>S58</lpage>
          <pub-id pub-id-type="pmid">7570466</pub-id>
        </element-citation>
      </ref>
      <ref id="b162">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maeyama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kuwano</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kawasaki</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kunitake</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hagimoto</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Matsuba</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Upregulation of Fas-signalling molecules in lung epithelial cells from patients with idiopathic pulmonary fibrosis</article-title>
          <source>Eur Respir J</source>
          <year>2001</year>
          <volume>17</volume>
          <fpage>180</fpage>
          <lpage>189</lpage>
          <pub-id pub-id-type="pmid">11334117</pub-id>
        </element-citation>
      </ref>
      <ref id="b163">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maher</surname>
              <given-names>TM</given-names>
            </name>
          </person-group>
          <article-title>Pirfenidone in idiopathic pulmonary fibrosis</article-title>
          <source>Drugs Today (Barc)</source>
          <year>2010</year>
          <volume>46</volume>
          <fpage>473</fpage>
          <lpage>482</lpage>
          <pub-id pub-id-type="pmid">20683502</pub-id>
        </element-citation>
      </ref>
      <ref id="b164">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maher</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>IC</given-names>
            </name>
            <name>
              <surname>Bottoms</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Mercer</surname>
              <given-names>PF</given-names>
            </name>
            <name>
              <surname>Thorley</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Nicholson</surname>
              <given-names>AG</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Diminished prostaglandin E2 contributes to the apoptosis paradox in idiopathic pulmonary fibrosis</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2010a</year>
          <volume>182</volume>
          <fpage>73</fpage>
          <lpage>82</lpage>
          <pub-id pub-id-type="pmid">20203246</pub-id>
        </element-citation>
      </ref>
      <ref id="b165">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maher</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>IC</given-names>
            </name>
            <name>
              <surname>Laurent</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>McAnulty</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>PGE2 paradoxically increases fibroblast apoptosis but reduces airway epithelial cell apoptosis in response to FasL via activation of the EP4 receptor</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2010b</year>
          <volume>181</volume>
          <issue>Suppl.</issue>
          <fpage>A4182</fpage>
        </element-citation>
      </ref>
      <ref id="b166">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marchal-Somme</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Uzunhan</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Marchand-Adam</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kambouchner</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Valeyre</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Crestani</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Dendritic cells accumulate in human fibrotic interstitial lung disease</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2007</year>
          <volume>176</volume>
          <fpage>1007</fpage>
          <lpage>1014</lpage>
          <pub-id pub-id-type="pmid">17717200</pub-id>
        </element-citation>
      </ref>
      <ref id="b167">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Markart</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Luboeinski</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Korfei</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Wygrecka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mahavadi</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Alveolar oxidative stress is associated with elevated levels of nonenzymatic low-molecular-weight antioxidants in patients with different forms of chronic fibrosing interstitial lung diseases</article-title>
          <source>Antioxid Redox Signal</source>
          <year>2009</year>
          <volume>11</volume>
          <fpage>227</fpage>
          <lpage>240</lpage>
          <pub-id pub-id-type="pmid">18783310</pub-id>
        </element-citation>
      </ref>
      <ref id="b168">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Markart</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Nass</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ruppert</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hundack</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Wygrecka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Korfei</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Safety and tolerability of inhaled heparin in idiopathic pulmonary fibrosis</article-title>
          <source>J Aerosol Med Pulm Drug Deliv</source>
          <year>2010</year>
          <volume>23</volume>
          <fpage>161</fpage>
          <lpage>172</lpage>
          <pub-id pub-id-type="pmid">20109123</pub-id>
        </element-citation>
      </ref>
      <ref id="b169">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marshall</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Webb</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bellingan</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Montgomery</surname>
              <given-names>HE</given-names>
            </name>
            <name>
              <surname>Chaudhari</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>McAnulty</surname>
              <given-names>RJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2002</year>
          <volume>166</volume>
          <fpage>646</fpage>
          <lpage>650</lpage>
          <pub-id pub-id-type="pmid">12204859</pub-id>
        </element-citation>
      </ref>
      <ref id="b170">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marshall</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Gohlke</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Chambers</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Howell</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Bottoms</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Unger</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Angiotensin II and the fibroproliferative response to acute lung injury</article-title>
          <source>Am J Physiol Lung Cell Mol Physiol</source>
          <year>2004</year>
          <volume>286</volume>
          <fpage>L156</fpage>
          <lpage>L164</lpage>
          <pub-id pub-id-type="pmid">12754187</pub-id>
        </element-citation>
      </ref>
      <ref id="b171">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mehrad</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Burdick</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Strieter</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>
          <article-title>Fibrocyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis</article-title>
          <source>Int J Biochem Cell Biol</source>
          <year>2009</year>
          <volume>41</volume>
          <fpage>1708</fpage>
          <lpage>1718</lpage>
          <pub-id pub-id-type="pmid">19433312</pub-id>
        </element-citation>
      </ref>
      <ref id="b172">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miyazaki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Araki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Vesin</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Garcia</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Kapanci</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Whitsett</surname>
              <given-names>JA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis</article-title>
          <source>J Clin Invest</source>
          <year>1995</year>
          <volume>96</volume>
          <fpage>250</fpage>
          <lpage>259</lpage>
          <pub-id pub-id-type="pmid">7542280</pub-id>
        </element-citation>
      </ref>
      <ref id="b173">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mizuno</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>MY</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis</article-title>
          <source>FASEB J</source>
          <year>2005</year>
          <volume>19</volume>
          <fpage>580</fpage>
          <lpage>582</lpage>
          <pub-id pub-id-type="pmid">15665032</pub-id>
        </element-citation>
      </ref>
      <ref id="b174">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moeller</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ask</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Warburton</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gauldie</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kolb</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?</article-title>
          <source>Int J Biochem Cell Biol</source>
          <year>2008</year>
          <volume>40</volume>
          <fpage>362</fpage>
          <lpage>382</lpage>
          <pub-id pub-id-type="pmid">17936056</pub-id>
        </element-citation>
      </ref>
      <ref id="b175">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moeller</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gilpin</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Ask</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Cox</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cook</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gauldie</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2009</year>
          <volume>179</volume>
          <fpage>588</fpage>
          <lpage>594</lpage>
          <pub-id pub-id-type="pmid">19151190</pub-id>
        </element-citation>
      </ref>
      <ref id="b176">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Montaldo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cannas</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ledda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rosetti</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Congiu</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Atzori</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Bronchoalveolar glutathione and nitrite/nitrate in idiopathic pulmonary fibrosis and sarcoidosis</article-title>
          <source>Sarcoidosis Vasc Diffuse Lung Dis</source>
          <year>2002</year>
          <volume>19</volume>
          <fpage>54</fpage>
          <lpage>58</lpage>
          <pub-id pub-id-type="pmid">12002386</pub-id>
        </element-citation>
      </ref>
      <ref id="b177">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Montuschi</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ciabattoni</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Paredi</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Pantelidis</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>du Bois</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Kharitonov</surname>
              <given-names>SA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>1998</year>
          <volume>158</volume>
          <fpage>1524</fpage>
          <lpage>1527</lpage>
          <pub-id pub-id-type="pmid">9817703</pub-id>
        </element-citation>
      </ref>
      <ref id="b178">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moodley</surname>
              <given-names>YP</given-names>
            </name>
            <name>
              <surname>Scaffidi</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Misso</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Keerthisingam</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>McAnulty</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Laurent</surname>
              <given-names>GJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Fibroblasts isolated from normal lungs and those with idiopathic pulmonary fibrosis differ in interleukin-6/gp130-mediated cell signaling and proliferation</article-title>
          <source>Am J Pathol</source>
          <year>2003</year>
          <volume>163</volume>
          <fpage>345</fpage>
          <lpage>354</lpage>
          <pub-id pub-id-type="pmid">12819039</pub-id>
        </element-citation>
      </ref>
      <ref id="b179">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moodley</surname>
              <given-names>YP</given-names>
            </name>
            <name>
              <surname>Caterina</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Scaffidi</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Misso</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Papadimitriou</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>McAnulty</surname>
              <given-names>RJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Comparison of the morphological and biochemical changes in normal human lung fibroblasts and fibroblasts derived from lungs of patients with idiopathic pulmonary fibrosis during FasL-induced apoptosis</article-title>
          <source>J Pathol</source>
          <year>2004</year>
          <volume>202</volume>
          <fpage>486</fpage>
          <lpage>495</lpage>
          <pub-id pub-id-type="pmid">15095276</pub-id>
        </element-citation>
      </ref>
      <ref id="b180">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moore</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Kolodsick</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Thannickal</surname>
              <given-names>VJ</given-names>
            </name>
            <name>
              <surname>Cooke</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Hogaboam</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury</article-title>
          <source>Am J Pathol</source>
          <year>2005</year>
          <volume>166</volume>
          <fpage>675</fpage>
          <lpage>684</lpage>
          <pub-id pub-id-type="pmid">15743780</pub-id>
        </element-citation>
      </ref>
      <ref id="b181">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moore</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Das</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wilke</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Herrygers</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Toews</surname>
              <given-names>GB</given-names>
            </name>
          </person-group>
          <article-title>The role of CCL12 in the recruitment of fibrocytes and lung fibrosis</article-title>
          <source>Am J Respir Cell Mol Biol</source>
          <year>2006</year>
          <volume>35</volume>
          <fpage>175</fpage>
          <lpage>181</lpage>
          <pub-id pub-id-type="pmid">16543609</pub-id>
        </element-citation>
      </ref>
      <ref id="b182">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Munger</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Kawakatsu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Griffiths</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Dalton</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis</article-title>
          <source>Cell</source>
          <year>1999</year>
          <volume>96</volume>
          <fpage>319</fpage>
          <lpage>328</lpage>
          <pub-id pub-id-type="pmid">10025398</pub-id>
        </element-citation>
      </ref>
      <ref id="b183">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murphy</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Ouyang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Farrar</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ranganath</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Asnagli</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Signaling and transcription in T helper development</article-title>
          <source>Annu Rev Immunol</source>
          <year>2000</year>
          <volume>18</volume>
          <fpage>451</fpage>
          <lpage>494</lpage>
          <pub-id pub-id-type="pmid">10837066</pub-id>
        </element-citation>
      </ref>
      <ref id="b184">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murphy-Ullrich</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Poczatek</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology</article-title>
          <source>Cytokine Growth Factor Rev</source>
          <year>2000</year>
          <volume>11</volume>
          <fpage>59</fpage>
          <lpage>69</lpage>
          <pub-id pub-id-type="pmid">10708953</pub-id>
        </element-citation>
      </ref>
      <ref id="b185">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mutsaers</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Marshall</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Goldsack</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>Laurent</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>McAnulty</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>Effect of endothelin receptor antagonists (BQ-485, Ro 47-0203) on collagen deposition during the development of bleomycin-induced pulmonary fibrosis in rats</article-title>
          <source>Pulm Pharmacol Ther</source>
          <year>1998</year>
          <volume>11</volume>
          <fpage>221</fpage>
          <lpage>225</lpage>
          <pub-id pub-id-type="pmid">9918760</pub-id>
        </element-citation>
      </ref>
      <ref id="b186">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nakazato</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Oku</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yamane</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tsuruta</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level</article-title>
          <source>Eur J Pharmacol</source>
          <year>2002</year>
          <volume>446</volume>
          <fpage>177</fpage>
          <lpage>185</lpage>
          <pub-id pub-id-type="pmid">12098600</pub-id>
        </element-citation>
      </ref>
      <ref id="b187">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nash</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>McLaughlin</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Butcher</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Corrin</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Expression of tumour necrosis factor-alpha in cryptogenic fibrosing alveolitis</article-title>
          <source>Histopathology</source>
          <year>1993</year>
          <volume>22</volume>
          <fpage>343</fpage>
          <lpage>347</lpage>
          <pub-id pub-id-type="pmid">8514277</pub-id>
        </element-citation>
      </ref>
      <ref id="b188">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nyhan</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Faherty</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cooey</surname>
              <given-names>LB</given-names>
            </name>
            <name>
              <surname>Godson</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Crean</surname>
              <given-names>JK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Jagged/Notch signalling is required for a subset of TGFbeta1 responses in human kidney epithelial cells</article-title>
          <source>Biochim Biophys Acta</source>
          <year>2010</year>
          <volume>1803</volume>
          <fpage>1386</fpage>
          <lpage>1395</lpage>
          <pub-id pub-id-type="pmid">20833210</pub-id>
        </element-citation>
      </ref>
      <ref id="b189">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oikonomou</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Harokopos</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Zalevsky</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Valavanis</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kotanidou</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Szymkowski</surname>
              <given-names>DE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Soluble TNF mediates the transition from pulmonary inflammation to fibrosis</article-title>
          <source>PloS ONE</source>
          <year>2006</year>
          <volume>1</volume>
          <fpage>e108</fpage>
          <pub-id pub-id-type="pmid">17205112</pub-id>
        </element-citation>
      </ref>
      <ref id="b190">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oku</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nakazato</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Horikawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tsuruta</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock</article-title>
          <source>Eur J Pharmacol</source>
          <year>2002</year>
          <volume>446</volume>
          <fpage>167</fpage>
          <lpage>176</lpage>
          <pub-id pub-id-type="pmid">12098599</pub-id>
        </element-citation>
      </ref>
      <ref id="b191">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oriente</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fedarko</surname>
              <given-names>NS</given-names>
            </name>
            <name>
              <surname>Pacocha</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Lichtenstein</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Essayan</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <article-title>Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts</article-title>
          <source>J Pharmacol Exp Ther</source>
          <year>2000</year>
          <volume>292</volume>
          <fpage>988</fpage>
          <lpage>994</lpage>
          <pub-id pub-id-type="pmid">10688614</pub-id>
        </element-citation>
      </ref>
      <ref id="b192">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ortiz</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Lasky</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hamilton</surname>
              <given-names>RF</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Holian</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hoyle</surname>
              <given-names>GW</given-names>
            </name>
            <name>
              <surname>Banks</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice</article-title>
          <source>Exp Lung Res</source>
          <year>1998</year>
          <volume>24</volume>
          <fpage>721</fpage>
          <lpage>743</lpage>
          <pub-id pub-id-type="pmid">9839161</pub-id>
        </element-citation>
      </ref>
      <ref id="b193">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Otsuka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Shiratori</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chiba</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Abe</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist</article-title>
          <source>Thorax</source>
          <year>2004</year>
          <volume>59</volume>
          <fpage>31</fpage>
          <lpage>38</lpage>
          <pub-id pub-id-type="pmid">14694243</pub-id>
        </element-citation>
      </ref>
      <ref id="b194">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Overall</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Wrana</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Sodek</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Transforming growth factor-beta regulation of collagenase, 72 kDa-progelatinase, TIMP and PAI-1 expression in rat bone cell populations and human fibroblasts</article-title>
          <source>Connect Tissue Res</source>
          <year>1989</year>
          <volume>20</volume>
          <fpage>289</fpage>
          <lpage>294</lpage>
          <pub-id pub-id-type="pmid">2558843</pub-id>
        </element-citation>
      </ref>
      <ref id="b195">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ozawa</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Suda</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Naito</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Enomoto</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Hashimoto</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Fujisawa</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cumulative incidence of and predictive factors for lung cancer in IPF</article-title>
          <source>Respirology</source>
          <year>2009</year>
          <volume>14</volume>
          <fpage>723</fpage>
          <lpage>728</lpage>
          <pub-id pub-id-type="pmid">19659650</pub-id>
        </element-citation>
      </ref>
      <ref id="b196">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pan</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Kleer</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>van Golen</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Irani</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bottema</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Bias</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis</article-title>
          <source>Cancer Res</source>
          <year>2002</year>
          <volume>62</volume>
          <fpage>4854</fpage>
          <lpage>4859</lpage>
          <pub-id pub-id-type="pmid">12208730</pub-id>
        </element-citation>
      </ref>
      <ref id="b197">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pandit</surname>
              <given-names>KV</given-names>
            </name>
            <name>
              <surname>Corcoran</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Yousef</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yarlagadda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tzouvelekis</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gibson</surname>
              <given-names>KF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Inhibition and role of let-7d in idiopathic pulmonary fibrosis</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2010</year>
          <volume>182</volume>
          <fpage>220</fpage>
          <lpage>229</lpage>
          <pub-id pub-id-type="pmid">20395557</pub-id>
        </element-citation>
      </ref>
      <ref id="b198">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Park</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Saleh</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Giaid</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Michel</surname>
              <given-names>RP</given-names>
            </name>
          </person-group>
          <article-title>Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>1997</year>
          <volume>156</volume>
          <fpage>600</fpage>
          <lpage>608</lpage>
          <pub-id pub-id-type="pmid">9279246</pub-id>
        </element-citation>
      </ref>
      <ref id="b199">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peacock</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Dawes</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Shock</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gray</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Reeves</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Laurent</surname>
              <given-names>GJ</given-names>
            </name>
          </person-group>
          <article-title>Endothelin-1 and endothelin-3 induce chemotaxis and replication of pulmonary artery fibroblasts</article-title>
          <source>Am J Respir Cell Mol Biol</source>
          <year>1992</year>
          <volume>7</volume>
          <fpage>492</fpage>
          <lpage>499</lpage>
          <pub-id pub-id-type="pmid">1419025</pub-id>
        </element-citation>
      </ref>
      <ref id="b200">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peao</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Aguas</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>de Sa</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Grande</surname>
              <given-names>NR</given-names>
            </name>
          </person-group>
          <article-title>Neoformation of blood vessels in association with rat lung fibrosis induced by bleomycin</article-title>
          <source>Anat Rec</source>
          <year>1994</year>
          <volume>238</volume>
          <fpage>57</fpage>
          <lpage>67</lpage>
          <pub-id pub-id-type="pmid">7509580</pub-id>
        </element-citation>
      </ref>
      <ref id="b201">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pedram</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Razandi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Levin</surname>
              <given-names>ER</given-names>
            </name>
          </person-group>
          <article-title>Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion</article-title>
          <source>J Biol Chem</source>
          <year>1997</year>
          <volume>272</volume>
          <fpage>17097</fpage>
          <lpage>17103</lpage>
          <pub-id pub-id-type="pmid">9202027</pub-id>
        </element-citation>
      </ref>
      <ref id="b202">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peters-Golden</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bailie</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Marshall</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Wilke</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Phan</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Toews</surname>
              <given-names>GB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Protection from pulmonary fibrosis in leukotriene-deficient mice</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2002</year>
          <volume>165</volume>
          <fpage>229</fpage>
          <lpage>235</lpage>
          <pub-id pub-id-type="pmid">11790660</pub-id>
        </element-citation>
      </ref>
      <ref id="b203">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Phan</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
          <article-title>The myofibroblast in pulmonary fibrosis</article-title>
          <source>Chest</source>
          <year>2002</year>
          <volume>122</volume>
          <fpage>286S</fpage>
          <lpage>289S</lpage>
          <pub-id pub-id-type="pmid">12475801</pub-id>
        </element-citation>
      </ref>
      <ref id="b204">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Phelps</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Deneke</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Daley</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Fanburg</surname>
              <given-names>BL</given-names>
            </name>
          </person-group>
          <article-title>Elevation of glutathione levels in bovine pulmonary artery endothelial cells by N-acetylcysteine</article-title>
          <source>Am J Respir Cell Mol Biol</source>
          <year>1992</year>
          <volume>7</volume>
          <fpage>293</fpage>
          <lpage>299</lpage>
          <pub-id pub-id-type="pmid">1520492</pub-id>
        </element-citation>
      </ref>
      <ref id="b205">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Phillips</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Burdick</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Lutz</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Xue</surname>
              <given-names>YY</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis</article-title>
          <source>J Clin Invest</source>
          <year>2004</year>
          <volume>114</volume>
          <fpage>438</fpage>
          <lpage>446</lpage>
          <pub-id pub-id-type="pmid">15286810</pub-id>
        </element-citation>
      </ref>
      <ref id="b206">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Piguet</surname>
              <given-names>PF</given-names>
            </name>
            <name>
              <surname>Collart</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Grau</surname>
              <given-names>GE</given-names>
            </name>
            <name>
              <surname>Kapanci</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Vassalli</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis</article-title>
          <source>J Exp Med</source>
          <year>1989</year>
          <volume>170</volume>
          <fpage>655</fpage>
          <lpage>663</lpage>
          <pub-id pub-id-type="pmid">2475571</pub-id>
        </element-citation>
      </ref>
      <ref id="b207">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Piguet</surname>
              <given-names>PF</given-names>
            </name>
            <name>
              <surname>Ribaux</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Karpuz</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Grau</surname>
              <given-names>GE</given-names>
            </name>
            <name>
              <surname>Kapanci</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis</article-title>
          <source>Am J Pathol</source>
          <year>1993</year>
          <volume>143</volume>
          <fpage>651</fpage>
          <lpage>655</lpage>
          <pub-id pub-id-type="pmid">8362967</pub-id>
        </element-citation>
      </ref>
      <ref id="b208">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Plataki</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Koutsopoulos</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Darivianaki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Delides</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Siafakas</surname>
              <given-names>NM</given-names>
            </name>
            <name>
              <surname>Bouros</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Expression of apoptotic and antiapoptotic markers in epithelial cells in idiopathic pulmonary fibrosis</article-title>
          <source>Chest</source>
          <year>2005</year>
          <volume>127</volume>
          <fpage>266</fpage>
          <lpage>274</lpage>
          <pub-id pub-id-type="pmid">15653994</pub-id>
        </element-citation>
      </ref>
      <ref id="b209">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Raghow</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Postlethwaite</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Keski-Oja</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Moses</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>AH</given-names>
            </name>
          </person-group>
          <article-title>Transforming growth factor-beta increases steady state levels of type I procollagen and fibronectin messenger RNAs posttranscriptionally in cultured human dermal fibroblasts</article-title>
          <source>J Clin Invest</source>
          <year>1987</year>
          <volume>79</volume>
          <fpage>1285</fpage>
          <lpage>1288</lpage>
          <pub-id pub-id-type="pmid">3470308</pub-id>
        </element-citation>
      </ref>
      <ref id="b210">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Raghu</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Depaso</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Cain</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hammar</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Wetzel</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Dreis</surname>
              <given-names>DF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial</article-title>
          <source>Am Rev Respir Dis</source>
          <year>1991</year>
          <volume>144</volume>
          <fpage>291</fpage>
          <lpage>296</lpage>
          <pub-id pub-id-type="pmid">1859050</pub-id>
        </element-citation>
      </ref>
      <ref id="b211">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Raghu</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Bradford</surname>
              <given-names>WZ</given-names>
            </name>
            <name>
              <surname>Starko</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Noble</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>DA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis</article-title>
          <source>N Engl J Med</source>
          <year>2004</year>
          <volume>350</volume>
          <fpage>125</fpage>
          <lpage>133</lpage>
          <pub-id pub-id-type="pmid">14711911</pub-id>
        </element-citation>
      </ref>
      <ref id="b212">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Raghu</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Costabel</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Cottin</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>du Bois</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Lasky</surname>
              <given-names>JA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2008</year>
          <volume>178</volume>
          <fpage>948</fpage>
          <lpage>955</lpage>
          <pub-id pub-id-type="pmid">18669816</pub-id>
        </element-citation>
      </ref>
      <ref id="b213">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rahman</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Skwarska</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Henry</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>O'Connor</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>FitzGerald</surname>
              <given-names>MX</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Systemic and pulmonary oxidative stress in idiopathic pulmonary fibrosis</article-title>
          <source>Free Radic Biol Med</source>
          <year>1999</year>
          <volume>27</volume>
          <fpage>60</fpage>
          <lpage>68</lpage>
          <pub-id pub-id-type="pmid">10443920</pub-id>
        </element-citation>
      </ref>
      <ref id="b214">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ramos</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Montano</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Garcia-Alvarez</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ruiz</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Uhal</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Selman</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression</article-title>
          <source>Am J Respir Cell Mol Biol</source>
          <year>2001</year>
          <volume>24</volume>
          <fpage>591</fpage>
          <lpage>598</lpage>
          <pub-id pub-id-type="pmid">11350829</pub-id>
        </element-citation>
      </ref>
      <ref id="b215">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reddy</surname>
              <given-names>NM</given-names>
            </name>
            <name>
              <surname>Kleeberger</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Cho</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kensler</surname>
              <given-names>TW</given-names>
            </name>
            <name>
              <surname>Biswal</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Deficiency in Nrf2-GSH signaling impairs type II cell growth and enhances sensitivity to oxidants</article-title>
          <source>Am J Respir Cell Mol Biol</source>
          <year>2007</year>
          <volume>37</volume>
          <fpage>3</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">17413030</pub-id>
        </element-citation>
      </ref>
      <ref id="b216">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Renzoni</surname>
              <given-names>EA</given-names>
            </name>
          </person-group>
          <article-title>Neovascularization in idiopathic pulmonary fibrosis: too much or too little?</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2004</year>
          <volume>169</volume>
          <fpage>1179</fpage>
          <lpage>1180</lpage>
          <pub-id pub-id-type="pmid">15161610</pub-id>
        </element-citation>
      </ref>
      <ref id="b217">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Renzoni</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Walsh</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Salmon</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wells</surname>
              <given-names>AU</given-names>
            </name>
            <name>
              <surname>Sestini</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Nicholson</surname>
              <given-names>AG</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Interstitial vascularity in fibrosing alveolitis</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2003</year>
          <volume>167</volume>
          <fpage>438</fpage>
          <lpage>443</lpage>
          <pub-id pub-id-type="pmid">12406847</pub-id>
        </element-citation>
      </ref>
      <ref id="b218">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rose</surname>
              <given-names>CE</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Sung</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Fu</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
          <article-title>Significant involvement of CCL2 (MCP-1) in inflammatory disorders of the lung</article-title>
          <source>Microcirculation</source>
          <year>2003</year>
          <volume>10</volume>
          <fpage>273</fpage>
          <lpage>288</lpage>
          <pub-id pub-id-type="pmid">12851645</pub-id>
        </element-citation>
      </ref>
      <ref id="b219">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rosenbloom</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Freundlich</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Jimenez</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of excessive scleroderma fibroblast collagen production by recombinant gamma-interferon. Association with a coordinate decrease in types I and III procollagen messenger RNA levels</article-title>
          <source>Arthritis Rheum</source>
          <year>1986</year>
          <volume>29</volume>
          <fpage>851</fpage>
          <lpage>856</lpage>
          <pub-id pub-id-type="pmid">3091039</pub-id>
        </element-citation>
      </ref>
      <ref id="b220">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rubin</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Osada</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Finch</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>WG</given-names>
            </name>
            <name>
              <surname>Rudikoff</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Aaronson</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
          <article-title>Purification and characterization of a newly identified growth factor specific for epithelial cells</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>1989</year>
          <volume>86</volume>
          <fpage>802</fpage>
          <lpage>806</lpage>
          <pub-id pub-id-type="pmid">2915979</pub-id>
        </element-citation>
      </ref>
      <ref id="b221">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Saito</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Okazaki</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sugawara</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Takizawa</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Potential action of IL-4 and IL-13 as fibrogenic factors on lung fibroblasts in vitro</article-title>
          <source>Int Arch Allergy Immunol</source>
          <year>2003</year>
          <volume>132</volume>
          <fpage>168</fpage>
          <lpage>176</lpage>
          <pub-id pub-id-type="pmid">14600429</pub-id>
        </element-citation>
      </ref>
      <ref id="b222">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Saleh</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Barnes</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Giaid</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Increased production of the potent oxidant peroxynitrite in the lungs of patients with idiopathic pulmonary fibrosis</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>1997a</year>
          <volume>155</volume>
          <fpage>1763</fpage>
          <lpage>1769</lpage>
          <pub-id pub-id-type="pmid">9154889</pub-id>
        </element-citation>
      </ref>
      <ref id="b223">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Saleh</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Furukawa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tsao</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Maghazachi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Corrin</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Yanagisawa</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines</article-title>
          <source>Am J Respir Cell Mol Biol</source>
          <year>1997b</year>
          <volume>16</volume>
          <fpage>187</fpage>
          <lpage>193</lpage>
          <pub-id pub-id-type="pmid">9032126</pub-id>
        </element-citation>
      </ref>
      <ref id="b224">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schlingensiepen</surname>
              <given-names>KH</given-names>
            </name>
            <name>
              <surname>Fischer-Blass</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Schmaus</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ludwig</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Antisense therapeutics for tumor treatment: the TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors</article-title>
          <source>Recent Results Cancer Res</source>
          <year>2008</year>
          <volume>177</volume>
          <fpage>137</fpage>
          <lpage>150</lpage>
          <pub-id pub-id-type="pmid">18084956</pub-id>
        </element-citation>
      </ref>
      <ref id="b225">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scotton</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Chambers</surname>
              <given-names>RC</given-names>
            </name>
          </person-group>
          <article-title>Molecular targets in pulmonary fibrosis: the myofibroblast in focus</article-title>
          <source>Chest</source>
          <year>2007</year>
          <volume>132</volume>
          <fpage>1311</fpage>
          <lpage>1321</lpage>
          <pub-id pub-id-type="pmid">17934117</pub-id>
        </element-citation>
      </ref>
      <ref id="b226">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scotton</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Chambers</surname>
              <given-names>RC</given-names>
            </name>
          </person-group>
          <article-title>Bleomycin revisited: towards a more representative model of IPF?</article-title>
          <source>Am J Physiol Lung Cell Mol Physiol</source>
          <year>2010</year>
          <volume>299</volume>
          <fpage>L439</fpage>
          <lpage>L441</lpage>
          <pub-id pub-id-type="pmid">20675435</pub-id>
        </element-citation>
      </ref>
      <ref id="b227">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scotton</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Krupiczojc</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Konigshoff</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mercer</surname>
              <given-names>PF</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>YC</given-names>
            </name>
            <name>
              <surname>Kaminski</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury</article-title>
          <source>J Clin Invest</source>
          <year>2009</year>
          <volume>119</volume>
          <fpage>2550</fpage>
          <lpage>2563</lpage>
          <pub-id pub-id-type="pmid">19652365</pub-id>
        </element-citation>
      </ref>
      <ref id="b228">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Selman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pardo</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorder</article-title>
          <source>Respir Res</source>
          <year>2002</year>
          <volume>3</volume>
          <fpage>3</fpage>
          <pub-id pub-id-type="pmid">11806838</pub-id>
        </element-citation>
      </ref>
      <ref id="b229">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Selman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Carrillo</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Salas</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Padilla</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Perez-Chavira</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sansores</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Colchicine, d-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial</article-title>
          <source>Chest</source>
          <year>1998</year>
          <volume>114</volume>
          <fpage>507</fpage>
          <lpage>512</lpage>
          <pub-id pub-id-type="pmid">9726738</pub-id>
        </element-citation>
      </ref>
      <ref id="b230">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shah</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Foreman</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Ferguson</surname>
              <given-names>MW</given-names>
            </name>
          </person-group>
          <article-title>Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring</article-title>
          <source>J Cell Sci</source>
          <year>1995</year>
          <volume>108</volume>
          <fpage>985</fpage>
          <lpage>1002</lpage>
          <pub-id pub-id-type="pmid">7542672</pub-id>
        </element-citation>
      </ref>
      <ref id="b231">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shahar</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Fireman</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Topilsky</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Grief</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Schwarz</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kivity</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effect of endothelin-1 on alpha-smooth muscle actin expression and on alveolar fibroblasts proliferation in interstitial lung diseases</article-title>
          <source>Int J Immunopharmacol</source>
          <year>1999</year>
          <volume>21</volume>
          <fpage>759</fpage>
          <lpage>775</lpage>
          <pub-id pub-id-type="pmid">10576621</pub-id>
        </element-citation>
      </ref>
      <ref id="b232">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shahzeidi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sarnstrand</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Jeffery</surname>
              <given-names>PK</given-names>
            </name>
            <name>
              <surname>McAnulty</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Laurent</surname>
              <given-names>GJ</given-names>
            </name>
          </person-group>
          <article-title>Oral N-acetylcysteine reduces bleomycin-induced collagen deposition in the lungs of mice</article-title>
          <source>Eur Respir J</source>
          <year>1991</year>
          <volume>4</volume>
          <fpage>845</fpage>
          <lpage>852</lpage>
          <pub-id pub-id-type="pmid">1720100</pub-id>
        </element-citation>
      </ref>
      <ref id="b233">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shi-Wen</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Denton</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Eastwood</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Renzoni</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Bou-Gharios</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts</article-title>
          <source>Mol Biol Cell</source>
          <year>2004</year>
          <volume>15</volume>
          <fpage>2707</fpage>
          <lpage>2719</lpage>
          <pub-id pub-id-type="pmid">15047866</pub-id>
        </element-citation>
      </ref>
      <ref id="b234">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sime</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Xing</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Graham</surname>
              <given-names>FL</given-names>
            </name>
            <name>
              <surname>Csaky</surname>
              <given-names>KG</given-names>
            </name>
            <name>
              <surname>Gauldie</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung</article-title>
          <source>J Clin Invest</source>
          <year>1997</year>
          <volume>100</volume>
          <fpage>768</fpage>
          <lpage>776</lpage>
          <pub-id pub-id-type="pmid">9259574</pub-id>
        </element-citation>
      </ref>
      <ref id="b235">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sime</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Marr</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Gauldie</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Xing</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Hewlett</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Graham</surname>
              <given-names>FL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Transfer of tumor necrosis factor-alpha to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-beta1 and myofibroblasts</article-title>
          <source>Am J Pathol</source>
          <year>1998</year>
          <volume>153</volume>
          <fpage>825</fpage>
          <lpage>832</lpage>
          <pub-id pub-id-type="pmid">9736031</pub-id>
        </element-citation>
      </ref>
      <ref id="b236">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Simler</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>Howell</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Marshall</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Goldsack</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>Hasleton</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Laurent</surname>
              <given-names>GJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats</article-title>
          <source>Eur Respir J</source>
          <year>2002</year>
          <volume>19</volume>
          <fpage>1124</fpage>
          <lpage>1127</lpage>
          <pub-id pub-id-type="pmid">12108867</pub-id>
        </element-citation>
      </ref>
      <ref id="b237">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sonnylal</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Shi-Wen</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Leoni</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Naff</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Van Pelt</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis</article-title>
          <source>Arthritis Rheum</source>
          <year>2010</year>
          <volume>62</volume>
          <fpage>1523</fpage>
          <lpage>1532</lpage>
          <pub-id pub-id-type="pmid">20213804</pub-id>
        </element-citation>
      </ref>
      <ref id="b238">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stefani</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Slack</surname>
              <given-names>FJ</given-names>
            </name>
          </person-group>
          <article-title>Small non-coding RNAs in animal development</article-title>
          <source>Nat Rev Mol Cell Biol</source>
          <year>2008</year>
          <volume>9</volume>
          <fpage>219</fpage>
          <lpage>230</lpage>
          <pub-id pub-id-type="pmid">18270516</pub-id>
        </element-citation>
      </ref>
      <ref id="b239">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Strieter</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>
          <article-title>Pathogenesis and natural history of usual interstitial pneumonia: the whole story or the last chapter of a long novel</article-title>
          <source>Chest</source>
          <year>2005</year>
          <volume>128</volume>
          <fpage>526S</fpage>
          <lpage>532S</lpage>
          <pub-id pub-id-type="pmid">16304243</pub-id>
        </element-citation>
      </ref>
      <ref id="b240">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Subramanian</surname>
              <given-names>SV</given-names>
            </name>
            <name>
              <surname>Polikandriotis</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Kelm</surname>
              <given-names>RJ</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>David</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Orosz</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Strauch</surname>
              <given-names>AR</given-names>
            </name>
          </person-group>
          <article-title>Induction of vascular smooth muscle alpha-actin gene transcription in transforming growth factor beta1-activated myofibroblasts mediated by dynamic interplay between the Pur repressor proteins and Sp1/Smad coactivators</article-title>
          <source>Mol Biol Cell</source>
          <year>2004</year>
          <volume>15</volume>
          <fpage>4532</fpage>
          <lpage>4543</lpage>
          <pub-id pub-id-type="pmid">15282343</pub-id>
        </element-citation>
      </ref>
      <ref id="b241">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Suga</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Iyonaga</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ichiyasu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Saita</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Yamasaki</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ando</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases</article-title>
          <source>Eur Respir J</source>
          <year>1999</year>
          <volume>14</volume>
          <fpage>376</fpage>
          <lpage>382</lpage>
          <pub-id pub-id-type="pmid">10515417</pub-id>
        </element-citation>
      </ref>
      <ref id="b242">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Suganuma</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tamura</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Chida</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Enhanced migration of fibroblasts derived from lungs with fibrotic lesions</article-title>
          <source>Thorax</source>
          <year>1995</year>
          <volume>50</volume>
          <fpage>984</fpage>
          <lpage>989</lpage>
          <pub-id pub-id-type="pmid">8539681</pub-id>
        </element-citation>
      </ref>
      <ref id="b243">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sutinen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rainio</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sutinen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Huhti</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Pokela</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Ultrastructure of terminal respiratory epithelium and prognosis in chronic interstitial pneumonia</article-title>
          <source>Eur J Respir Dis</source>
          <year>1980</year>
          <volume>61</volume>
          <fpage>325</fpage>
          <lpage>336</lpage>
          <pub-id pub-id-type="pmid">7202604</pub-id>
        </element-citation>
      </ref>
      <ref id="b244">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tabata</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Tabata</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kadokawa</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hisamori</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mishima</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice</article-title>
          <source>J Immunol</source>
          <year>2007</year>
          <volume>179</volume>
          <fpage>708</fpage>
          <lpage>714</lpage>
          <pub-id pub-id-type="pmid">17579094</pub-id>
        </element-citation>
      </ref>
      <ref id="b245">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tager</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>LaCamera</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Shea</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Campanella</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Selman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>Z</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak</article-title>
          <source>Nat Med</source>
          <year>2008</year>
          <volume>14</volume>
          <fpage>45</fpage>
          <lpage>54</lpage>
          <pub-id pub-id-type="pmid">18066075</pub-id>
        </element-citation>
      </ref>
      <ref id="b246">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tamargo</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Bok</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Brem</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Angiogenesis inhibition by minocycline</article-title>
          <source>Cancer Res</source>
          <year>1991</year>
          <volume>51</volume>
          <fpage>672</fpage>
          <lpage>675</lpage>
          <pub-id pub-id-type="pmid">1702361</pub-id>
        </element-citation>
      </ref>
      <ref id="b247">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tang</surname>
              <given-names>YW</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Browning</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Cruz-Gervis</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Graham</surname>
              <given-names>BS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis</article-title>
          <source>J Clin Microbiol</source>
          <year>2003</year>
          <volume>41</volume>
          <fpage>2633</fpage>
          <lpage>2640</lpage>
          <pub-id pub-id-type="pmid">12791891</pub-id>
        </element-citation>
      </ref>
      <ref id="b248">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Taniguchi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ebina</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kondoh</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ogura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Azuma</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Suga</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pirfenidone in idiopathic pulmonary fibrosis</article-title>
          <source>Eur Respir J</source>
          <year>2010</year>
          <volume>35</volume>
          <fpage>821</fpage>
          <lpage>829</lpage>
          <pub-id pub-id-type="pmid">19996196</pub-id>
        </element-citation>
      </ref>
      <ref id="b249">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Turner-Warwick</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Precapillary systemic-pulmonary anastomoses</article-title>
          <source>Thorax</source>
          <year>1963</year>
          <volume>18</volume>
          <fpage>225</fpage>
          <lpage>237</lpage>
          <pub-id pub-id-type="pmid">14064617</pub-id>
        </element-citation>
      </ref>
      <ref id="b250">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Turner-Warwick</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Burrows</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival</article-title>
          <source>Thorax</source>
          <year>1980</year>
          <volume>35</volume>
          <fpage>593</fpage>
          <lpage>599</lpage>
          <pub-id pub-id-type="pmid">7444826</pub-id>
        </element-citation>
      </ref>
      <ref id="b251">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Uhal</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Joshi</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>WF</given-names>
            </name>
            <name>
              <surname>Ramos</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pardo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Selman</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Alveolar epithelial cell death adjacent to underlying myofibroblasts in advanced fibrotic human lung</article-title>
          <source>Am J Physiol</source>
          <year>1998</year>
          <volume>275</volume>
          <fpage>L1192</fpage>
          <lpage>L1199</lpage>
          <pub-id pub-id-type="pmid">9843857</pub-id>
        </element-citation>
      </ref>
      <ref id="b252">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Uhal</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Molina-Molina</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Angiotensin-TGF-beta 1 crosstalk in human idiopathic pulmonary fibrosis: autocrine mechanisms in myofibroblasts and macrophages</article-title>
          <source>Curr Pharm Des</source>
          <year>2007</year>
          <volume>13</volume>
          <fpage>1247</fpage>
          <lpage>1256</lpage>
          <pub-id pub-id-type="pmid">17504233</pub-id>
        </element-citation>
      </ref>
      <ref id="b253">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ulloa</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Doody</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Massague</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway</article-title>
          <source>Nature</source>
          <year>1999</year>
          <volume>397</volume>
          <fpage>710</fpage>
          <lpage>713</lpage>
          <pub-id pub-id-type="pmid">10067896</pub-id>
        </element-citation>
      </ref>
      <ref id="b254">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Waghray</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cui</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Horowitz</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Subramanian</surname>
              <given-names>IM</given-names>
            </name>
            <name>
              <surname>Martinez</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Toews</surname>
              <given-names>GB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts</article-title>
          <source>FASEB J</source>
          <year>2005</year>
          <volume>19</volume>
          <fpage>854</fpage>
          <lpage>856</lpage>
          <pub-id pub-id-type="pmid">15857893</pub-id>
        </element-citation>
      </ref>
      <ref id="b255">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Walters</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Cho</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Kleeberger</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
          <article-title>Oxidative stress and antioxidants in the pathogenesis of pulmonary fibrosis: a potential role for Nrf2</article-title>
          <source>Antioxid Redox Signal</source>
          <year>2008</year>
          <volume>10</volume>
          <fpage>321</fpage>
          <lpage>332</lpage>
          <pub-id pub-id-type="pmid">17999635</pub-id>
        </element-citation>
      </ref>
      <ref id="b256">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Zagariya</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ibarra-Sunga</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Gidea</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ang</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Deshmukh</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Angiotensin II induces apoptosis in human and rat alveolar epithelial cells</article-title>
          <source>Am J Physiol</source>
          <year>1999</year>
          <volume>276</volume>
          <fpage>L885</fpage>
          <lpage>L889</lpage>
          <pub-id pub-id-type="pmid">10330045</pub-id>
        </element-citation>
      </ref>
      <ref id="b257">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ibarra-Sunga</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Verlinski</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Pick</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Uhal</surname>
              <given-names>BD</given-names>
            </name>
          </person-group>
          <article-title>Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor</article-title>
          <source>Am J Physiol Lung Cell Mol Physiol</source>
          <year>2000a</year>
          <volume>279</volume>
          <fpage>L143</fpage>
          <lpage>L151</lpage>
          <pub-id pub-id-type="pmid">10893213</pub-id>
        </element-citation>
      </ref>
      <ref id="b258">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>WL</given-names>
            </name>
            <name>
              <surname>Healy</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Sattler</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Verma</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Maulik</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571</article-title>
          <source>Oncogene</source>
          <year>2000b</year>
          <volume>19</volume>
          <fpage>3521</fpage>
          <lpage>3528</lpage>
          <pub-id pub-id-type="pmid">10918610</pub-id>
        </element-citation>
      </ref>
      <ref id="b259">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Watterson</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Lanning</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Diegelmann</surname>
              <given-names>RF</given-names>
            </name>
            <name>
              <surname>Spiegel</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Regulation of fibroblast functions by lysophospholipid mediators: potential roles in wound healing</article-title>
          <source>Wound Repair Regen</source>
          <year>2007</year>
          <volume>15</volume>
          <fpage>607</fpage>
          <lpage>616</lpage>
          <pub-id pub-id-type="pmid">17971005</pub-id>
        </element-citation>
      </ref>
      <ref id="b260">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Whyte</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hubbard</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Meliconi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Whidborne</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Eaton</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Bingle</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2000</year>
          <volume>162</volume>
          <fpage>755</fpage>
          <lpage>758</lpage>
          <pub-id pub-id-type="pmid">10934117</pub-id>
        </element-citation>
      </ref>
      <ref id="b261">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wilborn</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Crofford</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Burdick</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Kunkel</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Strieter</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Peters-Golden</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2</article-title>
          <source>J Clin Invest</source>
          <year>1995</year>
          <volume>95</volume>
          <fpage>1861</fpage>
          <lpage>1868</lpage>
          <pub-id pub-id-type="pmid">7706493</pub-id>
        </element-citation>
      </ref>
      <ref id="b262">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wilborn</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bailie</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Coffey</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Burdick</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Strieter</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Peters-Golden</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis</article-title>
          <source>J Clin Invest</source>
          <year>1996</year>
          <volume>97</volume>
          <fpage>1827</fpage>
          <lpage>1836</lpage>
          <pub-id pub-id-type="pmid">8621765</pub-id>
        </element-citation>
      </ref>
      <ref id="b263">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Willis</surname>
              <given-names>BC</given-names>
            </name>
            <name>
              <surname>Liebler</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Luby-Phelps</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nicholson</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Crandall</surname>
              <given-names>ED</given-names>
            </name>
            <name>
              <surname>du Bois</surname>
              <given-names>RM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis</article-title>
          <source>Am J Pathol</source>
          <year>2005</year>
          <volume>166</volume>
          <fpage>1321</fpage>
          <lpage>1332</lpage>
          <pub-id pub-id-type="pmid">15855634</pub-id>
        </element-citation>
      </ref>
      <ref id="b264">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wipff</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Hinz</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Integrins and the activation of latent transforming growth factor beta1 &#x2013; an intimate relationship</article-title>
          <source>Eur J Cell Biol</source>
          <year>2008</year>
          <volume>87</volume>
          <fpage>601</fpage>
          <lpage>615</lpage>
          <pub-id pub-id-type="pmid">18342983</pub-id>
        </element-citation>
      </ref>
      <ref id="b265">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wipff</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Rifkin</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Meister</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Hinz</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix</article-title>
          <source>J Cell Biol</source>
          <year>2007</year>
          <volume>179</volume>
          <fpage>1311</fpage>
          <lpage>1323</lpage>
          <pub-id pub-id-type="pmid">18086923</pub-id>
        </element-citation>
      </ref>
      <ref id="b266">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wynn</surname>
              <given-names>TA</given-names>
            </name>
          </person-group>
          <article-title>Fibrotic disease and the T(H)1/T(H)2 paradigm</article-title>
          <source>Nat Rev Immunol</source>
          <year>2004</year>
          <volume>4</volume>
          <fpage>583</fpage>
          <lpage>594</lpage>
          <pub-id pub-id-type="pmid">15286725</pub-id>
        </element-citation>
      </ref>
      <ref id="b267">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xaubet</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Marin-Arguedas</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lario</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ancochea</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Morell</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ruiz-Manzano</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Transforming growth factor-beta1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2003</year>
          <volume>168</volume>
          <fpage>431</fpage>
          <lpage>435</lpage>
          <pub-id pub-id-type="pmid">12746254</pub-id>
        </element-citation>
      </ref>
      <ref id="b268">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xaubet</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Roca-Ferrer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pujols</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ramirez</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Mullol</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Marin-Arguedas</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cyclooxygenase-2 is up-regulated in lung parenchyma of chronic obstructive pulmonary disease and down-regulated in idiopathic pulmonary fibrosis</article-title>
          <source>Sarcoidosis Vasc Diffuse Lung Dis</source>
          <year>2004</year>
          <volume>21</volume>
          <fpage>35</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="pmid">15127973</pub-id>
        </element-citation>
      </ref>
      <ref id="b269">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Denton</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Holmes</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dashwood</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Abraham</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Black</surname>
              <given-names>CM</given-names>
            </name>
          </person-group>
          <article-title>Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts</article-title>
          <source>J Cardiovasc Pharmacol</source>
          <year>1998</year>
          <volume>31</volume>
          <issue>Suppl 1</issue>
          <fpage>S360</fpage>
          <lpage>S363</lpage>
          <pub-id pub-id-type="pmid">9595482</pub-id>
        </element-citation>
      </ref>
      <ref id="b270">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>YD</given-names>
            </name>
            <name>
              <surname>Hua</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Mui</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>O'Connor</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Grotendorst</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Khalil</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Release of biologically active TGF-beta1 by alveolar epithelial cells results in pulmonary fibrosis</article-title>
          <source>Am J Physiol Lung Cell Mol Physiol</source>
          <year>2003</year>
          <volume>285</volume>
          <fpage>L527</fpage>
          <lpage>L539</lpage>
          <pub-id pub-id-type="pmid">12598227</pub-id>
        </element-citation>
      </ref>
      <ref id="b271">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>MY</given-names>
            </name>
            <name>
              <surname>Porte</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Knox</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Weinreb</surname>
              <given-names>PH</given-names>
            </name>
            <name>
              <surname>Maher</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Violette</surname>
              <given-names>SM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q)</article-title>
          <source>Am J Pathol</source>
          <year>2009</year>
          <volume>174</volume>
          <fpage>1264</fpage>
          <lpage>1279</lpage>
          <pub-id pub-id-type="pmid">19147812</pub-id>
        </element-citation>
      </ref>
      <ref id="b272">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamada</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kuwano</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Maeyama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hamada</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Yoshimi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nakanishi</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Dual-immunohistochemistry provides little evidence for epithelial-mesenchymal transition in pulmonary fibrosis</article-title>
          <source>Histochem Cell Biol</source>
          <year>2008</year>
          <volume>129</volume>
          <fpage>453</fpage>
          <lpage>462</lpage>
          <pub-id pub-id-type="pmid">18236067</pub-id>
        </element-citation>
      </ref>
      <ref id="b273">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yanagisawa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Osada</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Masuda</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kondo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Saito</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yatabe</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Induction of apoptosis by Smad3 and down-regulation of Smad3 expression in response to TGF-beta in human normal lung epithelial cells</article-title>
          <source>Oncogene</source>
          <year>1998</year>
          <volume>17</volume>
          <fpage>1743</fpage>
          <lpage>1747</lpage>
          <pub-id pub-id-type="pmid">9796704</pub-id>
        </element-citation>
      </ref>
      <ref id="b274">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zappala</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Latsi</surname>
              <given-names>PI</given-names>
            </name>
            <name>
              <surname>Nicholson</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Colby</surname>
              <given-names>TV</given-names>
            </name>
            <name>
              <surname>Cramer</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Renzoni</surname>
              <given-names>EA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis</article-title>
          <source>Eur Respir J</source>
          <year>2010</year>
          <volume>35</volume>
          <fpage>830</fpage>
          <lpage>836</lpage>
          <pub-id pub-id-type="pmid">19840957</pub-id>
        </element-citation>
      </ref>
      <ref id="b275">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zavadil</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cermak</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Soto-Nieves</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Bottinger</surname>
              <given-names>EP</given-names>
            </name>
          </person-group>
          <article-title>Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition</article-title>
          <source>EMBO J</source>
          <year>2004</year>
          <volume>23</volume>
          <fpage>1155</fpage>
          <lpage>1165</lpage>
          <pub-id pub-id-type="pmid">14976548</pub-id>
        </element-citation>
      </ref>
      <ref id="b276">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Gharaee-Kermani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>McGarry</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Phan</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
          <article-title>In situ hybridization analysis of rat lung alpha 1(I) and alpha 2(I) collagen gene expression in pulmonary fibrosis induced by endotracheal bleomycin injection</article-title>
          <source>Lab Invest</source>
          <year>1994a</year>
          <volume>70</volume>
          <fpage>192</fpage>
          <lpage>202</lpage>
          <pub-id pub-id-type="pmid">7511187</pub-id>
        </element-citation>
      </ref>
      <ref id="b277">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Rekhter</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Phan</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
          <article-title>Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis. A combined immunohistochemical and in situ hybridization study</article-title>
          <source>Am J Pathol</source>
          <year>1994b</year>
          <volume>145</volume>
          <fpage>114</fpage>
          <lpage>125</lpage>
          <pub-id pub-id-type="pmid">7518191</pub-id>
        </element-citation>
      </ref>
      <ref id="b278">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Gharaee-Kermani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>McGarry</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Remick</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Phan</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
          <article-title>TNF-alpha-mediated lung cytokine networking and eosinophil recruitment in pulmonary fibrosis</article-title>
          <source>J Immunol</source>
          <year>1997</year>
          <volume>158</volume>
          <fpage>954</fpage>
          <lpage>959</lpage>
          <pub-id pub-id-type="pmid">8993016</pub-id>
        </element-citation>
      </ref>
      <ref id="b279">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Nielsen</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Lucas</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Mason</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>Transforming growth factor-beta antagonizes alveolar type II cell proliferation induced by keratinocyte growth factor</article-title>
          <source>Am J Respir Cell Mol Biol</source>
          <year>2004</year>
          <volume>31</volume>
          <fpage>679</fpage>
          <lpage>686</lpage>
          <pub-id pub-id-type="pmid">15333329</pub-id>
        </element-citation>
      </ref>
      <ref id="b280">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Qian</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>rAAV2-TGF-beta(3) decreases collagen synthesis and deposition in the liver of experimental hepatic fibrosis rat</article-title>
          <source>Dig Dis Sci</source>
          <year>2010</year>
          <volume>55</volume>
          <fpage>2821</fpage>
          <lpage>2830</lpage>
          <pub-id pub-id-type="pmid">20108118</pub-id>
        </element-citation>
      </ref>
      <ref id="b281">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Xiang</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice</article-title>
          <source>Respir Res</source>
          <year>2010</year>
          <volume>11</volume>
          <fpage>34</fpage>
          <pub-id pub-id-type="pmid">20302663</pub-id>
        </element-citation>
      </ref>
      <ref id="b282">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ziegenhagen</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Schrum</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Zissel</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Zipfel</surname>
              <given-names>PF</given-names>
            </name>
            <name>
              <surname>Schlaak</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Muller-Quernheim</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressing idiopathic pulmonary fibrosis and sarcoidosis</article-title>
          <source>J Investig Med</source>
          <year>1998</year>
          <volume>46</volume>
          <fpage>223</fpage>
          <lpage>231</lpage>
        </element-citation>
      </ref>
      <ref id="b283">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ziesche</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hofbauer</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Wittmann</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Petkov</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Block</surname>
              <given-names>LH</given-names>
            </name>
          </person-group>
          <article-title>A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis</article-title>
          <source>N Engl J Med</source>
          <year>1999</year>
          <volume>341</volume>
          <fpage>1264</fpage>
          <lpage>1269</lpage>
          <pub-id pub-id-type="pmid">10528036</pub-id>
        </element-citation>
      </ref>
      <ref id="b284">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zisman</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Lynch</surname>
              <given-names>JP</given-names>
              <suffix>3rd</suffix>
            </name>
            <name>
              <surname>Toews</surname>
              <given-names>GB</given-names>
            </name>
            <name>
              <surname>Kazerooni</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Flint</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Martinez</surname>
              <given-names>FJ</given-names>
            </name>
          </person-group>
          <article-title>Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids</article-title>
          <source>Chest</source>
          <year>2000</year>
          <volume>117</volume>
          <fpage>1619</fpage>
          <lpage>1626</lpage>
          <pub-id pub-id-type="pmid">10858393</pub-id>
        </element-citation>
      </ref>
      <ref id="b285">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zisman</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Schwarz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Anstrom</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Collard</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Flaherty</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Hunninghake</surname>
              <given-names>GW</given-names>
            </name>
          </person-group>
          <article-title>A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis</article-title>
          <source>N Engl J Med</source>
          <year>2010</year>
          <volume>363</volume>
          <fpage>620</fpage>
          <lpage>628</lpage>
          <pub-id pub-id-type="pmid">20484178</pub-id>
        </element-citation>
      </ref>
      <ref id="b286">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zuo</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Kaminski</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Eugui</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Allard</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yakhini</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Ben-Dor</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>2002</year>
          <volume>99</volume>
          <fpage>6292</fpage>
          <lpage>6297</lpage>
          <pub-id pub-id-type="pmid">11983918</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <glossary>
      <def-list>
        <title>Abbreviations</title>
        <def-item>
          <term>5-LO</term>
          <def>
            <p>5-lipooxygenase</p>
          </def>
        </def-item>
        <def-item>
          <term>A-a</term>
          <def>
            <p>alveolar-arterial</p>
          </def>
        </def-item>
        <def-item>
          <term>ACE</term>
          <def>
            <p>angiotensin converting enzyme</p>
          </def>
        </def-item>
        <def-item>
          <term>AEC</term>
          <def>
            <p>alveolar epithelial cell</p>
          </def>
        </def-item>
        <def-item>
          <term>AGT</term>
          <def>
            <p>angiotensinogen</p>
          </def>
        </def-item>
        <def-item>
          <term>ALK</term>
          <def>
            <p>activin-like kinase receptor</p>
          </def>
        </def-item>
        <def-item>
          <term>ANGII</term>
          <def>
            <p>angiotensin II</p>
          </def>
        </def-item>
        <def-item>
          <term>AT(1)</term>
          <def>
            <p>angiotensin II type 1 receptor</p>
          </def>
        </def-item>
        <def-item>
          <term>BALF</term>
          <def>
            <p>bronchoalveolar lavage fluid</p>
          </def>
        </def-item>
        <def-item>
          <term>CCL2</term>
          <def>
            <p>chemokine (C-C motif) ligand 2</p>
          </def>
        </def-item>
        <def-item>
          <term>CCR2</term>
          <def>
            <p>C-C chemokine receptor 2</p>
          </def>
        </def-item>
        <def-item>
          <term>COX</term>
          <def>
            <p>cyclooxygenase</p>
          </def>
        </def-item>
        <def-item>
          <term>CTGF</term>
          <def>
            <p>connective tissue growth factor</p>
          </def>
        </def-item>
        <def-item>
          <term>CXCL12</term>
          <def>
            <p>C-X-C motif chemokine ligand-12</p>
          </def>
        </def-item>
        <def-item>
          <term>CXCR4</term>
          <def>
            <p>C-X-C motif chemokine receptor-4</p>
          </def>
        </def-item>
        <def-item>
          <term>DL<sub>co</sub></term>
          <def>
            <p>carbon monoxide diffusing capacity</p>
          </def>
        </def-item>
        <def-item>
          <term>ECM</term>
          <def>
            <p>extracellular matrix</p>
          </def>
        </def-item>
        <def-item>
          <term>EMT</term>
          <def>
            <p>epithelial&#x2013;mesenchymal transition</p>
          </def>
        </def-item>
        <def-item>
          <term>ET-1</term>
          <def>
            <p>endothelin-1</p>
          </def>
        </def-item>
        <def-item>
          <term>(F)VC</term>
          <def>
            <p>(forced) vital capacity</p>
          </def>
        </def-item>
        <def-item>
          <term>HGF</term>
          <def>
            <p>hepatocyte growth factor</p>
          </def>
        </def-item>
        <def-item>
          <term>HRCT</term>
          <def>
            <p>high resolution computed tomography</p>
          </def>
        </def-item>
        <def-item>
          <term>HSP</term>
          <def>
            <p>heat shock protein</p>
          </def>
        </def-item>
        <def-item>
          <term>IFN-&#x3B3;</term>
          <def>
            <p>interferon-&#x3B3;</p>
          </def>
        </def-item>
        <def-item>
          <term>IL-13</term>
          <def>
            <p>interleukin-13</p>
          </def>
        </def-item>
        <def-item>
          <term>IPF</term>
          <def>
            <p>idiopathic pulmonary fibrosis</p>
          </def>
        </def-item>
        <def-item>
          <term>KGF</term>
          <def>
            <p>keratinocyte growth factor</p>
          </def>
        </def-item>
        <def-item>
          <term>LAP</term>
          <def>
            <p>latency-associated peptide</p>
          </def>
        </def-item>
        <def-item>
          <term>LOXL2</term>
          <def>
            <p>lysyl oxidase-2</p>
          </def>
        </def-item>
        <def-item>
          <term>LPA</term>
          <def>
            <p>lysophosphaditic acid</p>
          </def>
        </def-item>
        <def-item>
          <term>LTB<sub>4</sub></term>
          <def>
            <p>leukotriene B<sub>4</sub></p>
          </def>
        </def-item>
        <def-item>
          <term>MCP-1</term>
          <def>
            <p>monocyte chemotactic protein 1</p>
          </def>
        </def-item>
        <def-item>
          <term>mTOR</term>
          <def>
            <p>mammalian target of rapamycin</p>
          </def>
        </def-item>
        <def-item>
          <term>NAC</term>
          <def>
            <p>N-acetylcysteine</p>
          </def>
        </def-item>
        <def-item>
          <term>NOX</term>
          <def>
            <p>NADPH-oxidase</p>
          </def>
        </def-item>
        <def-item>
          <term>PAR</term>
          <def>
            <p>proteinase-activated receptor</p>
          </def>
        </def-item>
        <def-item>
          <term>PDGF</term>
          <def>
            <p>platelet derived growth factor</p>
          </def>
        </def-item>
        <def-item>
          <term>PGE<sub>2</sub></term>
          <def>
            <p>prostaglandin E<sub>2</sub></p>
          </def>
        </def-item>
        <def-item>
          <term>PGI<sub>2</sub></term>
          <def>
            <p>prostacyclin</p>
          </def>
        </def-item>
        <def-item>
          <term>PHT</term>
          <def>
            <p>pulmonary hypertension</p>
          </def>
        </def-item>
        <def-item>
          <term>QoL</term>
          <def>
            <p>quality of life</p>
          </def>
        </def-item>
        <def-item>
          <term>ROS</term>
          <def>
            <p>reactive oxidative species</p>
          </def>
        </def-item>
        <def-item>
          <term>TGF-&#x3B2;</term>
          <def>
            <p>transforming growth factor-&#x3B2;</p>
          </def>
        </def-item>
        <def-item>
          <term>Th</term>
          <def>
            <p>T-helper</p>
          </def>
        </def-item>
        <def-item>
          <term>TM</term>
          <def>
            <p>tetrathiomolybdate</p>
          </def>
        </def-item>
        <def-item>
          <term>TNF-&#x3B1;</term>
          <def>
            <p>tumour necrosis factor-&#x3B1;</p>
          </def>
        </def-item>
        <def-item>
          <term>VEGF</term>
          <def>
            <p>vascular endothelial growth factor</p>
          </def>
        </def-item>
        <def-item>
          <term>&#x3B1;-SMA</term>
          <def>
            <p>&#x3B1;-smooth muscle actin</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <sec sec-type="supplementary-material">
      <title>Supporting Information</title>
      <p>Teaching Materials; Fig 1&#x2013;2 as PowerPoint slide.</p>
      <supplementary-material content-type="local-data" id="SD1">
        <media xlink:href="bph0163-0141-SD1.pptx" xlink:type="simple" id="d32e15154" position="anchor" mimetype="application" mime-subtype="vnd.ms-powerpoint"/>
      </supplementary-material>
    </sec>
  </back>
</article>
